

(19) **DANMARK**

(10) **DK/EP 2670411 T3**



Patent- og
Varemærkestyrelsen

(12) Oversættelse af
europæisk patentskrift

-
- (51) Int.Cl.: **A 61 K 31/7088 (2006.01)** **A 61 K 31/712 (2006.01)** **A 61 K 45/06 (2006.01)**
A 61 P 17/02 (2006.01)
- (45) Oversættelsen bekendtgjort den: **2019-05-13**
- (80) Dato for Den Europæiske Patentmyndigheds bekendtgørelse om meddelelse af patentet: **2019-04-10**
- (86) Europæisk ansøgning nr.: **12742348.1**
- (86) Europæisk indleveringsdag: **2012-02-02**
- (87) Den europæiske ansøgnings publiceringsdag: **2013-12-11**
- (86) International ansøgning nr.: **US2012023620**
- (87) Internationalt publikationsnr.: **WO2012106508**
- (30) Prioritet: **2011-02-02 US 201161438879 P** **2011-05-20 US 201161488666 P**
2011-08-26 US 201161527821 P
- (84) Designerede stater: **AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR**
- (73) Patenthaver: **Excaliard Pharmaceuticals, Inc., 235 East 42nd Street, New York, NY 10017, USA**
- (72) Opfinder: **DEAN, Nicholas, M., 2110 Whisper Wind Lane, Encinitas, CA 92024, USA**
KROCHMAL, Lincoln, 15891 Shannon Road, Los Gatos, CA 95032, USA
HARDEE, Gregory, 12951 Caminito En Flor, Del Mar, CA 92014, USA
FOULKES, J., Gordon, 3756 Brand Crest, Encinitas, CA 92024, USA
O'DONNELL, Niall, 1046 Dewitt Avenue, Encinitas, California 92024, USA
JEWELL, Mark, Jewell Plastic Surgery Center, 10 Coburg Rd., Suite 300, Eugene, Oregon 97401, USA
YOUNG, Leroy, Body Aesthetic Plastic Surgery, 969 N. Mason Rd. No. 170, St. Louis, Missouri 63141, USA
- (74) Fuldmægtig i Danmark: **Zacco Denmark A/S, Arne Jacobsens Allé 15, 2300 København S, Danmark**
- (54) Benævnelse: **Antisense-forbindelser rettet mod bindevæsvækstfaktor (CTGF) til anvendelse i en fremgangsmåde til behandling af keloider eller hypertrofiske ar**
- (56) Fremdragne publikationer:
WO-A2-2010/027830
WO-A2-2010/042281
US-A1- 2003 144 223
US-A1- 2003 180 300
US-A1- 2005 113 326
US-A1- 2009 137 475
US-A1- 2010 130 595

DESCRIPTION

[0001] This application claims priority of U.S. Provisional Application Nos. 61/527,821, filed August 26, 2011, 61/488,666, filed May 20, 2011, and 61/438,879, filed February 2, 2011.

[0002] This application incorporates-by-reference nucleotide and/or amino acid sequences which are present in the file named "120202_5056_81583_A_PCT_Sequence_Listing_BI.txt," which is 62 kilobytes in size, and which was created February 1, 2012 in the IBM-PC machine format, having an operating system compatibility with MS-Windows, which is contained in the text file filed February 2, 2012 as part of this application.

Field of Invention

[0003] This invention concerns compositions for preventing formation of, or treating, fibrotic lesions, including skin scars such as keloids and hypertrophic scars.

Background of the Invention

[0004] Antisense compounds are an effective means for reducing the expression of specific gene products and may be uniquely useful in a number of therapeutic applications, for example, for the modulation of expression of proteins involved in fibrosis such as connective tissue growth factor (CTGF). (See U.S. Patent No. 6,965,025B2 to Gaarde et al.)

[0005] Antisense compounds are oligomeric compounds that are capable of hybridizing to a target nucleic acid (e.g. a target mRNA molecule) and inhibiting expression of the target nucleic acid.

[0006] Antisense compounds, compositions and methods for modulating expression of CTGF and for treating diseases associated with expression of CTGF are disclosed in U.S. Pat. No. 6,965,025B2. However, there remains a need for additional such compounds capable of providing enhanced inhibition of CTGF expression as well as other advantageous properties.

[0007] Connective tissue growth factor (CTGF; also known as ctgrofact, fibroblast inducible secreted protein, fisp-12, NOV2, insulin-like growth factor-binding protein-related protein 2, IGFBP-rP2, IGFBP-8, HBGF-0.8, Hcs24, and ecogenin) is a member of the CCN (CTGF/CYR61/NOV) family of modular proteins, named for the first family members identified, connective tissue growth factor, cysteine-rich (CYR61), and nephroblastoma overexpressed (NOV), but the family also includes the proteins ELM-1 (expressed in low-metastatic cells), WISP-3 (Wnt-1-induced secreted protein), and COP-1 (WISP-2). CCN proteins have been found to be secreted, extracellular matrix-associated proteins that regulate cellular processes such as adhesion, migration, mitogenesis, differentiation, survival, angiogenesis, atherosclerosis, chondrogenesis, wound healing, tumorigenesis, and vascular and fibrotic diseases like

scleroderma (Lau and Lam, *Exp. Cell Res.*, 1999, 248, 44-57). The connective tissue growth factor protein was shown to stimulate DNA synthesis and promote chemotaxis of fibroblasts (Bradham et al., *J. Cell Biol.*, 1991, 114, 1285-1294).

[0008] Connective tissue growth factor is expressed in fibroblasts during normal differentiation processes that involve extracellular matrix (ECM) production and remodeling. Connective tissue growth factor is also frequently overexpressed in fibrotic skin disorders such as systemic sclerosis, localized skin sclerosis, keloids, scar tissue, eosinophilic fasciitis, nodular fasciitis, and Dupuytren's contracture. Connective tissue growth factor mRNA or protein levels are elevated in fibrotic lesions of major organs and tissues including the liver, kidney, lung, cardiovascular system, pancreas, bowel, eye, and gingiva. In mammary, pancreatic and fibrohistiocytic tumors characterized by significant connective tissue involvement, connective tissue growth factor is overexpressed in the stromal compartment.

The Role of CTGF in Keloid Diseases

[0009] Keloid disease (KD) is a benign dermal fibro-proliferative tumor characterized by an excessive accumulation of extracellular matrix proteins, leading to an overabundance of collagen formation. Abnormal skin scarring can occur, post-injury in genetically susceptible individuals. KD can also be a familial condition, occurring more commonly in ethnic groups with darker skin. The highest incidence of keloids is found in the black population, where it has been estimated to be around 4-6% and up to 16% in random samples of black Africans. Various modes of inheritance have been proposed for KD ranging from autosomal recessive to autosomal dominant with incomplete clinical penetrance and variable expression. The majority of keloids can lead to considerable cosmetic defects, but can also grow large enough to become symptomatic, by causing deformity or limiting joint mobility.

[0010] Although low levels of CTGF are expressed in normal skin, CTGF becomes up-regulated following dermal injury, and it becomes persistently over-expressed when scarring is severe, as in keloids or systemic sclerosis. Fibroblasts cultured from both hypertrophic scars, keloids, and scleroderma lesions express increased basal CTGF (*Exp. Cell Res.* 2000, 259: 213-224), and cells cultured from hypertrophic scars and keloids were shown to express more CTGF basally and also elaborate more CTGF in response to stimulation with TGF- β (*Plast. Reconstr. Surg.* 2005, 116: 1387-90). Similarly, transcription of CTGF after serum stimulation was significantly higher in keloid versus normal fibroblasts in cell culture (*Ann. Surg.* 2007, 246 (5) : 886-95).

[0011] In keloid tissue, fibroblasts expressing CTGF mRNA were found distributed throughout the lesions, especially in the peripheral areas (*J. Invest. Derm.* 1996, 106:729-733). CTGF mRNA expression levels have been compared in normal skin, keloid scars, hypertrophic scars, and mature scars. CTGF mRNA was strongly detected in all cases of the keloids, although not in mature scars. There was a significant difference between levels found in keloids and normal skin (*J. Japan Soc. Plastic Reconstr. Surg.* 2002, 22:560-565). Recent data also suggests that, relative to normal fibroblasts, keloid scar fibroblasts synthesize 100-150-fold more CTGF in response to exogenous TGF- β 1 than do normal fibroblasts (*Plast. Reconstr. Surg.* 2005,

116:1387-1390). When compared to normal skin, increased localization of CTGF was seen in the basal layer of keloid epidermis and higher expression of CTGF was observed in keloid tissue extract (J. Cell Physiol. 2006, 208 (2) :336-43) . Previously no data has been generated to validate the role of CTGF in keloid disease by showing that inhibition of CTGF expression inhibits keloid growth.

[0012] Currently, no effective single therapeutic regimen has been established for treatment of keloids or prevention of keloids growth after surgery. Existing therapeutic approaches include occlusive dressings, compression therapy, intra-lesional steroid injections, cryosurgery, surgical excision, laser treatment, radiation therapy, Kenalog (triamcinolone), interferon therapy, bleomycin, 5-flouracil, verapamil, imiquimod cream, and combinations thereof. Both silicone and non-silicone-based occlusive dressings have been a widely used clinical option for keloids for the last 30 years, but all of these methods result in very limited efficacy and it is widely understood that a new therapy for keloids is urgently needed.

[0013] Various forms of radiotherapy have been attempted as a mono-therapy for keloids, but remain quite controversial because of anecdotal reports of carcinogenesis after treatment. Laser therapy using argon, CO₂, and pulse dye have been repeatedly attempted during the last 40 years, but none of them have proven to be efficacious. All three forms of laser therapy, according to multiple studies, have recurrence rates of upwards of 90%, showing little to no benefit. Cryotherapy has been used as a mono-therapy. However, side effects associated with this approach include pain at the therapeutic site and hypo- or hyper-pigmentation. Intra-lesional triamcinolone acetone injections, a type of corticosteroid, is frequently used as first-line therapy for the treatment of keloids, but again, actual reported clinical efficacy varies widely. In addition, the need for multiple injections, along with the side effects of injection pain, skin atrophy, telangiectasias, and altered pigmentation have caused clinicians and researchers to continue seeking other means of treatment.

[0014] Consequently, there remains a long felt need for additional methods and agents to effectively prevent the formation of keloids, hypertrophic scars, and other types of fibrotic lesions as well as to treat keloids, hypertrophic scars and fibrotic lesion so as to eliminate or reduce them and/or to prevent their reoccurrence. The clinical results described herein clearly demonstrate for the first time the ability of an antisense oligonucleotide targeting CTGF to reduce the growth and severity of keloids post surgery.

Antisense dosing into skin

[0015] It has also been demonstrated for the first time that antisense oligonucleotides do not diffuse laterally very far after dosing into skin (see Example 2) which could lead to irregular effects of this class of drug on a linear incision/healing scar or keloid if dosing was conducted as a single bolus type of administration, resulting in variable concentrations of antisense along the length of the developing scar. To overcome this drawback, a method for delivering antisense oligonucleotides by an intradermal threading technique has been developed. This technique effectively delivers a constant amount of antisense drug along the full length of the scar, and

results in effective and consistent scar reduction along the full length of the scar or keloid.

[0016] Intradermal threading consists of introducing a needle into the dermis at an angle as parallel to the skin as possible, and threading the needle into and along the dermis for a distance of typically between 1 and 5 cm. At this point, the needle is withdrawn and drug injected into the dermis along the full length of the needle tract as the needle is withdrawn, resulting in an equal amount and volume of drug being deposited along the full length of the needle tract.

[0017] WO2010042281 and WO2010027830 disclose methods of treating hypertrophic scars and keloids comprising an antisense oligonucleotide comprising 12 to 30 linked nucleosides targeted to a nucleic acid encoding CTGF. The antisense oligonucleotide was administered in aliquots injected around the wound's periphery.

Summary of the Invention

[0018] This invention provides a composition which comprises a modified antisense oligonucleotide consisting of 12-30 linked nucleosides, at least a 12 nucleobase sequence portion of which is complementary to nucleotides present within a region selected from nucleotides 1388-1423, 1394-1423 and 1399-1423 of SEQ ID NO: 9, or a salt or ester thereof, for use in treating a keloid, or preventing the formation, reformation, or growth of a keloid after an injury to the skin, in a subject in need thereof, wherein the composition is administered to the subject by one or more threading injections at the site of the keloid or of the injury to the skin, in an amount effective to treat, or to prevent the formation, reformation, or growth of, the keloid, wherein the effective amount is from 0.1 to 50 mg of the modified oligonucleotide per injection per linear centimeter of the keloid or of the injury to the skin.

[0019] This invention also provides a composition which comprises a modified antisense oligonucleotide consisting of 12-30 linked nucleosides, at least a 12 nucleobase sequence portion of which is complementary to nucleotides present within a region selected from nucleotides 1388-1423, 1394-1423 and 1399-1423 of SEQ ID NO: 9, or a salt or ester thereof, for use in treating a hypertrophic scar, or preventing the formation, reformation, or growth of a hypertrophic scar after an injury to the skin, in a subject in need thereof, wherein the composition is administered to the subject by one or more threading injections at the site of the hypertrophic scar or of the injury to the skin, in an amount effective to treat, or to prevent the formation, reformation, or growth of, the hypertrophic scar, wherein the effective amount is from 0.1 to 25 mg of the modified oligonucleotide per injection per linear centimeter of the hypertrophic scar or of the injury to the skin.

Brief Description of the Figures

[0020]

FIGURE 1 shows that 2'MOE containing antisense oligonucleotides diffuse over relatively short

distances (~0.5 - 1.0 cm) in rabbit skin when given by intradermal injection (described in Example 2).

FIGURE 2 shows that treatment of keloids in an animal model, with a CTGF antisense oligonucleotide resulted in reduction in both CTGF (**Figure 2A**) and Col3a1 (**Figure 2B**) mRNA expression in intact human keloid tissue transplanted into mice (described in Example 3).

FIGURE 3 shows that treatment with a CTGF antisense oligonucleotide, (EXC 001 or SEQ ID NO: 39) inhibits growth of both hypertrophic scars and keloids at 24 weeks post scar revision surgery in humans. The scores below each set of pictures represent the degree of improvement between placebo- and EXC 001-treated keloids. A negative score represents an improvement in scarring resulting from EXC 001 treatment. **FIGURE 3A** show placebo- and EXC 001-treated hypertrophic scars 24 weeks post scar revision surgery. **FIGURE 3B** show placebo- and EXC 001-treated keloid scars 24 weeks post scar revision surgery (described in Example 4).

FIGURE 4 shows that treatment with CTGF antisense oligonucleotide, (EXC 001 or SEQ ID NO: 39) inhibits the formation and growth of a hypertrophic scar 12 weeks post abdominoplasty surgery. The scores below the pictures represent the degree of improvement between placebo- and EXC 001-treated scar. A negative score represents an improvement in scarring resulting from EXC 001 treatment (described in Example 5).

FIGURE 5 shows the limited diffusion of EXC 001 when dosed adjacent to a scar (described in Example 5). The section of the abdominoplasty scar on the right side of the scar (to the right of the vertical line) was treated with EXC 001 whereas the scar to the left of the vertical line did not receive any treatment. Clearly the scar severity to the right is less than to the left. This example demonstrates that the EXC 001 therapeutic benefit is limited to the region of scar directly adjacent to the site of drug delivery by intradermal threading. Therefore the drug appears to have limited diffusion away from the site of administration and will require dosing immediately adjacent to and along the length of the potential scar site, for example by intradermal threading.

FIGURE 6 shows an example of the ability of EXC 001 to reduce the growth and formation of hypertrophic scars (described in Example 6). In this example, two matching 2cm abdominal scars are shown, one treated with 5mg/cm EXC 001 and one with placebo. The severity of the EXC 001 treated scar is less than the placebo treated scar. Histological analysis of these two scars also revealed an EXC 001 mediated reduction in the expression of CTGF protein (by immunohistochemistry) clearly demonstrating that EXC 001 is functioning to reduce the expression of its intended target (CTGF).

FIGURE 7 shows the effects of EXC 001 on mRNA expression in abdominal scars of various genes at various times post treatment (described in Example 6). **FIGURE 7A** shows the effect of EXC 001 in suppressing CTGF mRNA expression. **FIGURE 7B** shows the effect of EXC 001 in suppressing Collagen III- α 1 (Col3A1) mRNA expression. **FIGURE 7C** shows the effect of EXC 001 in suppressing elastin (ELASF) mRNA expression. **Figure 7D and E** shows there was no significant inhibition of either SMAD3 or TGF- β 1 mRNA expression by EXC 001 as compared to placebo.

Detailed Description of the Invention

[0021] This invention provides a composition which comprises a modified antisense oligonucleotide consisting of 12-30 linked nucleosides, at least a 12 nucleobase sequence portion of which is complementary to nucleotides present within a region selected from nucleotides 1388-1423, 1394-1423 and 1399-1423 of SEQ ID NO: 9, or a salt or ester thereof, for use in treating a keloid, or preventing the formation, reformation, or growth of a keloid after an injury to the skin, in a subject in need thereof, wherein the composition is administered to the subject by one or more threading injections at the site of the keloid or of the injury to the skin, in an amount effective to treat, or to prevent the formation, reformation, or growth of, the keloid, wherein the effective amount is from 0.1 to 50 mg of the modified oligonucleotide per injection per linear centimeter of the keloid or of the injury to the skin.

[0022] This invention also provides a composition which comprises a modified antisense oligonucleotide consisting of 12-30 linked nucleosides, at least a 12 nucleobase sequence portion of which is complementary to nucleotides present within a region selected from nucleotides 1388-1423, 1394-1423 and 1399-1423 of SEQ ID NO: 9, or a salt or ester thereof, for use in treating a hypertrophic scar, or preventing the formation, reformation, or growth of a hypertrophic scar after an injury to the skin, in a subject in need thereof, wherein the composition is administered to the subject by one or more threading injections at the site of the hypertrophic scar or of the injury to the skin, in an amount effective to treat, or to prevent the formation, reformation, or growth of, the hypertrophic scar, wherein the effective amount is from 0.1 to 25 mg of the modified oligonucleotide per injection per linear centimeter of the hypertrophic scar or of the injury to the skin.

[0023] The disclosure provides a method for treating a keloid, or preventing the formation, reformation, or growth of a keloid after an injury to the skin, in a subject in need thereof, which comprises administering to the subject by one or more injections at the site of the keloid or of the injury to the skin, a composition which comprises a modified oligonucleotide consisting of 12-30 linked nucleosides, at least a 12 nucleobase sequence portion of which is present within a region selected from nucleotides 553-611, 718-751, 1388-1423, 1457-1689, 2040-2069, 2120-2147, 2728-2797, 2267-2301, 1394-1423, 1469-1508, 1559-1605, 1659-1689, 2100-2129 and 1399-1423 of SEQ ID NO: 9, or a salt or ester thereof, in an amount effective to treat, or to prevent the formation, reformation, or growth of, the keloid, wherein the effective amount is from 0.1 to 50 mg of the modified oligonucleotide per injection per linear centimeter of the keloid or of the injury to the skin.

[0024] This disclosure also provides a method for treating a hypertrophic scar, or preventing the formation, reformation, or growth of a hypertrophic scar after an injury to the skin, in a subject in need thereof, which comprises administering to the subject by one or more injections at the site of the hypertrophic scar or of the injury to the skin, a composition which comprises a modified oligonucleotide consisting of 12-30 linked nucleosides, at least a 12 nucleobase sequence portion of which is present within a region selected from nucleotides 553-611, 718-751, 1388-1423, 1457-1689, 2040-2069, 2120-2147, 2728-2797, 2267-2301, 1394-1423, 1469-1508, 1559-1605,

1659-1689, 2100-2129 and 1399-1423 of SEQ ID NO: 9, or a salt or ester thereof, in an amount effective to treat, or to prevent the formation, reformation, or growth of, the hypertrophic scar, wherein the effective amount is from 0.1 to 25 mg of the modified oligonucleotide per injection per linear centimeter of the hypertrophic scar or of the injury to the skin.

[0025] This disclosure further provides a method for reducing formation, reformation, or growth of a scar or keloid at a site of an injury to the skin, or of treating a pre-existing scar or keloid, in a subject in need thereof, which comprises administering to the subject by one or more threading injections at the site of the injury or of the pre-existing scar or keloid, a composition which comprises a modified oligonucleotide, or a salt or ester thereof, targeted to a nucleic acid encoding a protein involved in fibrosis in an amount effective to inhibit expression of the protein and thereby reduce scar or keloid formation, reformation, or growth at the site of the injury or of treat the pre-existing scar or keloid. This invention still further provides a method for reducing formation, reformation, or growth of a fibrotic lesion at a site of an injury, or of treating a pre-existing fibrotic lesion, in a subject in need thereof, which comprises administering to the subject by one or more threading injections at the site of the injury or of the pre-existing fibrotic lesion, a composition which comprises a modified oligonucleotide, or a salt or ester thereof, targeted to a nucleic acid encoding a protein involved in fibrosis in an amount effective to inhibit expression of the protein and thereby reduce formation, reformation, or growth of the fibrotic lesion at the site of the injury or to treat the pre-existing fibrotic lesion.

[0026] In one embodiment of the invention, the one or more threading injections comprise multiple intradermal threading injections per scar.

[0027] The protein involved in fibrosis may be connective tissue growth factor, transforming growth factor beta-1, mothers against decapentaplegic homolog-3, early growth response-1, monocyte chemotactic protein-1, a collagen, or an elastin. Examples of suitable collagens are Collagen 3A1, Collagen 1A2, and Collagen 1A1.

[0028] In certain embodiments of the invention, the effective amount is from 0.1 to 50 mg, e.g. 0.1 to 25 mg, of the modified oligonucleotide per injection per linear centimeter of the site of the injury to the skin or of the pre-existing scar.

[0029] In certain embodiments, the modified oligonucleotide is administered at least once every two weeks for at least four weeks, i.e. at least twice.

[0030] In other embodiments, the modified oligonucleotide is administered at least once every three weeks for at least six weeks, i.e. at least twice.

[0031] In still other embodiments, the modified oligonucleotide is administered at least once every four weeks for at least eight weeks. In yet other embodiments, the modified oligonucleotide is administered at least once every eight weeks for at least sixteen weeks.

[0032] It is currently contemplated that it may be preferable that the modified oligonucleotide is administered over a period of at least nine weeks, for example over a period of 26 weeks.

[0033] In certain embodiments, the modified oligonucleotide consists of 12-30 linked nucleosides, at least a 12 nucleobase sequence portion of which is present within a region selected from the group consisting of nucleotides 1388-1423, 1394-1423, and 1399-1423 of SEQ ID NO: 9.

[0034] In other instances of the disclosure, the modified oligonucleotide consists of 12-30 linked nucleosides, at least a 12 nucleobase sequence portion of which is present within a region selected from the group consisting of nucleotides 553-611, 718-751, 1457-1689, 2040-2069, 2120-2147, 2728-2797, 2267-2301, 1469-1508, 1559-1605, 1659-1689, and 2100-2129 of SEQ ID NO: 9.

[0035] In certain embodiments of the invention, at least a 12 nucleobase sequence portion of the modified oligonucleotide is present within the nucleobase sequence set forth in any of the sequences set forth in SEQ ID NO: 39, 40, or 166.

[0036] In certain embodiments, the modified oligonucleotide consists of at least 14, e.g. 20, linked nucleosides.

[0037] In certain embodiments, the modified oligonucleotide is a single-stranded oligonucleotide. In others, the modified oligonucleotide is a double-stranded oligonucleotide.

[0038] In still other embodiments, the modified oligonucleotide comprises at least one oligodeoxyribonucleotide or at least one oligoribonucleotide.


[0039] In certain embodiments, the modified oligonucleotide has a sequence which is 100% identical over its length to a portion of any one of the sequences set forth in SEQ ID NO: 39, 40, or 166.

[0040] In certain embodiments, the modified oligonucleotide comprises at least one modified internucleoside linkage, e.g. a phosphothioate internucleoside linkage, such that some or all of the internucleoside linkages may be phosphothioate internucleoside linkages.

[0041] In certain embodiments, at least one nucleoside in the modified oligonucleotide comprises a modified sugar, such as a bicyclic sugar. In some such embodiments, at least one of the modified sugar comprises a 2'-O-methoxyethyl.

[0042] In other embodiments, the modified oligonucleotide comprises at least one tetrahydropyran modified nucleoside wherein a tetrahydropyran ring replaces the furanose ring.

[0043] In some such embodiments, each of the at least one tetrahydropyran modified nucleoside has the structure:



wherein Bx is an optionally protected heterocyclic base moiety.

[0044] In certain embodiments, at least one nucleoside comprises a modified nucleobase, e.g. a modified deoxynucleoside, a ribonucleoside, or a 5'-methylcytosine.

[0045] In certain embodiments, the modified oligonucleotide comprises:

1. (a) a gap segment consisting of linked deoxynucleosides;
2. (b) a 5' wing segment consisting of linked modified nucleosides; and
3. (c) a 3' wing segment consisting of linked modified nucleosides;

wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment and wherein each modified nucleoside within each wing segment comprises a modified sugar.

[0046] In certain currently preferred embodiments, the modified oligonucleotide comprises:

1. (a) a gap segment consisting of thirteen linked deoxynucleosides;
2. (b) a 5' wing segment consisting of two linked modified nucleosides; and
3. (c) a 3' wing segment consisting of five linked modified nucleosides;

wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment, wherein each modified nucleoside within each wing segment comprises a 2'-O-methoxyethyl sugar; and wherein each internucleoside linkage is a phosphothioate linkage.

[0047] In certain embodiments, the sequence of the nucleobase is the sequences set forth in SEQ ID NO: 39.

[0048] In other embodiments, the sequence of the nucleobase is the sequences set forth in SEQ ID NO: 40.

[0049] In yet other embodiments, the sequence of the nucleobase is the sequences set forth in SEQ ID NO: 166.

[0050] In certain embodiments, the composition comprises the modified oligonucleotide or a salt thereof, and a pharmaceutically acceptable carrier or diluent.

[0051] In certain embodiments, the modified oligonucleotide directly or indirectly inhibits expression of collagen or elastin or both, so as to treat the keloid, prevent the formation, reformation, or growth of the keloid, treat the hypertrophic scar, prevent the formation, reformation, or growth of the hypertrophic scar, reduce scar formation at the site of the injury, treat the pre-existing scar, reduce formation of the fibrotic lesion at the site of the injury, or treat the pre-existing fibrotic lesion.

[0052] It is currently contemplated that the preceding embodiments further comprise administering to the subject a second compound.

[0053] In certain embodiments, the second compound may be an antisense compound targeting the same or a different sequence, and the modified oligonucleotide and the second compound

may be administered simultaneously or sequentially.

[0054] In certain embodiments, the modified oligonucleotide is present in a conjugate with a moiety which enhances uptake of the compound into, and/or increases residence time of the compound in, the subject, wherein the residence time is preferably 7 to 60 days. The conjugate moiety is polyethylene glycol, hyaluronic acid, cholesterol, adamantine acetic acid, 1-pyrene butyric acid, dihydrotestosterone, 1,3-Bis-O-(hexadecyl)glycerol, hexadecylglycerol, hexadecylamine, geranyloxyhexyl, palmitic acid, myristic acid, spermine, spermidine, folic acid, vitamin E, a carbohydrate cluster, a peptide (including antennapedia helix, HIV Tat fragments, integrin binding peptide), transportin, or porphyrin.

[0055] In certain embodiments, the modified oligonucleotide is administered in a delivery system which enhances uptake of the compound into, and/or increases residence time of the compound in, the subject, wherein the residence time is preferably 7 to 60 days. The delivery system comprises a cationic lipid, a liposome, a microparticle, a nanoparticle, a liquid formulation with suspended particles with or without drug in the solution for immediate release or with drug depot in particles (particularly PLGA and poly-Arg particles), a liquid formulation that gels after injections such as thermosetting/responsive liquids (e.g. pluronic gels), liquids that contain a polymer and drug in a biocompatible solvent that precipitate when the solvent is diluted by body fluids (e.g. atrigel), a gel, a semi-solid formulation such as hydrogel (with a matrix backing or as a spray solution), a powder to be sprinkled on during surgery, a resorbable suture, or a fast dissolving gel or polymer strip.

[0056] In certain embodiments, the modified oligonucleotide is administered to the subject following a surgical excision of the keloid, scar, or fibrotic lesion.

[0057] In certain embodiments, the injury to the skin is the result of a surgical incision, a biopsy, a skin piercing, a skin removal, a burn, or a wound.

[0058] In certain embodiments, the effective amount is about 5 mg of the modified oligonucleotide per injection per linear centimeter of the keloid, the hypertrophic scar, the injury to the skin, the site of the injury, the pre-existing scar, or the pre-existing fibrotic lesion.

[0059] In certain embodiments, the modified oligonucleotide is administered for up to 6 months. In other embodiments, the modified oligonucleotide is administered for up to 1 year.

[0060] In certain embodiments, the preceding embodiments further comprise administering to the subject another therapeutic agent which may be a steroid, a silicone wrap, TGF- β 3 (i.e. Juvista), collagenase (i.e. Xyflex), 17 β -estradiol (i.e. Zesteem), IL-10 (i.e. Prevascar), mannose 6-phosphate (i.e. Juvidex), a smooth muscle relaxant (i.e. AZX100, a 24-amino acid synthetic peptide), a stem cell therapy (i.e. GBT009), serum amyloid protein, antibodies targeting integrin α v β 6, CTGF, TGF β , or molecules that inhibit the activity of ALK-4 and/or ALK-5 (the TGF beta receptors), any inhibitor designed to block TNF activity (for example etanercept), occlusive dressings, compression therapy, cryosurgery, surgical excision, laser treatment, radiation therapy, interferon therapy, bleomycin, 5-fluorouracil, verapamil, imiquimod cream, one capable of

promoting wound healing, such as Dermagraft, Apligraf, PDGF (i.e. Regranex), electrical stimulation, "growth factors" as a category, dressings as a category, small intestinal submucosa (SIS), Promogran, hyperbaric oxygen, or combinations thereof.

[0061] In certain embodiments, the modified oligonucleotide is administered by means of a formulation, ultrasound, electroporation, iontophoresis or micro-needle.

[0062] In certain embodiments, the modified oligonucleotide is administered adjacent to the keloid, the hypertrophic scar, the injury to the skin, the site of the injury, the pre-existing scar, or the pre-existing fibrotic lesion.

[0063] In other embodiments, the modified oligonucleotide is administered along the entire length of the keloid, the hypertrophic scar, the injury to the skin, the site of the injury, the pre-existing scar, or the pre-existing fibrotic lesion.

[0064] In still other embodiments, the modified oligonucleotide is administered along each side of the keloid, the hypertrophic scar, the injury to the skin, the site of the injury, the pre-existing scar, or the pre-existing fibrotic lesion.

[0065] In yet other embodiments, the modified oligonucleotide is administered directly into the keloid, the hypertrophic scar, the injury to the skin, the site of the injury, the pre-existing scar, or the pre-existing fibrotic lesion.

[0066] In certain embodiments, the subject is genetically predisposed to formation of keloids or hypertrophic scars or both.

[0067] In certain embodiments, the modified oligonucleotide is administered intradermally.

[0068] In other embodiments, the modified oligonucleotide is administered intradermally by threading technique.

[0069] In still other embodiments, the modified oligonucleotide is administered sub-cutaneously.

[0070] This invention also provides a kit which comprises:

1. a. a device pre-filled with the composition comprising the modified oligonucleotide; and
2. b. instruction for uses.

[0071] In a certain instance of the disclosure the antisense oligonucleotide is complementary to a portion of the region of CTGF targeted by active oligonucleotides which stretches from target sites 1396 through 1424. This is the sequence space targeted by oligo 418899, 412295 and 412294/EXC 001 (SEQ ID NOs: 166, 40 and 39, respectively).

[0072] This invention also provides a modified oligonucleotide comprising at least 12, preferably

at least 14, linked nucleosides, the nucleobase sequence of which is a portion of one of the nucleobase sequences set forth in SEQ ID NOs: 39, 40, and 166.

[0073] The antisense compounds described herein can comprise an oligonucleotide having 12 to 30, 12 to 20, and preferably 14 to 20 linked nucleosides.

[0074] In one embodiment of the invention, the modified oligonucleotide is a single-stranded or a double-stranded oligonucleotide.

[0075] The present invention employs oligomeric compounds, particularly antisense oligonucleotides, for use in modulating the function of nucleic acid molecules encoding proteins involved in fibrosis, ultimately modulating the amount of protein produced. This is accomplished by providing antisense compounds which specifically hybridize with one or more nucleic acids encoding a protein involved in fibrosis. As used herein, the terms "target nucleic acid" and "nucleic acid encoding connective tissue growth factor" encompass DNA encoding a protein involved in fibrosis, RNA (including pre-mRNA and mRNA) transcribed from such DNA, and also cDNA derived from such RNA.

[0076] The specific hybridization of an oligomeric compound with its target nucleic acid interferes with the normal function of the nucleic acid. This modulation of function of a target nucleic acid by compounds which specifically hybridize to it is generally referred to as "antisense". The functions of DNA to be interfered with include replication and transcription. The functions of RNA to be interfered with include all vital functions such as, for example, translocation of the RNA to the site of protein translation, translation of protein from the RNA, splicing of the RNA to yield one or more mRNA species, and catalytic activity which may be engaged in or facilitated by the RNA. The overall effect of such interference with target nucleic acid function is modulation of the expression of connective tissue growth factor. In the context of the present invention, "modulation" means either an increase (stimulation) or a decrease (inhibition) in the expression of a gene. In the context of the present invention, inhibition is the preferred form of modulation of gene expression and mRNA is a preferred target.

Target Nucleic Acids, Target Regions and Nucleotide Sequences

[0077] It is preferred to target specific nucleic acids for antisense. "Targeting" an antisense compound to a particular nucleic acid, in the context of this invention, is a multistep process.

[0078] It is understood that the sequence set forth in each SEQ ID NO in the Examples contained herein is independent of any modification to a sugar moiety, an internucleoside linkage, or a nucleobase. As such, antisense compounds defined by a SEQ ID NO may comprise, independently, one or more modifications to a sugar moiety, an internucleoside linkage, or a nucleobase. Antisense compounds described by Isis Number (Isis No) indicate a combination of nucleobase sequence and motif.

[0079] In one embodiment, a target region is a structurally defined region of the nucleic acid. For

example, a target region may encompass a 3' UTR, a 5' UTR, an exon, an intron, a coding region, a translation initiation region, translation termination region, or other defined nucleic acid region. The structurally defined regions for the nucleic acid can be obtained by accession number from sequence databases such as NCBI. In other embodiments, a target region may encompass the sequence from a 5' target site of one target segment within the target region to a 3' target site of another target segment within the target region.

[0080] Targeting includes determination of at least one target segment to which an antisense compound hybridizes, such that a desired effect occurs. In certain embodiments, the desired effect is a reduction in mRNA target nucleic acid levels. In other embodiments, the desired effect is reduction of levels of protein encoded by the target nucleic acid or a phenotypic change associated with the target nucleic acid.

[0081] A target region may contain one or more target segments. Multiple target segments within a target region may be overlapping. Alternatively, they may be non-overlapping. In one embodiment, target segments within a target region are separated by no more than about 300 nucleotides. In other embodiments, target segments within a target region are separated by no more than about, 250, 200, 150, 100, 90, 80, 70, 60, 50, 40, 30, 20, or 10 nucleotides on the target nucleic acid. In another embodiment, target segments within a target region are separated by no more than about 5 nucleotides on the target nucleic acid. In additional embodiments, target segments are contiguous.

[0082] Suitable target segments may be found within a 5' UTR, a coding region, a 3' UTR, an intron, or an exon. Target segments containing a start codon or a stop codon are also suitable target segments. A suitable target segment may specifically exclude a certain structurally defined region such as the start codon or stop codon.

[0083] The determination of suitable target segments may include a comparison of the sequence of a target nucleic acid to other sequences throughout the genome. For example, the BLAST algorithm may be used to identify regions of similarity amongst different nucleic acids. This comparison can prevent the selection of antisense compound sequences that may hybridize in a non-specific manner to sequences other than a selected target nucleic acid (i.e., non-target or off-target sequences).

[0084] There may be variation in activity (e.g., as defined by percent reduction of target nucleic acid levels) of the antisense compounds within an active target region. In one embodiment, reductions in CTGF mRNA levels are indicative of inhibition of CTGF expression. Reductions in levels of a CTGF protein are also indicative of inhibition of target mRNA expression. Further, phenotypic changes are indicative of inhibition of CTGF expression.

Antisense Compounds

[0085] In the context of this invention, the term "oligonucleotide" refers to an oligomer or polymer of ribonucleic acid (RNA) or deoxyribonucleic acid (DNA) or mimetics thereof. This term includes

oligonucleotides composed of naturally-occurring nucleobases, sugars and covalent internucleoside (backbone) linkages as well as oligonucleotides having non-naturally-occurring portions which function similarly. Such modified or substituted oligonucleotides are often preferred over native forms because of desirable properties such as, for example, enhanced cellular uptake, enhanced affinity for nucleic acid target and increased stability in the presence of nucleases.

[0086] While antisense oligonucleotides are a preferred form of antisense compound, the present invention comprehends other oligomeric antisense compounds, including but not limited to oligonucleotide mimetics.

[0087] Antisense compound means an oligomeric compound capable of undergoing hybridization to a target nucleic acid through hydrogen bonding. Antisense compounds include, but are not limited to oligonucleotides, oligonucleosides, oligonucleotide analogs, oligonucleotide mimetics, antisense oligonucleotides, siRNA, RNAi, ribozymes, external guide sequence (EGS) oligonucleotides (oligozymes), and other oligonucleotides which hybridize to the target nucleic acid and modulate its expression.

[0088] In certain embodiments, an antisense compound has a nucleobase sequence that, when written in the 5' to 3' direction, comprises the reverse complement of the target segment of a target nucleic acid to which it is targeted. In certain such embodiments, an antisense oligonucleotide has a nucleobase sequence that, when written in the 5' to 3' direction, comprises the reverse complement of the target segment of a target nucleic acid to which it is targeted.

[0089] In certain embodiments, an antisense compound targeted to a nucleic acid is 12 to 30 subunits in length. In other words, antisense compounds are from 12 to 30 linked subunits. In other embodiments, the antisense compound is 8 to 80, 12 to 50, 15 to 30, 18 to 24, 19 to 22, or 20 linked subunits. In certain such embodiments, the antisense compounds are 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, or 80 linked subunits in length, or a range defined by any two of the above values. In some embodiments the antisense compound is an antisense oligonucleotide, and the linked subunits are nucleotides.

[0090] In one preferred embodiment of the invention, the compound comprises 20 or at least 14 linked nucleosides, wherein the modified oligonucleotide has a sequence which is 100% identical to one of the sequences set forth in SEQ ID NOs: 39, 40, and 166. In another preferred embodiment, the lead compound of interest has the sequence set forth in SEQ ID No: 39 (ISIS 412294).

[0091] In certain embodiments, a shortened or truncated antisense compound targeted to a nucleic acid has a single subunit deleted from the 5' end (5' truncation), or alternatively from the 3' end (3' truncation). A shortened or truncated antisense compound targeted to a nucleic acid may have two subunits deleted from the 5' end, or alternatively may have two subunits deleted from the 3' end, of the antisense compound. Alternatively, the deleted nucleosides may be

dispersed throughout the antisense compound, for example, in an antisense compound having one nucleoside deleted from the 5' end and one nucleoside deleted from the 3' end.

[0092] When a single additional subunit is present in a lengthened antisense compound, the additional subunit may be located at the 5' or 3' end of the antisense compound. When two or more additional subunits are present, the added subunits may be adjacent to each other, for example, in an antisense compound having two subunits added to the 5' end (5' addition), or alternatively to the 3' end (3' addition), of the antisense compound. Alternatively, the added subunits may be dispersed throughout the antisense compound, for example, in an antisense compound having one subunit added to the 5' end and one subunit added to the 3' end.

[0093] It is possible to increase or decrease the length of an antisense compound, such as an antisense oligonucleotide, and/or introduce mismatch bases without eliminating activity. For example, in Woolf et al. (Proc. Natl. Acad. Sci. USA 89:7305-7309, 1992), a series of antisense oligonucleotides 13-25 nucleobases in length were tested for their ability to induce cleavage of a target RNA in an oocyte injection model. Antisense oligonucleotides 25 nucleobases in length with 8 or 11 mismatch bases near the ends of the antisense oligonucleotides were able to direct specific cleavage of the target mRNA, albeit to a lesser extent than the antisense oligonucleotides that contained no mismatches. Similarly, target specific cleavage was achieved using 13 nucleobase antisense oligonucleotides, including those with 1 or 3 mismatches.

[0094] Gautschi et al (J. Natl. Cancer Inst. 93:463-471, March 2001) demonstrated the ability of an oligonucleotide having 100% complementarity to the bcl-2 mRNA and having 3 mismatches to the bcl-xL mRNA to reduce the expression of both bcl-2 and bcl-xL in vitro and in vivo. Furthermore, this oligonucleotide demonstrated potent anti-tumor activity in vivo.

[0095] Maher and Dolnick (Nuc. Acid. Res. 16:3341-3358, 1988) tested a series of tandem 14 nucleobase antisense oligonucleotides, and a 28 and 42 nucleobase antisense oligonucleotides comprised of the sequence of two or three of the tandem antisense oligonucleotides, respectively, for their ability to arrest translation of human DHFR in a rabbit reticulocyte assay. Each of the three 14 nucleobase antisense oligonucleotides alone was able to inhibit translation, albeit at a more modest level than the 28 or 42 nucleobase antisense oligonucleotides.

[0096] Bhanot et al. (PCT/US2007/068401) provided short antisense compounds, including compounds comprising chemically-modified high-affinity monomers 8 to 16 monomers in length. These short antisense compounds were shown to be useful for reducing target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Short antisense compounds were effective at lower doses than previously described antisense compounds, allowing for a reduction in toxicity and cost of treatment. In addition, the described short antisense compounds have greater potential for oral dosing.

Hybridizations

[0097] Once one or more target sites have been identified, oligonucleotides are chosen which are

sufficiently complementary to the target, i.e., hybridize sufficiently well and with sufficient specificity, to give the desired effect.

[0098] In the context of this invention, "hybridization" means hydrogen bonding, which may be Watson-Crick, Hoogsteen or reversed Hoogsteen hydrogen bonding, between complementary nucleoside or nucleotide bases. For example, adenine and thymine are complementary nucleobases which pair through the formation of hydrogen bonds.

Identity

[0099] The antisense compounds provided herein may also have a defined percent identity to a particular nucleotide sequence, SEQ ID NO, or compound represented by a specific oligo (Isis) number. As used herein, an antisense compound is identical to the sequence disclosed herein if it has the same nucleobase pairing ability. For example, a RNA which contains uracil in place of thymidine in a disclosed DNA sequence would be considered identical to the DNA sequence since both uracil and thymidine pair with adenine. Shortened and lengthened versions of the antisense compounds described herein as well as compounds having non-identical bases relative to the antisense compounds provided herein also are contemplated. The non-identical bases may be adjacent to each other or dispersed throughout the antisense compound. Percent identity of an antisense compound is calculated according to the number of bases that have identical base pairing relative to the sequence to which it is being compared.

[0100] In one embodiment, the antisense compounds are at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to one or more of the antisense compounds or SEQ ID NOs, or a portion thereof, disclosed herein.

Modifications

[0101] In a certain embodiment of the invention, modifications to antisense compounds encompass substitutions or changes to internucleoside linkages, sugar moieties, or nucleobases.

[0102] In one embodiment of the invention the compound comprises at least one modification selected from the group consisting of a modified internucleoside linkage, a modified sugar, and a modified nucleobase.

[0103] Although antisense oligonucleotides containing a variety of modified internucleoside linkages may be employed, the currently preferred modified internucleoside linkage is a phosphothioate linkage between one or more of the nucleosides or wherein all of the internucleoside linkages are phosphothioate internucleoside linkages.

[0104] In general, it is also preferred that the antisense oligonucleotide contains at least one and typically more than one modified sugar, wherein the sugar is a bicyclic sugar. Although various modified sugars may be employed it is presently preferred to employ a 2'-O-methoxyethyl sugar.

[0105] Further, at least one and typically more than one of the nucleobases contained in the antisense oligonucleotide will be a modified nucleotide such as a 5-methylcytosine.

[0106] A nucleoside is a base-sugar combination. The nucleobase (also known as base) portion of the nucleoside is normally a heterocyclic base moiety. Nucleotides are nucleosides that further include a phosphate group covalently linked to the sugar portion of the nucleoside. For those nucleosides that include a pentofuranosyl sugar, the phosphate group can be linked to the 2', 3' or 5' hydroxyl moiety of the sugar. Oligonucleotides are formed through the covalent linkage of adjacent nucleosides to one another, to form a linear polymeric oligonucleotide. Within the oligonucleotide structure, the phosphate groups are commonly referred to as forming the internucleoside linkages of the oligonucleotide.

[0107] Modifications to antisense compounds encompass substitutions or changes to internucleoside linkages, sugar moieties, or nucleobases. Modified antisense compounds are often preferred over native forms because of desirable properties such as, for example, enhanced cellular uptake, enhanced affinity for nucleic acid target, increased stability in the presence of nucleases, or increased inhibitory activity.

[0108] Chemically modified nucleosides may also be employed to increase the binding affinity of a shortened or truncated antisense oligonucleotide for its target nucleic acid. Consequently, comparable results can often be obtained with shorter antisense compounds that have such chemically modified nucleosides.

Modified Internucleotide Linkages

[0109] The naturally occurring internucleoside linkage of RNA and DNA is a 3' to 5' phosphodiester linkage. Antisense compounds having one or more modified, i.e. non-naturally occurring, internucleoside linkages are often selected over antisense compounds having naturally occurring internucleoside linkages because of desirable properties such as, for example, enhanced cellular uptake, enhanced affinity for target nucleic acids, and increased stability in the presence of nucleases.

[0110] Oligonucleotides having modified internucleoside linkages include internucleoside linkages that retain a phosphorus atom as well as internucleoside linkages that do not have a phosphorus atom. Representative phosphorus containing internucleoside linkages include, but are not limited to, phosphodiesters, phosphotriesters, methylphosphonates, phosphoramidate, and phosphorothioates. Methods of preparation of phosphorous-containing and non-phosphorous-containing linkages are well known.

[0111] In one embodiment, antisense compounds targeted to a CTGF nucleic acid comprise one or more modified internucleoside linkages. In some embodiments, the modified internucleoside linkages are phosphorothioate linkages. In other embodiments, each internucleoside linkage of an antisense compound is a phosphorothioate internucleoside linkage.

[0112] As is known in the art, a nucleoside is a base-sugar combination. The base portion of the nucleoside is normally a heterocyclic base. The two most common classes of such heterocyclic bases are the purines and the pyrimidines. Nucleotides are nucleosides that further include a phosphate group covalently linked to the sugar portion of the nucleoside. For those nucleosides that include a pentofuranosyl sugar, the phosphate group can be linked to either the 2', 3' or 5' hydroxyl moiety of the sugar. In forming oligonucleotides, the phosphate groups covalently link adjacent nucleosides to one another to form a linear polymeric compound. In turn the respective ends of this linear polymeric structure can be further joined to form a circular structure, however, open linear structures are generally preferred. Within the oligonucleotide structure, the phosphate groups are commonly referred to as forming the internucleoside backbone of the oligonucleotide. The normal linkage or backbone of RNA and DNA is a 3' to 5' phosphodiester linkage.

[0113] Specific examples of preferred antisense compounds useful in this invention include oligonucleotides containing modified backbones or non-natural internucleoside linkages. As defined in this specification, oligonucleotides having modified backbones include those that retain a phosphorus atom in the backbone and those that do not have a phosphorus atom in the backbone. For the purposes of this specification, and as sometimes referenced in the art, modified oligonucleotides that do not have a phosphorus atom in their internucleoside backbone can also be considered to be oligonucleosides.

[0114] Preferred modified oligonucleotide backbones include, for example, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkylphosphotriesters, methyl and other alkyl phosphonates including 3'-alkylene phosphonates, 5'-alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates including 3'-amino phosphoramidate and aminoalkylphosphoramidates, thiono-phosphoramidates, thionoalkylphosphonates, thionoalkylphospho-triesters, selenophosphates and boranophosphates having normal 3'-5' linkages, 2'-5' linked analogs of these, and those having inverted polarity wherein one or more internucleotide linkages is a 3' to 3', 5' to 5' or 2' to 2' linkage. Preferred oligonucleotides having inverted polarity comprise a single 3' to 3' linkage at the 3'-most internucleotide linkage i.e. a single inverted nucleoside residue which may be abasic (the nucleobase is missing or has a hydroxyl group in place thereof). Various salts, mixed salts and free acid forms are also included.

[0115] Representative United States patents that teach the preparation of the above phosphorus-containing linkages include, but are not limited to, U.S. Pat. Nos.: 3,687,808; 4,469,863; 4,476,301; 5,023,243; 5,177,196; 5,188,897; 5,264,423; 5,276,019; 5,278,302; 5,286,717; 5,321,131; 5,399,676; 5,405,939; 5,453,496; 5,455,233; 5,466,677; 5,476,925; 5,519,126; 5,536,821; 5,541,306; 5,550,111; 5,563,253; 5,571,799; 5,587,361; 5,194,599; 5,565,555; 5,527,899; 5,721,218; 5,672,697 and 5,625,050, certain of which are commonly owned with this application.

[0116] Preferred modified oligonucleotide backbones that do not include a phosphorus atom therein have backbones that are formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatom and alkyl or cycloalkyl internucleoside linkages, or one or more short

chain heteroatomic or heterocyclic internucleoside linkages. These include those having morpholino linkages (formed in part from the sugar portion of a nucleoside); siloxane backbones; sulfide, sulfoxide and sulfone backbones; formacetyl and thioformacetyl backbones; methylene formacetyl and thioformacetyl backbones; riboacetyl backbones; alkene containing backbones; sulfamate backbones; methyleneimino and methylenehydrazino backbones; sulfonate and sulfonamide backbones; amide backbones; and others having mixed N, O, S and CH₂ component parts.

[0117] Representative United States patents that teach the preparation of the above oligonucleosides include, but are not limited to, U.S. Pat. Nos.: 5,034,506; 5,166,315; 5,185,444; 5,214,134; 5,216,141; 5,235,033; 5,264,562; 5,264,564; 5,405,938; 5,434,257; 5,466,677; 5,470,967; 5,489,677; 5,541,307; 5,561,225; 5,596,086; 5,602,240; 5,610,289; 5,602,240; 5,608,046; 5,610,289; 5,618,704; 5,623,070; 5,663,312; 5,633,360; 5,677,437; 5,792,608; 5,646,269 and 5,677,439, certain of which are commonly owned with this application.

[0118] In other preferred oligonucleotide mimetics, both the sugar and the internucleoside linkage, i.e., the backbone, of the nucleotide units are replaced with novel groups. The base units are maintained for hybridization with an appropriate nucleic acid target compound. One such oligomeric compound, an oligonucleotide mimetic that has been shown to have excellent hybridization properties, is referred to as a peptide nucleic acid (PNA). In PNA compounds, the sugar-backbone of an oligonucleotide is replaced with an amide containing backbone, in particular an aminoethylglycine backbone. The nucleobases are retained and are bound directly or indirectly to aza nitrogen atoms of the amide portion of the backbone. Representative United States patents that teach the preparation of PNA compounds include, but are not limited to, U.S. Pat. Nos.: 5,539,082; 5,714,331; and 5,719,262. Further teaching of PNA compounds can be found in Nielsen et al., Science, 1991, 254, 1497-1500.

[0119] Most preferred embodiments of the invention are oligonucleotides with phosphorothioate backbones and oligonucleosides with heteroatom backbones, and in particular -CH₂-NH-O-CH₂-, -CH₂-N(CH₃)-O-CH₂- [known as a methylene (methylimino) or MMI backbone], -CH₂-O-N(CH₃)-CH₂-, -CH₂-N(CH₃)-N(CH₃)-CH₂- and -O-N(CH₃)-CH₂-CH₂- [wherein the native phosphodiester backbone is represented as -O-P-O-CH₂-] of the above referenced U.S. Pat. No. 5,489,677, and the amide backbones of the above referenced U.S. Pat. No. 5,602,240. Also preferred are oligonucleotides having morpholino backbone structures of the above-referenced U.S. Pat. No. 5,034,506.

Modified Sugar Moieties

[0120] Modified oligonucleotides may also contain one or more substituted sugar moieties. For example, the furanosyl sugar ring can be modified in a number of ways including substitution with a substituent group, bridging to form a bicyclic nucleic acid "BNA" and substitution of the 4'-O with a heteroatom such as S or N(R) as described in U.S. Pat. No.: 7,399,845 to Seth et al. Other examples of BNAs are described in published International Patent Application No. WO

2007/146511.

[0121] Antisense compounds of the invention can optionally contain one or more nucleotides having modified sugar moieties. Sugar modifications may impart nuclease stability, binding affinity or some other beneficial biological property to the antisense compounds. The furanosyl sugar ring of a nucleoside can be modified in a number of ways including, but not limited to: addition of a substituent group, particularly at the 2' position; bridging of two non-geminal ring atoms to form a bicyclic nucleic acid (BNA); and substitution of an atom or group such as -S-, -N(R)- or -C(R1)(R2) for the ring oxygen at the 4'-position. Modified sugars include, but are not limited to: substituted sugars, especially 2'-substituted sugars having a 2'-F, 2'-OCH₂ (2'-OMe) or a 2'-O(CH₂)₂-OCH₃ (2'-O-methoxyethyl or 2'-MOE) substituent group; and bicyclic modified sugars (BNAs), having a 4'-(CH₂)_n-O-2' bridge, where n=1 or n=2. Methods for the preparations of modified sugars are well known to those skilled in the art.

[0122] In certain embodiments, a 2'-modified nucleoside has a bicyclic sugar moiety. In certain such embodiments, the bicyclic sugar moiety is a D sugar in the alpha configuration. In certain such embodiments, the bicyclic sugar moiety is a D sugar in the beta configuration. In certain such embodiments, the bicyclic sugar moiety is an L sugar in the alpha configuration. In certain such embodiments, the bicyclic sugar moiety is an L sugar in the beta configuration.

[0123] In certain embodiments, the bicyclic sugar moiety comprises a bridge group between the 2' and the 4'-carbon atoms. In certain such embodiments, the bridge group comprises from 1 to 8 linked biradical groups. In certain embodiments, the bicyclic sugar moiety comprises from 1 to 4 linked biradical groups. In certain embodiments, the bicyclic sugar moiety comprises 2 or 3 linked biradical groups. In certain embodiments, the bicyclic sugar moiety comprises 2 linked biradical groups. In certain embodiments, a linked biradical group is selected from -O-, -S-, -N(R1)-, -C(R1)(R2)-, -C(R1)=C(R1)-, -C(R1)=N-, -C(=NR1)-, -Si(R1)(R2)-, -S(=O)₂-, -S(=O)-, -C(=O)- and -C(=S)-; where each R1 and R2 is, independently, H, hydroxyl, C1-C12 alkyl, substituted C1-C12 alkyl, C2-C12 alkenyl, substituted C2-C12 alkenyl, C2-C12 alkynyl, substituted C2-C12 alkynyl, C5-C20 aryl, substituted C5-C20 aryl, a heterocycle radical, a substituted hetero-cycle radical, heteroaryl, substituted heteroaryl, C5-C7 alicyclic radical, substituted C5-C7 alicyclic radical, halogen, substituted oxy (-O-), amino, substituted amino, azido, carboxyl, substituted carboxyl, acyl, substituted acyl, CN, thiol, substituted thiol, sulfonyl (S(=O)₂-H), substituted sulfonyl, sulfoxyl (S(=O)-H) or substituted sulfoxyl; and each substituent group is, independently, halogen, C1-C12 alkyl, substituted C1-C12 alkyl, C2-C12 alkenyl, substituted C2-C12 alkenyl, C2-C12 alkynyl, substituted C2-C12 alkynyl, amino, substituted amino, acyl, substituted acyl, C1-C12 aminoalkyl, C1-C12 aminoalkoxy, substituted C1-C12 aminoalkyl, substituted C1-C12 aminoalkoxy or a protecting group.

[0124] In some embodiments, the bicyclic sugar moiety is bridged between the 2' and 4' carbon atoms with a biradical group selected from -O-(CH₂)_p-, -O-CH₂-, -O-CH₂CH₂-, -O-CH(alkyl)-, -NH-(CH₂)_p-, -N(alkyl)-(CH₂)_p-, -O-CH(alkyl)-, -(CH(alkyl))-(CH₂)_p-, -NH-O-(CH₂)_p-, -N(alkyl)-O-(CH₂)_p-, or -O-N(alkyl)-(CH₂)_p-, wherein p is 1, 2, 3, 4 or 5 and each alkyl group can be further substituted. In certain embodiments, p is 1, 2 or 3.

[0125] In one aspect, each of said bridges is, independently, $-\text{C}(\text{R}1)(\text{R}2)]_n-$, $-\text{C}(\text{R}1)(\text{R}2)]_n\text{-O-}$, $-\text{C}(\text{R}1\text{R}2)\text{-N}(\text{R}1)\text{-O-}$ or $-\text{C}(\text{R}1\text{R}2)\text{-O-N}(\text{R}1)-$. In another aspect, each of said bridges is, independently, 4'-(CH_2)₃-2', 4'-(CH_2)₂-2', 4'- $\text{CH}_2\text{-O-2'}$, 4'-(CH_2)₂-O-2', 4'- $\text{CH}_2\text{-O-N}(\text{R}1)\text{-2'}$ and 4'- $\text{CH}_2\text{-N}(\text{R}1)\text{-O-2'}$ wherein each R1 is, independently, H, a protecting group or C1-C12 alkyl.

[0126] In nucleotides having modified sugar moieties, the nucleobase moieties (natural, modified or a combination thereof) are maintained for hybridization with an appropriate nucleic acid target.

[0127] In one embodiment, antisense compounds targeted to a nucleic acid comprise one or more nucleotides having modified sugar moieties.


[0128] In a preferred embodiment, the modified sugar moiety is 2'-MOE. In other embodiments, the 2'-MOE modified nucleotides are arranged in a gapmer motif.

[0129] Currently preferred oligonucleotides comprise one of the following at the 2' position: OH; F; O-, S-, or N-alkyl; O-, S-, or N-alkenyl; O-, S- or N-alkynyl; or O-alkyl-O-alkyl, wherein the alkyl, alkenyl and alkynyl may be substituted or unsubstituted C₁ to C₁₀ alkyl or C₂ to C₁₀ alkenyl and alkynyl. Particularly preferred are $\text{O}[(\text{CH}_2)_n\text{O}]_m\text{CH}_3$, $\text{O}(\text{CH}_2)_n\text{OCH}_3$, $\text{O}(\text{CH}_2)_n\text{NH}_2$, $\text{O}(\text{CH}_2)_n\text{CH}_3$, $\text{O}(\text{CH}_2)_n\text{ONH}_2$, and $\text{O}(\text{CH}_2)_n\text{ON}[(\text{CH}_2)_n\text{CH}_3]_2$, where n and m are from 1 to about 10. Other preferred oligonucleotides comprise one of the following at the 2' position: C₁ to C₁₀ lower alkyl, substituted lower alkyl, alkenyl, alkynyl, alkaryl, aralkyl, O-alkaryl or O-aralkyl, SH, SCH₃, OCN, Cl, Br, CN, CF₃, OCF₃, SOCH₃, SO₂CH₃, ONO₂, NO₂, N₃, NH₂, heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, an RNA cleaving group, a reporter group, an intercalator, a group for improving the pharmacokinetic properties of an oligonucleotide, or a group for improving the pharmacodynamic properties of an oligonucleotide, and other substituents having similar properties. A preferred modification includes 2'-methoxyethoxy (2'-O-CH₂CH₂OCH₃, also known as 2'-O-(2-methoxyethyl) or 2'-MOE) (Martin et al., *Helv. Chim. Acta*, 1995, 78, 486-504) i.e., an alkoxyalkoxy group. A further preferred modification includes 2'-dimethylaminoethoxyethoxy, i.e., a $\text{O}(\text{CH}_2)_2\text{ON}(\text{CH}_3)_2$ group, also known as 2'-DMAOE, and 2'-dimethylaminoethoxyethoxy (also known in the art as 2'-O-dimethylaminoethoxyethyl or 2'-DMAEOE), i.e., 2'-O--CH₂--O--CH₂-N(CH₂)₂. A further preferred modification includes bicyclic nucleic acid (also referred to as locked nucleic acids (LNAs)) in which the 2'-hydroxyl group is linked to the 3' or 4' carbon atom of the sugar ring thereby forming a bicyclic sugar moiety. The linkage is preferably a methylene (--CH₂--)_n group bridging the 2' oxygen atom and the 4' carbon atom wherein n is 1 or 2 including α-L-Methyleneoxy (4'-CH₂-O-2') BNA, β-D-Methyleneoxy (4'-CH₂-O-2') BNA and Ethyleneoxy (4'-(CH₂)₂-O-2') BNA. Bicyclic modified sugars also include (6'S)-6'methyl BNA, Aminooxy (4'-CH₂-O-N(R)-2') BNA, Oxyamino (4'-CH₂-N(R)-O-2') BNA wherein, R is, independently, H, a protecting group, or C1-C12 alkyl. LNAs also form duplexes with complementary DNA, RNA or LNA with high thermal affinities. Circular dichroism (CD) spectra show that duplexes involving fully modified LNA (esp. LNA:RNA) structurally resemble an A-form RNA:RNA duplex. Nuclear magnetic resonance (NMR) examination of an LNA:DNA duplex confirmed the 3'-endo conformation of an LNA monomer. Recognition of double-stranded DNA has also been demonstrated suggesting strand invasion by LNA. Studies of mismatched

sequences show that LNAs obey the Watson-Crick base pairing rules with generally improved selectivity compared to the corresponding unmodified reference strands.

[0130] LNAs in which the 2'-hydroxyl group is linked to the 4' carbon atom of the sugar ring thereby forming a 2'-C,4'-C-oxymethylene linkage thereby forming a bicyclic sugar moiety. The linkage may be a methylene ($-\text{CH}_2-$)_n group bridging the 2' oxygen atom and the 4' carbon atom wherein n is 1 or 2 (Singh et al., Chem. Commun., 1998, 4, 455-456). LNA and LNA analogs display very high duplex thermal stabilities with complementary DNA and RNA (T_m =+3 to +10 °C), stability towards 3'-exonucleolytic degradation and good solubility properties. Other preferred bridge groups include the 2'-deoxy-2'- CH_2OCH_2 -4' bridge. LNAs and preparation thereof are described in published International Patent Application Nos. WO 98/39352 and WO 99/14226.


[0131] Other preferred modifications include 2'-methoxy (2'-O- CH_3), 2'-aminopropoxy (2'- $\text{OCH}_2\text{CH}_2\text{CH}_2\text{NH}_2$), 2'-allyl (2'- $\text{CH}_2\text{-CH=CH}_2$), 2'-O-allyl (2'-O- $\text{CH}_2\text{-CH=CH}_2$) and 2'-fluoro (2'-F). The 2'-modification may be in the arabino (up) position or ribo (down) position. A preferred 2'-arabino modification is 2'-F. Similar modifications may also be made at other positions on the oligonucleotide, particularly the 3' position of the sugar on the 3' terminal nucleotide or in 2'-5' linked oligonucleotides and the 5' position of 5' terminal nucleotide. Oligonucleotides may also have sugar mimetics or surrogates (sometimes referred to as DNA analogs) such as cyclobutyl moieties in place of the pentofuranosyl sugar. Representative United States patents that teach the preparation of such modified sugar structures include, but are not limited to, U.S. Pat. Nos.: 4,981,957; 5,118,800; 5,319,080; 5,359,044; 5,393,878; 5,446,137; 5,466,786; 5,514,785; 5,519,134; 5,567,811; 5,576,427; 5,591,722; 5,597,909; 5,610,300; 5,627,053; 5,639,873; 5,646,265; 5,658,873; 5,670,633; 5,792,747; and 5,700,920, certain of which are commonly owned with the instant application. In certain embodiments, nucleosides are modified by replacement of the ribosyl ring with a surrogate ring system such as a morpholino ring, a cyclohexenyl ring, a cyclohexyl ring or a tetrahydropyranyl ring such as one having one of the formulae:




[0132] Many other bicyclo and tricyclo sugar surrogate ring systems are also known in the art that can be used to modify nucleosides for incorporation into antisense compounds (see for example review article: Leumann, Christian J.). Such ring systems can undergo various additional substitutions to enhance activity.

[0133] In one embodiment of the invention, the compound comprising at least one tetrahydropyran modified nucleoside wherein a tetrahydropyran ring replaces the furanose ring.

[0134] In another embodiment of the invention, wherein each of the at least one tetrahydropyran modified nucleoside has the structure:





wherein Bx is an optionally protected heterocyclic base moiety.

Modified Nucleobases

[0135] Oligonucleotides may also include nucleobase (often referred to in the art simply as "base") modifications or substitutions. Nucleobase modifications or substitutions are structurally distinguishable from, yet functionally interchangeable with, naturally occurring or synthetic unmodified nucleobases. Both natural and modified nucleobases are capable of participating in hydrogen bonding. Such nucleobase modifications may impart nuclease stability, binding affinity or some other beneficial biological property to antisense compounds. Modified nucleobases include synthetic and natural nucleobases such as, for example, 5-methylcytosine (5-me-C). Certain nucleobase substitutions, including 5-methylcytosine substitutions, are particularly useful for increasing the binding affinity of an antisense compound for a target nucleic acid. For example, 5-methylcytosine substitutions have been shown to increase nucleic acid duplex stability by 0.6-1.2°C (Sanghvi, Y.S., Crooke, S.T. and Lebleu, B., eds., *Antisense Research and Applications*, CRC Press, Boca Raton, 1993, pp. 276-278).

[0136] Additional unmodified nucleobases include 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyl ($-C\equiv C-CH_3$) uracil and cytosine and other alkynyl derivatives of pyrimidine bases, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl and other 8-substituted adenines and guanines, 5-halo particularly 5-bromo, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine and 7-methyladenine, 2-F-adenine, 2-amino-adenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine and 7-deazaadenine and 3-deazaguanine and 3-deazaadenine.

[0137] Heterocyclic base moieties may also include those in which the purine or pyrimidine base is replaced with other heterocycles, for example 7-deaza-adenine, 7-deazaguanosine, 2-aminopyridine and 2-pyridone. Nucleobases that are particularly useful for increasing the binding affinity of antisense compounds include 5-substituted pyrimidines, 6-azapyrimidines and N-2, N-6 and O-6 substituted purines, including 2 aminopropyladenine, 5-propynyluracil and 5-propynylcytosine.

[0138] In one embodiment, antisense compounds targeted to a CTGF nucleic acid comprise one or more modified nucleobases. In an additional embodiment, gap-widened antisense oligonucleotides targeted to a CTGF nucleic acid comprise one or more modified nucleobases. In some embodiments, the modified nucleobase is 5-methylcytosine. In further embodiments, each cytosine is a 5-methylcytosine.

[0139] As used herein, "unmodified" or "natural" nucleobases include the purine bases adenine

(A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C) and uracil (U). Modified nucleobases include other synthetic and natural nucleobases such as 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyl ($-C\equiv C-CH_3$) uracil and cytosine and other alkynyl derivatives of pyrimidine bases, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl and other 8-substituted adenines and guanines, 5-halo particularly 5-bromo, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine and 7-methyladenine, 2-F-adenine, 2-amino-adenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine and 7-deazaadenine and 3-deazaguanine and 3-deazaadenine. Further modified nucleobases include tricyclic pyrimidines such as phenoxazine cytidine (1H-pyrimido[5,4-b][1,4]benzoxazin-2(3H)-one), phenothiazine cytidine (1H-pyrimido[5,4-b][1,4]benzothiazin-2(3H)-one), G-clamps such as a substituted phenoxazine cytidine (e.g. 9-(2-aminoethoxy)-H-pyrimido[5,4-b][1,4]benzoxazin-2(3H)-one), carbazole cytidine (2H-pyrimido[4,5-b]indol-2-one), pyridoindole cytidine (H-pyrido[3',2':4,5]pyrrolo[2,3-d]pyrimidin-2-one). Modified nucleobases may also include those in which the purine or pyrimidine base is replaced with other heterocycles, for example 7-deaza-adenine, 7-deazaguanosine, 2-aminopyridine and 2-pyridone. Further nucleobases include those disclosed in U.S. Pat. No. 3,687,808, those disclosed in The Concise Encyclopedia Of Polymer Science And Engineering, pages 858-859, Kroschwitz, J. I., ed. John Wiley & Sons, 1990, those disclosed by Englisch et al., Angewandte Chemie, International Edition, 1991, 30, 613, and those disclosed by Sanghvi, Y. S., Chapter 15, Antisense Research and Applications, pages 289-302, Crooke, S. T. and Lebleu, B. ed., CRC Press, 1993. Certain of these nucleobases are particularly useful for increasing the binding affinity of the oligomeric compounds of the invention. These include 5-substituted pyrimidines, 6-azapyrimidines and N-2, N-6 and O-6 substituted purines, including 2-aminopropyladenine, 5-propynyluracil and 5-propynylcytosine. 5-methylcytosine substitutions have been shown to increase nucleic acid duplex stability by 0.6-1.2°C (Sanghvi, Y. S., Crooke, S. T. and Lebleu, B., eds., Antisense Research and Applications, CRC Press, Boca Raton, 1993, pp. 276-278) and are presently preferred base substitutions, even more particularly when combined with 2'-O-methoxyethyl sugar modifications.

[0140] Representative United States patents that teach the preparation of certain of the above noted modified nucleobases as well as other modified nucleobases include, but are not limited to, the above noted U.S. Pat. No. 3,687,808, as well as U.S. Pat. Nos.: 4,845,205; 5,130,302; 5,134,066; 5,175,273; 5,367,066; 5,432,272; 5,457,187; 5,459,255; 5,484,908; 5,502,177; 5,525,711; 5,552,540; 5,587,469; 5,594,121, 5,596,091; 5,614,617; 5,645,985; 5,830,653; 5,763,588; 6,005,096; and 5,681,941, certain of which are commonly owned with the instant application, and U.S. Pat. No. 5,750,692, which has an owner in common with the owners of the instant application.

Antisense Compound Motifs

[0141] In certain embodiment of the invention, the compound comprises a modified oligonucleotide comprised of (a) a gap segment consisting of linked deoxynucleosides, preferably

consists of a thirteen linked modified deoxynucleosides; (b) a 5' wing segment consisting of linked modified nucleosides, preferably consists of two linked modified nucleosides; and (c) a 3' wing segment consisting of linked modified nucleosides, preferably consists of five linked nucleosides; wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment, and wherein each modified nucleoside within each wing segment comprises a modified sugar, preferably comprises a 2'-O-methoxyethyl sugar; and wherein each internucleoside linkage is a phosphothioate linkage.

[0142] These patterns of modified nucleotides in an antisense compound are called motif. These motifs, confer to the antisense compounds properties such to enhance the inhibitory activity, increase binding affinity for a target nucleic acid, or increase resistance to degradation by *in vivo* nucleases.

[0143] In certain embodiments, antisense compounds targeted to a CTGF nucleic acid have chemically modified subunits arranged in patterns, or motifs, to confer to the antisense compounds properties such as enhanced the inhibitory activity, increased binding affinity for a target nucleic acid, or resistance to degradation by *in vivo* nucleases.

[0144] Chimeric antisense compounds typically contain at least one region modified so as to confer increased resistance to nuclease degradation, increased cellular uptake, increased binding affinity for the target nucleic acid, and/or increased inhibitory activity. A second region of a chimeric antisense compound may optionally serve as a substrate for the cellular endonuclease RNase H, which cleaves the RNA strand of an RNA:DNA duplex.

[0145] Antisense compounds having a gapmer motif are considered chimeric antisense compounds. In a gapmer an internal region having a plurality of nucleotides that supports RNaseH cleavage is positioned between external regions having a plurality of nucleotides that are chemically distinct from the nucleosides of the internal region. In the case of an antisense oligonucleotide having a gapmer motif, the gap segment generally serves as the substrate for endonuclease cleavage, while the wing segments comprise modified nucleosides. In a preferred embodiment, the regions of a gapmer are differentiated by the types of sugar moieties comprising each distinct region. The types of sugar moieties that are used to differentiate the regions of a gapmer may in some embodiments include β -D-ribonucleosides, β -D-deoxyribonucleosides, 2'-modified nucleosides (such 2'-modified nucleosides may include 2'-MOE, and 2'-O-CH₃, among others), and bicyclic sugar modified nucleosides (such bicyclic sugar modified nucleosides may include those having a 4'-(CH₂)_n-O-2' bridge, where n=1 or n=2). Preferably, each distinct region comprises uniform sugar moieties. The wing-gap-wing motif is frequently described as "X-Y-Z", where "X" represents the length of the 5' wing region, "Y" represents the length of the gap region, and "Z" represents the length of the 3' wing region. Any of the antisense compounds described herein can have a gapmer motif. In some embodiments, X and Z are the same, in other embodiments they are different. In a preferred embodiment, Y is between 8 and 15 nucleotides. X, Y or Z can be any of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30 or more nucleotides. Thus, gapmers of the present invention include, but are not limited to, for example 2-13-5, 5-10-5, 4-8-4, 4-12-3, 4-12-4, 3-14-3, 2-16-2, 1-18-1, 3-10-3, 2-10-2, 1-10-1 or 2-8-2.

[0146] In some embodiments, the antisense compound as a "wingmer" motif, having a wing-gap or gap-wing configuration, i.e. an X-Y or Y-Z configuration as described above for the gapmer configuration. Thus, wingmer configurations of the present invention include, but are not limited to, for example 5-10, 8-4, 4-12, 12-4, 3-14, 16-2, 18-1, 10-3, 2-10, 1-10 or 8-2.

[0147] In one embodiment, antisense compounds targeted to a nucleic acid possess a 2-13-5 gapmer motif.

[0148] In some embodiments, an antisense compound targeted to a CTGF nucleic acid has a gap-widened motif. In other embodiments, an antisense oligonucleotide targeted to a CTGF nucleic acid has a gap-widened motif.

[0149] In one embodiment, a gap-widened antisense oligonucleotide targeted to a CTGF nucleic acid has a gap segment of fourteen 2'-deoxyribonucleotides positioned between wing segments of three chemically modified nucleosides. In one embodiment, the chemical modification comprises a 2'-sugar modification. In another embodiment, the chemical modification comprises a 2'-MOE sugar modification.

[0150] Antisense compounds having a gapmer motif are considered "chimeric" antisense compounds or "chimeras," which contain two or more chemically distinct regions, each made up of at least one monomer unit, i.e., a nucleotide in the case of an oligonucleotide compound. These oligonucleotides typically contain at least one region modified so as to confer increased resistance to nuclease degradation, increased cellular uptake, increased binding affinity for the target nucleic acid, and/or increased inhibitory activity. It is not necessary for all positions in a given compound to be uniformly modified, and in fact more than one of the aforementioned modifications may be incorporated in a single compound or even at a single nucleoside within an oligonucleotide.

[0151] An additional region of the oligonucleotide may serve as a substrate for enzymes capable of cleaving RNA:DNA or RNA:RNA hybrids. By way of example, RNase H is a cellular endonuclease which cleaves the RNA strand of an RNA:DNA duplex. Activation of RNase H, therefore, results in cleavage of the RNA target, thereby greatly enhancing the efficiency of oligonucleotide inhibition of gene expression. Consequently, comparable results can often be obtained with shorter oligonucleotides when chimeric oligonucleotides are used, compared to phosphorothioate deoxyoligonucleotides hybridizing to the same target region. Cleavage of the RNA target can be routinely detected by gel electrophoresis and, if necessary, associated nucleic acid hybridization techniques known in the art.

[0152] Chimeric antisense compounds of the invention may be formed as composite structures of two or more oligonucleotides, modified oligonucleotides, oligonucleosides and/or oligonucleotide mimetics as described above. Such compounds have also been referred to in the art as hybrids or gapmers. Representative United States patents that teach the preparation of such hybrid structures include, but are not limited to, U.S. Pat. Nos.: 5,013,830; 5,149,797; 5,220,007; 5,256,775; 5,366,878; 5,403,711; 5,491,133; 5,565,350; 5,623,065; 5,652,355; 5,652,356; and 5,700,922, certain of which are commonly owned with the instant application.

[0153] In the case of an antisense oligonucleotide having a gapmer motif, the gap segment generally serves as the substrate for endonuclease cleavage, while the wing segments comprise modified nucleosides. In a preferred embodiment, the regions of a gapmer are differentiated by the types of sugar moieties comprising each distinct region. The types of sugar moieties that are used to differentiate the regions of a gapmer may include β -D-ribonucleosides, β -D-deoxyribonucleosides, 2'-modified nucleosides (such as 2'-phosphorylated nucleosides may include 2'-MOE), and bicyclic sugar modified nucleosides.

[0154] Another modification of the oligonucleotides of the invention involves chemically linking to the oligonucleotide one or more moieties or conjugates which enhance the activity, cellular distribution or cellular uptake of the oligonucleotide. The compounds of the invention can include conjugate groups covalently bound to functional groups such as primary or secondary hydroxyl groups. Conjugate groups of the invention include intercalators, reporter molecules, polyamines, polyamides, polyethylene glycols, polyethers, groups that enhance the pharmacodynamic properties of oligomers, and groups that enhance the pharmacokinetic properties of oligomers. Typical conjugate groups include cholesterol, lipids, phospholipids, biotin, phenazine, folate, phenanthridine, anthraquinone, acridine, fluoresceins, rhodamines, coumarins, and dyes. Groups that enhance the pharmacodynamic properties, in the context of this invention, include groups that improve oligomer uptake, enhance oligomer resistance to degradation, and/or strengthen sequence-specific hybridization with RNA. Groups that enhance the pharmacokinetic properties, in the context of this invention, include groups that improve oligomer uptake, distribution, metabolism or excretion. Representative conjugate groups are disclosed in International Patent Application PCT/US92/09196, filed Oct. 23, 1992. Conjugate moieties include but are not limited to lipid moieties such as a cholesterol moiety (Letsinger et al., *Proc. Natl. Acad. Sci. USA*, 1989, 86, 6553-6556), cholic acid (Manoharan et al., *Bioorg. Med. Chem. Lett.*, 1994, 4, 1053-1060), a thioether, e.g., hexyl-S-tritylthiol (Manoharan et al., *Ann. N.Y. Acad. Sci.*, 1992, 660, 306-309; Manoharan et al., *Bioorg. Med. Chem. Lett.*, 1993, 3, 2765-2770), a thiocholesterol (Oberhauser et al., *Nucl. Acids Res.*, 1992, 20, 533-538), an aliphatic chain, e.g., dodecandiol or undecyl residues (Saison-Behmoaras et al., *EMBO J.*, 1991, 10, 1111-1118; Kabanov et al., *FEBS Lett.*, 1990, 259, 327-330; Svinarchuk et al., *Biochimie*, 1993, 75, 49-54), a phospholipid, e.g., di-hexadecyl-rac-glycerol or triethyl-ammonium 1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate (Manoharan et al., *Tetrahedron Lett.*, 1995, 36, 3651-3654; Shea et al., *Nucl. Acids Res.*, 1990, 18, 3777-3783), a polyamine or a polyethylene glycol chain (Manoharan et al., *Nucleosides & Nucleotides*, 1995, 14, 969-973), or adamantane acetic acid (Manoharan et al., *Tetrahedron Lett.*, 1995, 36, 3651-3654), a palmitoyl moiety (Mishra et al., *Biochim. Biophys. Acta*, 1995, 1264, 229-237), or an octadecylamine or hexylamino-carbonyl-oxycholesterol moiety (Crooke et al., *J. Pharmacol. Exp. Ther.*, 1996, 277, 923-937). Oligonucleotides of the invention may also be conjugated to active drug substances, for example, aspirin, warfarin, phenylbutazone, ibuprofen, suprofen, fenbufen, ketoprofen, (S)-(+)-pranoprofen, carprofen, dansylsarcosine, 2,3,5-triiodobenzoic acid, flufenamic acid, folinic acid, a benzothiadiazide, chlorothiazide, a diazepam, indomethacin, a barbiturate, a cephalosporin, a sulfa drug, an antidiabetic, an antibacterial or an antibiotic. Oligonucleotide-drug conjugates and their preparation are described in U.S. patent application Ser. No. 09/334,130 (filed Jun. 15, 1999).

[0155] Representative United States patents that teach the preparation of such oligonucleotide conjugates include, but are not limited to, U.S. Pat. Nos.: 4,828,979; 4,948,882; 5,218,105; 5,525,465; 5,541,313; 5,545,730; 5,552,538; 5,578,717; 5,580,731; 5,580,731; 5,591,584; 5,109,124; 5,118,802; 5,138,045; 5,414,077; 5,486,603; 5,512,439; 5,578,718; 5,608,046; 4,587,044; 4,605,735; 4,667,025; 4,762,779; 4,789,737; 4,824,941; 4,835,263; 4,876,335; 4,904,582; 4,958,013; 5,082,830; 5,112,963; 5,214,136; 5,082,830; 5,112,963; 5,214,136; 5,245,022; 5,254,469; 5,258,506; 5,262,536; 5,272,250; 5,292,873; 5,317,098; 5,371,241; 5,391,723; 5,416,203; 5,451,463; 5,510,475; 5,512,667; 5,514,785; 5,565,552; 5,567,810; 5,574,142; 5,585,481; 5,587,371; 5,595,726; 5,597,696; 5,599,923; 5,599,928 and 5,688,941, certain of which are commonly owned with the instant application.

[0156] In another embodiment of the invention, the compound comprises the modified oligonucleotide consists of 20 linked nucleosides.

[0157] In a preferred embodiment of the invention, the compound comprises the nucleobase sequence is the sequence set forth in SEQ ID NOs: 39, 40 and 166.

[0158] In one embodiment of the invention the composition comprises a modified oligonucleotide comprising linked nucleosides, the nucleobase sequence of which is a sequence set forth in one of SEQ ID NOs: 39, 40 and 166 or a salt thereof, and a pharmaceutically acceptable carrier or diluent. Examples of pharmaceutically acceptable salts are well known to those skilled in the art.

[0159] In one embodiment of the invention, the antisense compound is complementary within a range of nucleotides on the CTGF sequence. In certain embodiments the antisense compound is complementary within the range of nucleotides 1388-1423, and in certain instances of the disclosure is complementary to nucleotides 718-751, 1457-1689, 2040-2069, 2120-2147, or 2267-2301, of SEQ ID NO: 9. In a certain instance the antisense compound is complementary within the range of nucleotides 2728-2797 of SEQ ID NO: 10. Compounds targeted to these ranges demonstrate at least 50% inhibition (i.e. SEQ ID NOs: 15, 29, 31, 42, 46-49, 53, 72, 81, 82, 152-154, 164, and 165). Certain target sites listed in Table 1 also demonstrate at least 50% inhibition (i.e. SEQ ID NOs: 12, 20, 33, 34, 76, 107, 129, 132, 134, 136, and 146). In certain instances the antisense compound is complementary within the range of nucleotides 553-611, 1394-1423, 1469-1508, 1559-1605, 1659-1689 or 2100-2129 of SEQ ID NO: 9 and 2623-2647 of SEQ ID NO: 10. Compounds targeted therein demonstrate at least 60% inhibition (i.e. SEQ ID NOs: 27, 28, 38, 39, 40, 43, 44, 45, 50, 51, 52, 54, 55, 56, 77, 78, 79, 138 and 139). Certain additional target sites listed in Table 1 also demonstrate at least 60% inhibition (i.e. SEQ ID NOs: 24, 30, 61, 63, 67, 69, 73, 86, 125, 128, and 161). In certain embodiments the antisense compound is complementary within the range of nucleotides 1399-1423. Compounds targeted therein demonstrate at least 70% inhibition (i.e. SEQ ID NOs: 39 and 40). Certain target sites listed in Table 1 also demonstrate at least 70% inhibition (i.e. SEQ ID NOs: 28, 30, 44, 45, 51, 56, 78, 128, and 138). One target site listed in Table 1 also demonstrates at least 80% inhibition (i.e. SEQ ID NO: 44). In certain embodiments, the percent inhibition is achieved when the antisense compound is delivered to HuVec cells at a concentration of 50nm. Refer to Example 8, provided herein below, for more details.

[0160] In an embodiment of the composition, the modified oligonucleotide is a single-stranded or double stranded oligonucleotide. In another embodiment of the invention, comprising a modified oligonucleotide, wherein the modified oligonucleotide consists of 20 linked nucleosides

[0161] In another embodiment of the invention, provides a method for inhibiting expression of connective tissue growth factor in a cell or a tissue which comprises contacting the cell or tissue with the compound of interest under conditions such that expression of connective tissue growth factor is inhibited.

[0162] Antisense oligonucleotides may be combined with pharmaceutically acceptable active and/or inert substances for the preparation of pharmaceutical compositions or formulations. Compositions and methods for the formulation of pharmaceutical compositions are dependent upon a number of criteria, including, but not limited to, route of administration, extent of disease, or dose to be administered.

[0163] Antisense compound targeted to a nucleic acid can be utilized in pharmaceutical compositions by combining the antisense compound with a suitable pharmaceutically acceptable diluent or carrier. A pharmaceutically acceptable diluent includes phosphate-buffered saline (PBS). PBS is a diluent suitable for use in compositions to be delivered parenterally. Accordingly, in one embodiment, employed in the methods described herein is a pharmaceutical composition comprising an antisense compound targeted to a nucleic acid and a pharmaceutically acceptable diluent. In one embodiment, the pharmaceutically acceptable diluent is PBS. In another embodiment, the pharmaceutically acceptable diluent is pharmaceutical grade saline or pharmaceutical grade PBS. In other embodiments, the antisense compound is an antisense oligonucleotide.

[0164] Pharmaceutical compositions comprising antisense compounds encompass any pharmaceutically acceptable salts, esters, or salts of such esters, or any other oligonucleotide which, upon administration to an animal, including a human, is capable of providing (directly or indirectly) the biologically active metabolite or residue thereof. Accordingly, for example, the disclosure is also drawn to pharmaceutically acceptable salts of antisense compounds, prodrugs, pharmaceutically acceptable salts of such prodrugs, and other bioequivalents. Suitable pharmaceutically acceptable salts include, but are not limited to, sodium and potassium salts.

[0165] A prodrug can include the incorporation of additional nucleosides at one or both ends of an antisense compound which are cleaved by endogenous nucleases within the body, to form the active antisense compound. In particular, prodrug versions of the oligonucleotides of the invention are prepared as SATE [(S-acetyl-2-thioethyl)phosphate] derivatives according to the methods disclosed in WO 93/24510 to Gosselin et al., published Dec. 9, 1993 or in WO 94/26764 and U.S. Pat. No. 5,770,713 to Imbach et al.

[0166] The term "pharmaceutically acceptable salts" refers to physiologically and pharmaceutically acceptable salts of the compounds of the invention: i.e., salts that retain the desired biological activity of the parent compound and do not impart undesired toxicological effects thereto.

[0167] Pharmaceutically acceptable base addition salts are formed with metals or amines, such as alkali and alkaline earth metals or organic amines. Examples of metals used as cations are sodium, potassium, magnesium, calcium, and the like. Examples of suitable amines are N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, dicyclohexylamine, ethylenediamine, N-methylglucamine, and procaine (see, for example, Berge et al., "Pharmaceutical Salts," J. of Pharma Sci., 1977, 66, 1-19). The base addition salts of said acidic compounds are prepared by contacting the free acid form with a sufficient amount of the desired base to produce the salt in the conventional manner. The free acid form may be regenerated by contacting the salt form with an acid and isolating the free acid in the conventional manner. The free acid forms differ from their respective salt forms somewhat in certain physical properties such as solubility in polar solvents, but otherwise the salts are equivalent to their respective free acid for purposes of the present invention. As used herein, a "pharmaceutical addition salt" includes a pharmaceutically acceptable salt of an acid form of one of the components of the compositions of the invention. These include organic or inorganic acid salts of the amines. Preferred acid salts are the hydrochlorides, acetates, salicylates, nitrates and phosphates. Other suitable pharmaceutically acceptable salts are well known to those skilled in the art and include basic salts of a variety of inorganic and organic acids, such as, for example, with inorganic acids, such as for example hydrochloric acid, hydrobromic acid, sulfuric acid or phosphoric acid; with organic carboxylic, sulfonic, sulfo or phospho acids or N-substituted sulfamic acids, for example acetic acid, propionic acid, glycolic acid, succinic acid, maleic acid, hydroxymaleic acid, methylmaleic acid, fumaric acid, malic acid, tartaric acid, lactic acid, oxalic acid, gluconic acid, glucaric acid, glucuronic acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, salicylic acid, 4-aminosalicylic acid, 2-phenoxybenzoic acid, 2-acetoxybenzoic acid, embonic acid, nicotinic acid or isonicotinic acid; and with amino acids, such as the 20 alpha-amino acids involved in the synthesis of proteins in nature, for example glutamic acid or aspartic acid, and also with phenylacetic acid, methanesulfonic acid, ethanesulfonic acid, 2-hydroxyethanesulfonic acid, ethane-1,2-disulfonic acid, benzenesulfonic acid, 4-methylbenzenesulfonic acid, naphthalene-2-sulfonic acid, naphthalene-1,5-disulfonic acid, 2- or 3-phosphoglycerate, glucose-6-phosphate, N-cyclohexylsulfamic acid (with the formation of cyclamates), or with other acid organic compounds, such as ascorbic acid. Pharmaceutically acceptable salts of compounds may also be prepared with a pharmaceutically acceptable cation. Suitable pharmaceutically acceptable cations are well known to those skilled in the art and include alkaline, alkaline earth, ammonium and quaternary ammonium cations. Carbonates or hydrogen carbonates are also possible.

[0168] For oligonucleotides, preferred examples of pharmaceutically acceptable salts include but are not limited to (a) salts formed with cations such as sodium, potassium, ammonium, magnesium, calcium, polyamines such as spermine and spermidine, etc.; (b) acid addition salts formed with inorganic acids, for example hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid and the like; (c) salts formed with organic acids such as, for example, acetic acid, oxalic acid, tartaric acid, succinic acid, maleic acid, fumaric acid, gluconic acid, citric acid, malic acid, ascorbic acid, benzoic acid, tannic acid, palmitic acid, alginic acid, polyglutamic acid, naphthalenesulfonic acid, methanesulfonic acid, p-toluenesulfonic acid, naphthalenedisulfonic acid, polygalacturonic acid, and the like; and (d) salts formed from elemental anions such as chlorine, bromine, and iodine.

[0169] In certain embodiment of the invention, a pharmaceutically acceptable carrier or diluent is an ingredient in a composition that lacks pharmacological activity, but is pharmaceutically necessary or desirable as a solvent, suspending agent or any other pharmaceutically inert vehicle for delivering one or more nucleic acids to a human or non-human animal. Pharmaceutical carriers are well known to those skilled in the art.

Carriers

[0170] Certain compositions of the present invention also incorporate carrier compounds in the formulation. As used herein, "carrier compound" or "carrier" can refer to a nucleic acid, or analog thereof, which is inert (i.e., does not possess biological activity per se) but is recognized as a nucleic acid by *in vivo* processes that reduce the bioavailability of a nucleic acid having biological activity by, for example, degrading the biologically active nucleic acid or promoting its removal from circulation. The coadministration of a nucleic acid and a carrier compound, typically with an excess of the latter substance, can result in a substantial reduction of the amount of nucleic acid recovered in the liver, kidney or other extracirculatory reservoirs, presumably due to competition between the carrier compound and the nucleic acid for a common receptor. For example, the recovery of a partially phosphorothioate oligonucleotide in hepatic tissue can be reduced when it is coadministered with polyinosinic acid, dextran sulfate, polycytidic acid or 4-acetamido-4'-isothiocyano-stilbene-2,2'-disulfonic acid (Miyao et al., *Antisense Res. Dev.*, 1995, 5, 115-121; Takakura et al., *Antisense & Nucl. Acid Drug Dev.*, 1996, 6, 177-183).

Excipients

[0171] In contrast to a carrier compound, a "pharmaceutical carrier" or "excipient" is a pharmaceutically acceptable solvent, suspending agent or any other pharmacologically inert vehicle for delivering one or more nucleic acids to an animal. The excipient may be liquid or solid and is selected, with the planned manner of administration in mind, so as to provide for the desired bulk, consistency, etc., when combined with a nucleic acid and the other components of a given pharmaceutical composition. Typical pharmaceutical carriers include, but are not limited to, binding agents (e.g., pregelatinized maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose, etc.); fillers (e.g., lactose and other sugars, microcrystalline cellulose, pectin, gelatin, calcium sulfate, ethyl cellulose, polyacrylates or calcium hydrogen phosphate, etc.); lubricants (e.g., magnesium stearate, talc, silica, colloidal silicon dioxide, stearic acid, metallic stearates, hydrogenated vegetable oils, corn starch, polyethylene glycols, sodium benzoate, sodium acetate, etc.); disintegrants (e.g., starch, sodium starch glycolate, etc.); and wetting agents (e.g., sodium lauryl sulphate, etc.).

[0172] Pharmaceutically acceptable organic or inorganic excipient suitable for non-parenteral administration which does not deleteriously react with nucleic acids can also be used to formulate the compositions of the present invention. Suitable pharmaceutically acceptable carriers include, but are not limited to, water, salt solutions, alcohols, polyethylene glycols, gelatin, lactose, amylose, magnesium stearate, talc, silicic acid, viscous paraffin, hydroxymethylcellulose,

polyvinylpyrrolidone and the like.

[0173] Formulations for topical administration of nucleic acids may include sterile and non-sterile aqueous solutions, non-aqueous solutions in common solvents such as alcohols, or solutions of the nucleic acids in liquid or solid oil bases. The solutions may also contain buffers, diluents and other suitable additives. Pharmaceutically acceptable organic or inorganic excipients suitable for non-parenteral administration which do not deleteriously react with nucleic acids can be used.

[0174] In one embodiment of the invention, the composition comprises a modified oligonucleotide comprises a single-stranded or a doublestranded oligonucleotide, and wherein the modified oligonucleotide consists of 20 linked nucleosides.

[0175] Another instance of the disclosure involves a method for inhibiting expression of connective tissue growth factor in a cell or a tissue which comprises contacting the cell or tissue with any one of the above-mentioned compounds under conditions such that expression of connective tissue growth factor is inhibited.

[0176] A certain instance of the disclosure involves a method of treating an animal having a disease or condition associated with expression of connective tissue growth factor which comprises administering to the animal an amount of the compound described hereinabove effective to inhibit expression of connective tissue growth factor so as to thereby treat the animal.

[0177] In the practice of the medical use of this invention or method of this disclosure, an animal includes a human as well as a non-human animal, preferably human.

[0178] The present invention also includes pharmaceutical compositions and formulations which include the antisense compounds of the invention. The pharmaceutical compositions of the present invention may be administered in a number of ways depending upon whether local or systemic treatment is desired and upon the area to be treated. Administration may be by intradermal administration, including intradermal threading of the injection needle, sub-cutaneous, topical (including ophthalmic and to mucous membranes including vaginal and rectal delivery), pulmonary, e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal, intranasal, epidermal and transdermal), oral or parenteral. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal or intramuscular injection or infusion; or intracranial, e.g., intrathecal or intraventricular, administration.

[0179] Pharmaceutical compositions and formulations for topical administration may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable. Coated condoms, gloves and the like may also be useful. Preferred intradermal and topical formulations include those in which the oligonucleotides of the invention are in admixture with a topical delivery agent such as lipids, liposomes, fatty acids, fatty acid esters, steroids, chelating agents and surfactants. Preferred lipids and liposomes include neutral (e.g. dioleoylphosphatidyl DOPE ethanolamine, dimyristoylphosphatidyl choline DMPC, distearoylphosphatidyl choline) negative (e.g. dimyristoylphosphatidyl glycerol DMPG) and

cationic (e.g. dioleoyltetramethylaminopropyl DOTAP and dioleoylphosphatidyl ethanolamine DOTMA). Oligonucleotides of the invention may be encapsulated within liposomes or may form complexes thereto, in particular to cationic liposomes. Alternatively, oligonucleotides may be complexed to lipids, in particular to cationic lipids. Preferred fatty acids and esters include but are not limited arachidonic acid, oleic acid, eicosanoic acid, lauric acid, caprylic acid, capric acid, myristic acid, palmitic acid, stearic acid, linoleic acid, linolenic acid, dicaprate, tricaprate, monoolein, dilaurin, glyceryl 1-monocaprate, 1-dodecylazacycloheptan-2-one, an acylcarnitine, an acylcholine, or a C₁₋₁₀ alkyl ester (e.g. isopropylmyristate IPM), monoglyceride, diglyceride or pharmaceutically acceptable salt thereof. Topical formulations are described in detail in U.S. patent application Ser. No. 09/315,298 filed on May 20, 1999.

[0180] Pharmaceutical compositions of the present invention include, but are not limited to, solutions, emulsions, and liposome-containing formulations. These compositions may be generated from a variety of components that include, but are not limited to, preformed liquids, self-emulsifying solids and self-emulsifying semisolids.

[0181] The pharmaceutical formulations of the present invention, which may conveniently be presented in unit dosage form, may be prepared according to conventional techniques well known in the pharmaceutical industry. Such techniques include the step of bringing into association the active ingredients with the pharmaceutical carrier(s) or excipient(s). In general the formulations are prepared by uniformly and intimately bringing into association the active ingredients with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.

[0182] The compositions of the present invention may be formulated into any of many possible dosage forms such as, but not limited to, syringes, pre-filled syringes, tablets, capsules, gel capsules, liquid syrups, soft gels, suppositories, and enemas. The compositions of the present invention may also be formulated as suspensions in aqueous, non-aqueous or mixed media. Aqueous suspensions may further contain substances which increase the viscosity of the suspension including, for example, sodium carboxymethyl-cellulose, sorbitol and/or dextran. The suspension may also contain stabilizers.

[0183] In one embodiment of the present invention the pharmaceutical compositions may be formulated and used as foams. Pharmaceutical foams include formulations such as, but not limited to, emulsions, microemulsions, creams, jellies and liposomes. While basically similar in nature these formulations vary in the components and the consistency of the final product. The preparation of such compositions and formulations is generally known to those skilled in the pharmaceutical and formulation arts and may be applied to the formulation of the compositions of the present invention.

Liposomes

[0184] There are many organized surfactant structures besides microemulsions that have been studied and used for the formulation of drugs. These include monolayers, micelles, bilayers and

vesicles. Vesicles, such as liposomes, have attracted great interest because of their specificity and the duration of action they offer from the standpoint of drug delivery. As used in the present invention, the term "liposome" means a vesicle composed of amphiphilic lipids arranged in a spherical bilayer or bilayers.

[0185] Liposomes are unilamellar or multilamellar vesicles which have a membrane formed from a lipophilic material and an aqueous interior. The aqueous portion contains the composition to be delivered. Cationic liposomes possess the advantage of being able to fuse to the cell wall. Non-cationic liposomes, although not able to fuse as efficiently with the cell wall, are taken up by macrophages *in vivo*.

[0186] In order to cross intact mammalian skin, lipid vesicles must pass through a series of fine pores, each with a diameter less than 50 nm, under the influence of a suitable transdermal gradient. Therefore, it is desirable to use a liposome which is highly deformable and able to pass through such fine pores.

[0187] Further advantages of liposomes include; liposomes obtained from natural phospholipids are biocompatible and biodegradable; liposomes can incorporate a wide range of water and lipid soluble drugs; liposomes can protect encapsulated drugs in their internal compartments from metabolism and degradation (Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245). Important considerations in the preparation of liposome formulations are the lipid surface charge, vesicle size and the aqueous volume of the liposomes.

[0188] Liposomes are useful for the transfer and delivery of active ingredients to the site of action. Because the liposomal membrane is structurally similar to biological membranes, when liposomes are applied to a tissue, the liposomes start to merge with the cellular membranes. As the merging of the liposome and cell progresses, the liposomal contents are emptied into the cell where the active agent may act.

[0189] Liposomal formulations have been the focus of extensive investigation as the mode of delivery for many drugs. There is growing evidence that for intradermal and topical administration, liposomes present several advantages over other formulations. Such advantages include reduced side-effects related to high systemic absorption of the administered drug, increased accumulation of the administered drug at the desired target, and the ability to administer a wide variety of drugs, both hydrophilic and hydrophobic, into the skin.

[0190] Several reports have detailed the ability of liposomes to deliver agents including high-molecular weight DNA into the skin. Compounds including analgesics, antibodies, hormones and high-molecular weight DNAs have been administered to the skin. The majority of applications resulted in the targeting of the upper epidermis.

[0191] Liposomes fall into two broad classes. Cationic liposomes are positively charged liposomes which interact with the negatively charged DNA molecules to form a stable complex. The positively charged DNA/liposome complex binds to the negatively charged cell surface and is

internalized in an endosome. Due to the acidic pH within the endosome, the liposomes are ruptured, releasing their contents into the cell cytoplasm (Wang et al., *Biochem. Biophys. Res. Commun.*, 1987, 147, 980-985).

[0192] Liposomes which are pH-sensitive or negatively-charged, entrap DNA rather than complex with it. Since both the DNA and the lipid are similarly charged, repulsion rather than complex formation occurs. Nevertheless, some DNA is entrapped within the aqueous interior of these liposomes. pH-sensitive liposomes have been used to deliver DNA encoding the thymidine kinase gene to cell monolayers in culture. Expression of the exogenous gene was detected in the target cells (Zhou et al., *Journal of Controlled Release*, 1992, 19, 269-274).

[0193] One major type of liposomal composition includes phospholipids other than naturally-derived phosphatidylcholine. Neutral liposome compositions, for example, can be formed from dimyristoyl phosphatidylcholine (DMPC) or dipalmitoyl phosphatidylcholine (DPPC). Anionic liposome compositions generally are formed from dimyristoyl phosphatidylglycerol, while anionic fusogenic liposomes are formed primarily from dioleoyl phosphatidylethanolamine (DOPE). Another type of liposomal composition is formed from phosphatidylcholine (PC) such as, for example, soybean PC, and egg PC. Another type is formed from mixtures of phospholipid and/or phosphatidylcholine and/or cholesterol.

[0194] Several studies have assessed the topical delivery of liposomal drug formulations to the skin. Application of liposomes containing interferon to guinea pig skin resulted in a reduction of skin herpes sores while delivery of interferon via other means (e.g. as a solution or as an emulsion) were ineffective (Weiner et al., *Journal of Drug Targeting*, 1992, 2, 405-410). Further, an additional study tested the efficacy of interferon administered as part of a liposomal formulation to the administration of interferon using an aqueous system, and concluded that the liposomal formulation was superior to aqueous administration (du Plessis et al., *Antiviral Research*, 1992, 18, 259-265).

[0195] Non-ionic liposomal systems have also been examined to determine their utility in the delivery of drugs to the skin, in particular systems comprising non-ionic surfactant and cholesterol. Non-ionic liposomal formulations comprising Novasome™ I (glyceryl dilaurate/cholesterol/polyoxyethylene -10-stearyl ether) and Novasome™ II (glyceryl distearate/cholesterol/polyoxyethylene-10-stearyl ether) were used to deliver cyclosporin-A into the dermis of mouse skin. Results indicated that such non-ionic liposomal systems were effective in facilitating the deposition of cyclosporin-A into different layers of the skin (Hu et al. *S.T.P. Pharma. Sci.*, 1994, 4, 6, 466).

[0196] Liposomes also include "sterically stabilized" liposomes, a term which, as used herein, refers to liposomes comprising one or more specialized lipids that, when incorporated into liposomes, result in enhanced circulation lifetimes relative to liposomes lacking such specialized lipids. Examples of sterically stabilized liposomes are those in which part of the vesicle-forming lipid portion of the liposome (A) comprises one or more glycolipids, such as monosialoganglioside GM₁, or (B) is derivatized with one or more hydrophilic polymers, such as a polyethylene glycol (PEG) moiety. While not wishing to be bound by any particular theory, it is thought in the art that,

at least for sterically stabilized liposomes containing gangliosides, sphingomyelin, or PEG-derivatized lipids, the enhanced circulation half-life of these sterically stabilized liposomes derives from a reduced uptake into cells of the reticuloendothelial system (RES) (Allen et al., FEBS Letters, 1987, 223, 42; Wu et al., Cancer Research, 1993, 53, 3765).

[0197] Various liposomes comprising one or more glycolipids are known in the art. Papahadjopoulos et al. (Ann. N.Y. Acad. Sci., 1987, 507, 64) reported the ability of monosialoganglioside G_{M1} , galactocerebroside sulfate and phosphatidylinositol to improve blood half-lives of liposomes. These findings were expounded upon by Gabizon et al. (Proc. Natl. Acad. Sci. U.S.A., 1988, 85, 6949). U.S. Pat. No. 4,837,028 and WO 88/04924, both to Allen et al., disclose liposomes comprising (1) sphingomyelin and (2) the ganglioside G_{M1} or a galactocerebroside sulfate ester. U.S. Pat. No. 5,543,152 (Webb et al.) discloses liposomes comprising sphingomyelin. Liposomes comprising 1,2-sn-dimyristoylphosphatidylcholine are disclosed in WO 97/13499 (Lim et al.).

[0198] Many liposomes comprising lipids derivatized with one or more hydrophilic polymers, and methods of preparation thereof, are known in the art. Sunamoto et al. (Bull. Chem. Soc. Jpn., 1980, 53, 2778) described liposomes comprising a nonionic detergent, 2C₁₂ 15G, that contains a PEG moiety. Ilium et al. (FEBS Lett., 1984, 167, 79) noted that hydrophilic coating of polystyrene particles with polymeric glycols results in significantly enhanced blood half-lives. Synthetic phospholipids modified by the attachment of carboxylic groups of polyalkylene glycols (e.g., PEG) are described by Sears (U.S. Pat. Nos. 4,426,330 and 4,534,899). Klivanov et al. (FEBS Lett., 1990, 268, 235) described experiments demonstrating that liposomes comprising phosphatidylethanol-amine (PE) derivatized with PEG or PEG stearate have significant increases in blood circulation half-lives. Blume et al. (Biochimica et Biophysica Acta, 1990, 1029, 91) extended such observations to other PEG-derivatized phospholipids, e.g., DSPE-PEG, formed from the combination of distearoylphosphatidylethanolamine (DSPE) and PEG. Liposomes having covalently bound PEG moieties on their external surface are described in European Patent No. EP 0 445 131 B1 and WO 90/04384 to Fisher. Liposome compositions containing 1-20 mole percent of PE derivatized with PEG, and methods of use thereof, are described by Woodle et al. (U.S. Pat. Nos. 5,013,556 and 5,356,633) and Martin et al. (U.S. Pat. No. 5,213,804 and European Patent No. EP 0 496 813 B1). Liposomes comprising a number of other lipid-polymer conjugates are disclosed in WO 91/05545 and U.S. Pat. No. 5,225,212 (both to Martin et al.) and in WO 94/20073 (Zalipsky et al.). Liposomes comprising PEG-modified ceramide lipids are described in WO 96/10391 (Choi et al.). U.S. Pat. Nos. 5,540,935 (Miyazaki et al.) and 5,556,948 (Tagawa et al.) describe PEG-containing liposomes that can be further derivatized with functional moieties on their surfaces.

[0199] A limited number of liposomes comprising nucleic acids are known in the art. WO 96/40062 to Thierry et al. discloses methods for encapsulating high molecular weight nucleic acids in liposomes. U.S. Pat. No. 5,264,221 to Tagawa et al. discloses protein-bonded liposomes and asserts that the contents of such liposomes may include an antisense RNA. U.S. Pat. No. 5,665,710 to Rahman et al. describes certain methods of encapsulating oligodeoxynucleotides in liposomes. WO 97/04787 to Love et al. discloses liposomes comprising antisense oligonucleotides targeted to the raf gene.

[0200] Transfersomes are yet another type of liposomes, and are highly deformable lipid aggregates which are attractive candidates for drug delivery vehicles. Transfersomes may be described as lipid droplets which are so highly deformable that they are easily able to penetrate through pores which are smaller than the droplet. Transfersomes are adaptable to the environment in which they are used, e.g. they are self-optimizing (adaptive to the shape of pores in the skin), self-repairing, frequently reach their targets without fragmenting, and often self-loading. To make transfersomes it is possible to add surface edge-activators, usually surfactants, to a standard liposomal composition. Transfersomes have been used to deliver serum albumin to the skin. The transfersome-mediated delivery of serum albumin has been shown to be as effective as subcutaneous injection of a solution containing serum albumin.

[0201] Surfactants find wide application in formulations such as emulsions (including microemulsions) and liposomes. The most common way of classifying and ranking the properties of the many different types of surfactants, both natural and synthetic, is by the use of the hydrophile/lipophile balance (HLB). The nature of the hydrophilic group (also known as the "head") provides the most useful means for categorizing the different surfactants used in formulations (Rieger, in *Pharmaceutical Dosage Forms*, Marcel Dekker, Inc., New York, N.Y., 1988, p. 285).

[0202] If the surfactant molecule is not ionized, it is classified as a nonionic surfactant. Nonionic surfactants find wide application in pharmaceutical and cosmetic products and are usable over a wide range of pH values. In general their HLB values range from 2 to about 18 depending on their structure. Nonionic surfactants include nonionic esters such as ethylene glycol esters, propylene glycol esters, glyceryl esters, polyglyceryl esters, sorbitan esters, sucrose esters, and ethoxylated esters. Nonionic alkanolamides and ethers such as fatty alcohol ethoxylates, propoxylated alcohols, and ethoxylated/propoxylated block polymers are also included in this class. The polyoxyethylene surfactants are the most popular members of the nonionic surfactant class.

[0203] If the surfactant molecule carries a negative charge when it is dissolved or dispersed in water, the surfactant is classified as anionic. Anionic surfactants include carboxylates such as soaps, acyl lactylates, acyl amides of amino acids, esters of sulfuric acid such as alkyl sulfates and ethoxylated alkyl sulfates, sulfonates such as alkyl benzene sulfonates, acyl isethionates, acyl taurates and sulfosuccinates, and phosphates. The most important members of the anionic surfactant class are the alkyl sulfates and the soaps.

[0204] If the surfactant molecule carries a positive charge when it is dissolved or dispersed in water, the surfactant is classified as cationic. Cationic surfactants include quaternary ammonium salts and ethoxylated amines. The quaternary ammonium salts are the most used members of this class.

[0205] If the surfactant molecule has the ability to carry either a positive or negative charge, the surfactant is classified as amphoteric. Amphoteric surfactants include acrylic acid derivatives, substituted alkylamides, N-alkylbetaines and phosphatides.

[0206] The use of surfactants in drug products, formulations and in emulsions has been reviewed (Rieger, in *Pharmaceutical Dosage Forms*, Marcel Dekker, Inc., New York, N.Y., 1988, p. 285).

Penetration Enhancers

[0207] In one embodiment, the present invention employs various penetration enhancers to effect the efficient delivery of nucleic acids, particularly oligonucleotides, to the skin of animals. Most drugs are present in solution in both ionized and nonionized forms. However, usually only lipid soluble or lipophilic drugs readily cross cell membranes. It has been discovered that even non-lipophilic drugs may cross cell membranes if the membrane to be crossed is treated with a penetration enhancer. In addition to aiding the diffusion of non-lipophilic drugs across cell membranes, penetration enhancers also enhance the permeability of lipophilic drugs.

[0208] Penetration enhancers may be classified as belonging to one of five broad categories, i.e., surfactants, fatty acids, bile salts, chelating agents, and non-chelating non-surfactants (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, p. 92). Each of the above mentioned classes of penetration enhancers are described below in greater detail.

[0209] Surfactants: In connection with the present invention, surfactants (or "surface-active agents") are chemical entities which, when dissolved in an aqueous solution, reduce the surface tension of the solution or the interfacial tension between the aqueous solution and another liquid, with the result that absorption of oligonucleotides through the mucosa is enhanced. In addition to bile salts and fatty acids, these penetration enhancers include, for example, sodium lauryl sulfate, polyoxyethylene-9-lauryl ether and polyoxyethylene-20-cetyl ether) (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, p. 92); and perfluorochemical emulsions, such as FC-43. Takahashi et al., *J. Pharm. Pharmacol.*, 1988, 40, 252).

[0210] Fatty acids: Various fatty acids and their derivatives which act as penetration enhancers include, for example, oleic acid, lauric acid, capric acid (n-decanoic acid), myristic acid, palmitic acid, stearic acid, linoleic acid, linolenic acid, dicaprates, tricaprates, monoolein (1-monooleoyl-rac-glycerol), dilaurin, caprylic acid, arachidonic acid, glycerol 1-monocaprate, 1-dodecylazacycloheptan-2-one, acylcarnitines, acylcholines, C₁₋₁₀ alkyl esters thereof (e.g., methyl, isopropyl and t-butyl), and mono- and di-glycerides thereof (i.e., oleate, laurate, caprate, myristate, palmitate, stearate, linoleate, etc.) (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, p. 92; Muranishi, *Critical Reviews in Therapeutic Drug Carrier Systems*, 1990, 7, 1-33; El Hariri et al., *J. Pharm. Pharmacol.*, 1992, 44, 651-654).

[0211] Bile salts: The physiological role of bile includes the facilitation of dispersion and absorption of lipids and fat-soluble vitamins (Brunton, Chapter 38 in: *Goodman & Gilman's The Pharmacological Basis of Therapeutics*, 9th Ed., Hardman et al. Eds., McGraw-Hill, New York, 1996, pp. 934-935). Various natural bile salts, and their synthetic derivatives, act as penetration enhancers. Thus the term "bile salts" includes any of the naturally occurring components of bile as well as any of their synthetic derivatives. The bile salts of the invention include, for example, cholic acid (or its pharmaceutically acceptable sodium salt, sodium cholate), dehydrocholic acid

(sodium dehydrocholate), deoxycholic acid (sodium deoxycholate), glucolic acid (sodium glucolate), glycholic acid (sodium glycocholate), glycodeoxycholic acid (sodium glycodeoxycholate), taurocholic acid (sodium taurocholate), taurodeoxycholic acid (sodium taurodeoxy-cholate), chenodeoxycholic acid (sodium chenodeoxycholate), ursodeoxycholic acid (UDCA), sodium tauro-24,25-dihydro-fusidate (STDHF), sodium glycodihydrofusidate and polyoxyethylene-9-lauryl ether (POE) (Lee et al., Critical Reviews in Therapeutic Drug Carrier Systems, 1991, page 92; Swinyard, Chapter 39 In: Remington's Pharmaceutical Sciences, 18th Ed., Gennaro, ed., Mack Publishing Co., Easton, Pa., 1990, pages 782-783; Muranishi, Critical Reviews in Therapeutic Drug Carrier Systems, 1990, 7, 1-33; Yamamoto et al., J. Pharm. Exp. Ther., 1992, 263, 25; Yamashita et al., J. Pharm. Sci., 1990, 79, 579-583).

[0212] Chelating Agents: Chelating agents, as used in connection with the present invention, can be defined as compounds that remove metallic ions from solution by forming complexes therewith, with the result that absorption of oligonucleotides through the mucosa is enhanced. With regards to their use as penetration enhancers in the present invention, chelating agents have the added advantage of also serving as DNase inhibitors, as most characterized DNA nucleases require a divalent metal ion for catalysis and are thus inhibited by chelating agents (Jarrett, J. Chromatogr., 1993, 618, 315-339). Chelating agents of the invention include but are not limited to disodium ethylenediaminetetraacetate (EDTA), citric acid, salicylates (e.g., sodium salicylate, 5-methoxysalicylate and homovanilate), N-acyl derivatives of collagen, laureth-9 and N-amino acyl derivatives of beta-diketones (enamines)(Lee et al., Critical Reviews in Therapeutic Drug Carrier Systems, 1991, page 92; Muranishi, Critical Reviews in Therapeutic Drug Carrier Systems, 1990, 7, 1-33; Buur et al., J. Control Rel., 1990, 14, 43-51).

[0213] Non-chelating non-surfactants: As used herein, non-chelating non-surfactant penetration enhancing compounds can be defined as compounds that demonstrate insignificant activity as chelating agents or as surfactants but that nonetheless enhance absorption of oligonucleotides through the alimentary mucosa (Muranishi, Critical Reviews in Therapeutic Drug Carrier Systems, 1990, 7, 1-33). This class of penetration enhancers include, for example, unsaturated cyclic ureas, 1-alkyl- and 1-alkenylazacyclo-alkanone derivatives (Lee et al., Critical Reviews in Therapeutic Drug Carrier Systems, 1991, page 92); and non-steroidal anti-inflammatory agents such as diclofenac sodium, indomethacin and phenylbutazone (Yamashita et al., J. Pharm. Pharmacol., 1987, 39, 621-626).

[0214] Agents that enhance uptake of oligonucleotides at the cellular level may also be added to the pharmaceutical and other compositions of the present invention. For example, cationic lipids, such as lipofectin (Junichi et al, U.S. Pat. No. 5,705,188), cationic glycerol derivatives, and polycationic molecules, such as polylysine (Lollo et al., PCT Application WO 97/30731), are also known to enhance the cellular uptake of oligonucleotides.

[0215] Other agents may be utilized to enhance the penetration of the administered nucleic acids into and through the skin, including glycols such as ethylene glycol and propylene glycol, pyrrols such as 2-pyrrol, azones, and terpenes such as limonene and menthone.

Other Components

[0216] The compositions of the present invention may additionally contain other adjunct components conventionally found in pharmaceutical compositions, at their art-established usage levels. Thus, for example, the compositions may contain additional, compatible, pharmaceutically-active materials such as, for example, antipruritics, astringents, local anesthetics or anti-inflammatory agents, or may contain additional materials useful in physically formulating various dosage forms of the compositions of the present invention, such as dyes, flavoring agents, preservatives, antioxidants, opacifiers, thickening agents and stabilizers. However, such materials, when added, should not unduly interfere with the biological activities of the components of the compositions of the present invention. The formulations can be sterilized and, if desired, mixed with auxiliary agents, e.g., lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, colorings, flavorings and/or aromatic substances and the like which do not deleteriously interact with the nucleic acid(s) of the formulation.

[0217] Aqueous suspensions may contain substances which increase the viscosity of the suspension including, for example, sodium carboxymethylcellulose, sorbitol and/or dextran. The suspension may also contain stabilizers.

[0218] In another related embodiment, compositions of the invention may contain one or more antisense compounds, particularly oligonucleotides, targeted to a first nucleic acid and one or more additional antisense compounds targeted to a second nucleic acid target. Numerous examples of antisense compounds are known in the art. Two or more combined compounds may be used together or sequentially.

[0219] The antisense compounds used in accordance with this invention may be conveniently and routinely made through the well-known technique of solid phase synthesis. The compounds of the invention may also be admixed, encapsulated, conjugated or otherwise associated with other molecules, molecule structures or mixtures of compounds, as for example, liposomes, receptor targeted molecules, oral, rectal, topical or other formulations, for assisting in uptake, distribution and/or absorption. Representative United States patents that teach the preparation of such uptake, distribution and/or absorption assisting formulations include, but are not limited to, U.S. Pat. Nos.: 5,108,921; 5,354,844; 5,416,016; 5,459,127; 5,521,291; 5,543,158; 5,547,932; 5,583,020; 5,591,721; 4,426,330; 4,534,899; 5,013,556; 5,108,921; 5,213,804; 5,227,170; 5,264,221; 5,356,633; 5,395,619; 5,416,016; 5,417,978; 5,462,854; 5,469,854; 5,512,295; 5,527,528; 5,534,259; 5,543,152; 5,556,948; 5,580,575; and 5,595,756.

Certain Indications

[0220] The specificity and sensitivity of antisense is also harnessed by those of skill in the art for therapeutic uses. Antisense oligonucleotides have been employed as therapeutic moieties in the treatment of disease states in animals and man. Antisense oligonucleotide drugs, including ribozymes, have been safely and effectively administered to humans and numerous clinical trials are presently underway. It is thus established that oligonucleotides can be useful therapeutic

modalities that can be configured to be useful in treatment regimes for treatment of cells, tissues and animals, especially humans.

[0221] In one instance of the disclosure the method comprises treating a disease or condition, wherein the disease or disorder is a fibrotic disease. In one instance of the method of the disclosure, the fibrotic disease is hypertrophic scarring, keloids, skin scarring, liver fibrosis, pulmonary fibrosis, renal fibrosis, cardiac fibrosis, or restenosis.

[0222] In another instance, the method further comprises treating the above-mentioned disease or condition, wherein the disease or disorder is joint fibrosis (including frozen shoulder syndrome, tendon and peripheral nerve damage), surgical adhesions, spinal cord damage, coronary bypass, abdominal and peritoneal adhesions (including endometriosis, uterine leiomyomata and fibroids), radial keratotomy and photorefractive keratectomy, retinal reattachment surgery, device mediated fibrosis (in for example diabetes), tendon adhesions, Dupuytren contracture, or scleroderma.

[0223] In another embodiment of the invention also provides a medical use for reducing hypertrophic scarring or keloids resulting from dermal wound healing in a subject in need thereof which comprises administering to the subject an amount of compound of an antisense oligonucleotide effective to inhibit expression of connective tissue growth factor (CTGF) in the subject so as to thereby reduce scarring.

[0224] The formulation of therapeutic compositions and their subsequent administration is believed to be within the skill of those in the art. Dosing is dependent on severity and responsiveness of the disease state to be treated, with the course of treatment lasting from several days to several months, or until a cure is effected or a diminution of the disease state is achieved. In general, dosage from 0.1 to 25mg per injection per linear cm of scar is used, and may be given daily, weekly, every 3 weeks, monthly or bi-monthly.

[0225] In another embodiment of this invention, the medical use further comprises reducing hypertrophic scarring or keloids resulting from dermal wound healing, wherein wound healing is healing at a wound selected from the group consisting of skin breakage, surgical incisions and burns.

[0226] In certain embodiments, the invention provides medical uses of treating an individual comprising administering one or more pharmaceutical compositions of the present invention. In certain embodiments, the individual has one of the above mentioned disorders. In certain embodiments, the individual is at risk for one of the above mentioned disorders. In certain embodiments, the individual has been identified as in need of therapy. In certain embodiments the invention provides methods for prophylactically reducing CTGF expression in an individual.

[0227] Certain embodiments include treating an individual in need thereof by administering to an individual a therapeutically effective amount of an antisense compound targeted to a CTGF nucleic acid.

[0228] In one embodiment, administration of a therapeutically effective amount of an antisense

compound targeted to a CTGF nucleic acid is accompanied by monitoring of CTGF levels in the skin and/or serum of an individual, to determine an individual's response to administration of the antisense compound. An individual's response to administration of the antisense compound is used by a physician to determine the amount and duration of therapeutic intervention.

[0229] In one embodiment, administration of an antisense compound targeted to a CTGF nucleic acid results in reduction of CTGF expression by at least 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95 or 99%, or a range defined by any two of these values. In one embodiment, administration of an antisense compound targeted to a CTGF nucleic acid results in a change in a measure of CTGF as measured by a standard test, for example, but not limited to, CTGF. In some embodiments, administration of a CTGF antisense compound decreases the measure by at least 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95 or 99%, or a range defined by any two of these values.

[0230] In certain embodiments pharmaceutical composition comprising an antisense compound targeted to CTGF is used for the preparation of a medicament for treating a patient suffering or susceptible to any one of the above-mentioned disorders.

Certain Combination Therapies

[0231] In certain embodiments, one or more pharmaceutical compositions of the present invention are co-administered with one or more other pharmaceutical agents. In certain embodiments, such one or more other pharmaceutical agents are designed to treat the same disease or condition as the one or more pharmaceutical compositions of the present invention. In certain embodiments, such one or more other pharmaceutical agents are designed to treat a different disease or condition as the one or more pharmaceutical compositions of the present invention. In certain embodiments, such one or more other pharmaceutical agents are designed to treat an undesired effect of one or more pharmaceutical compositions of the present invention. In certain embodiments, one or more pharmaceutical compositions of the present invention are co-administered with another pharmaceutical agent to treat an undesired effect of that other pharmaceutical agent. In certain embodiments, one or more pharmaceutical compositions of the present invention and one or more other pharmaceutical agents are administered at the same time. In certain embodiments, one or more pharmaceutical compositions of the present invention and one or more other pharmaceutical agents are administered at different times. In certain embodiments, one or more pharmaceutical compositions of the present invention and one or more other pharmaceutical agents are prepared together in a single formulation. In certain embodiments, one or more pharmaceutical compositions of the present invention and one or more other pharmaceutical agents are prepared separately.

[0232] In certain embodiments, pharmaceutical agents that may be co-administered with a pharmaceutical composition of the present invention include a second therapeutic agent. In certain such embodiments, pharmaceutical agents that may be co-administered with a pharmaceutical composition of the present invention include, but are not limited to second therapeutic agent. In certain such embodiments, the second therapeutic agent is administered

prior to administration of a pharmaceutical composition of the present invention. In certain such embodiments, the second therapeutic agent is administered following administration of a pharmaceutical composition of the present invention. In certain such embodiments the second therapeutic agent is administered at the same time as a pharmaceutical composition of the present invention. In certain such embodiments the dose of a co-administered second therapeutic agent is the same as the dose that would be administered if the second therapeutic agent was administered alone. In certain such embodiments the dose of a co-administered second therapeutic agent is lower than the dose that would be administered if the second therapeutic agent was administered alone. In certain such embodiments the dose of a co-administered second therapeutic agent is greater than the dose that would be administered if the second therapeutic agent was administered alone.

[0233] In certain embodiments, the co-administration of a second compound enhances the therapeutic effect of a first compound, such that co-administration of the compounds results in a therapeutic effect that is greater than the effect of administering the first compound alone, a synergistic effect. In other embodiments, the co-administration results in therapeutic effects that are additive of the effects of the compounds when administered alone. In other embodiments, the co-administration results in therapeutic effects that are supra-additive of the effects of the compounds when administered alone. In some embodiments, the first compound is an antisense compound. In some embodiments, the second compound is an antisense compound.

[0234] This invention is illustrated in the Examples Section which follows. This section is set forth to aid in an understanding of the invention.

Examples

Example 1: Selection of Lead Human Connective Tissue Growth Factors (CTGF) Antisense Oligonucleotides Candidate

Introduction

[0235] A series of oligonucleotides were designed to target different regions of the human connective tissue growth factor RNA, using published sequences (GenBank accession number NM_001901.2, incorporated herein as SEQ ID NO: 9, and GenBank accession number NT_025741.14, incorporated herein as SEQ ID NO: 10).

[0236] This study analyzes available sequence space and modified antisense oligonucleotides targeting both exonic and intronic space of CTGF. Approximately 150 novel sequences per target were synthesized and evaluated for activity against CTGF in cell-culture. The oligonucleotides are shown in Table 1. All compounds in Table 1 are chimeric oligonucleotides ("gapmers") 20 nucleotides in length, composed of a central "gap" region consisting of either ten 2'-

deoxynucleotides, which is flanked on both sides (5' and 3' directions) by five-nucleotides "wings" or 13 2'-deoxynucleotides, which is flanked on both sides (5' and 3' directions) by two- and five-nucleotides "wings," respectively. The wings are composed of 2'-methoxyethyl (2'-MOE) nucleotides. The internucleoside (backbone) linkages are phosphorothioate (P=S) throughout the oligonucleotide. All cystidine residuals are 5-methylcytidines. The compounds were analyzed for their effect on human connective tissue growth factor mRNA levels by quantitative real-time PCR as described later. Data are averages from two experiments. If present, "N.D." indicates "no data".

TABLE 1

Inhibition of human connective tissue growth factor mRNA levels by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap						
ISIS #	REGION	TARGET SEQ ID NO	TARGET SITE	SEQUENCE	% INHIB	SEQ ID NO.
124173	CDS	9	380	CCAGCTGCTTGGCGCAGACG	35	11
124189	CDS	9	1003	GCCAGAAAGCTCAAACCTGA	57	12
124212	3'-UTR	9	1783	CCACAAGCTGTCCAGTCTAA	47	13
124235	3'-UTR	9	2267	GGTCACACTCTCAACAAATA	47	14
124238	3'-UTR	9	2282	AAACATGTAACCTTTTGGTCA	53	15
412271	5'-UTR	9	4	GGGAAGAGTTGTTGTGTGAG	0	16
412272	5'-UTR	9	38	AGGGTGGAGTCGCACTGGCT	46	17
412273	CDS	9	228	ACGAAGGCGACGCGGACGGG	35	18
412274	CDS	9	265	GCCGACGGCCGGCCGGCTGC	40	19
412275	CDS	9	475	GGTGCACACGCCGATCTTGC	52	20
412276	CDS	9	483	TCTTTGGCGGTGCACACGCC	0	21
412277	CDS	9	489	GCACCATCTTTGGCGGTGCA	0	22
412278	CDS	9	496	GCAGGGAGCACCATCTTTGG	16	23
412279	CDS	9	501	AAGATGCAGGGAGCACCATC	63	24
412280	CDS	9	507	CCACCGAAGATGCAGGGAGC	0	25
412281	CDS	9	512	CCGTACCACCGAAGATGCAG	47	26
412282	CDS	9	553	GTA CT TGCAGCTGCTCTGGA	68	27
412283	CDS	9	592	GGGCATGCAGCCCACCGCCC	72	28
412284	CDS	9	718	AGGCCCAACCACGGTTTGGT	59	29
412285	CDS	9	723	AGGGCAGGCCCAACCACGGT	79	30
412286	CDS	9	732	TAAGCCGCGAGGGCAGGCCC	55	31
412287	CDS	9	829	CCCACAGGTCTTGAACAGG	30	32
412288	CDS	9	839	AGATGCCCATCCCACAGGTC	55	33
412289	3'-UTR	9	1273	CCAGTCTAATGAGTTAATGT	56	34
412290	3'-UTR	9	1281	TTCAAGTTCAGTCTAATGA	10	35

Inhibition of human connective tissue growth factor mRNA levels by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap						
ISIS #	REGION	TARGET SEQ ID NO	TARGET SITE	SEQUENCE	% INHIB	SEQ ID NO.
412291	3'-UTR	9	1361	TTTTCCCCCAGTTAGAAAAA	38	36
412292	3'-UTR	9	1388	CACAATGTTTTGAATTGGGT	50	37
412293	3'-UTR	9	1394	ACATGGCACAATGTTTTGAA	67	38
412294	3'-UTR	9	1399	GTTTGACATGGCACAATGTT	73	39
412295	3'-UTR	9	1404	TATTTGTTTGACATGGCACA	74	40
412296	3'-UTR	9	1412	TGATAGACTATTTGTTTGAC	35	41
412297	3'-UTR	9	1457	GTTCCACTGTCAAGTCTTAA	55	42
412298	3'-UTR	9	1469	TGTACTAATGTAGTTCCACT	69	43
412299	3'-UTR	9	1482	CATTCTGGTGCTGTGTACTA	86	44
412300	3'-UTR	9	1489	TAATATACATTCTGGTGCTG	76	45
412301	3'-UTR	9	1495	ACACCTTAATATACATTCTG	54	46
412302	3'-UTR	9	1502	TAAAGCCACACCTTAATATA	54	47
412303	3'-UTR	9	1520	GTACCCTCCCACTGCTCCTA	53	48
412304	3'-UTR	9	1554	AAGATGCTATCTGATGATAC	52	49
412305	3'-UTR	9	1559	CGTATAAGATGCTATCTGAT	69	50
412306	3'-UTR	9	1577	AATAGCAGGCATATTACTCG	74	51
412307	3'-UTR	9	1586	TACACTTCAAATAGCAGGCA	69	52
412308	3'-UTR	9	1591	TCAATTACACTTCAAATAGC	50	53
412309	3'-UTR	9	1659	GGAGAATGCACATCCTAGCT	66	54
412310	3'-UTR	9	1665	ATGGCTGGAGAATGCACATC	60	55
412311	3'-UTR	9	1670	TCTTGATGGCTGGAGAATGC	71	56
412312	3'-UTR	9	1729	GAATCAGAATGTCAGAGCTG	37	57
412313	3'-UTR	9	1946	CATTGAAATATCAAAGCATT	0	58
412314	3'-UTR	9	1952	GGCTAACATTGAAATATCAA	25	59
412315	3'-UTR	9	1958	AATTGAGGCTAACATTGAAA	1	60
412316	3'-UTR	9	1965	G TTCAGAAATTGAGGCTAAC	65	61
412317	3'-UTR	9	1971	TATGGTGTT CAGAAATTGAG	13	62
412318	3'-UTR	9	1976	CTACCTATGGTGTT CAGAAA	61	63
412319	3'-UTR	9	1982	TACATTCTACCTATGGTGTT	38	64
412320	3'-UTR	9	1991	GACAAGCTTTACATTCTACC	24	65
412321	3'-UTR	9	1996	GATCAGACAAGCTTTACATT	37	66
412322	3'-UTR	9	2007	ATGCTTTGAACGATCAGACA	64	67
412323	3'-UTR	9	2012	ATTCATGCTTTGAACGATC	44	68

Inhibition of human connective tissue growth factor mRNA levels by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap						
ISIS #	REGION	TARGET SEQ ID NO	TARGET SITE	SEQUENCE	% INHIB	SEQ ID NO.
412324	3'-UTR	9	2018	GTATCCATTTCATGCTTTGA	60	69
412325	3'-UTR	9	2026	CCATATAAGTATCCATTTC	48	70
412326	3'-UTR	9	2032	GAATTTCCATATAAGTATCC	28	71
412327	3'-UTR	9	2040	TCTGAGCAGAATTTCCATAT	58	72
412328	3'-UTR	9	2050	TGTCATTCTATCTGAGCAGA	61	73
412329	3'-UTR	9	2060	TTTGACGGACTGTCATTCTA	47	74
412330	3'-UTR	9	2070	AACAATCTGTTTTGACGGAC	48	75
412331	3'-UTR	9	2088	TGATGCCTCCCCTTTGCAA	53	76
412332	3'-UTR	9	2100	TGCCAAGGACACTGATGCCT	68	77
412333	3'-UTR	9	2105	CAGCCTGCCAAGGACACTGA	75	78
412334	3'-UTR	9	2110	GAAATCAGCCTGCCAAGGAC	60	79
412335	3'-UTR	9	2115	ACCTAGAAATCAGCCTGCCA	46	80
412336	3'-UTR	9	2120	TTCCTACCTAGAAATCAGCC	51	81
412337	3'-UTR	9	2128	TACCACATTTCTACCTAGA	59	82
412338	3'-UTR	9	2134	TGAGGCTACCACATTTCTTA	0	83
412339	3'-UTR	9	2140	TAAAAGTGAGGCTACCACAT	48	84
412340	3'-UTR	9	2213	CAAATGCTTCCAGGTGAAAA	49	85
412341	3'-UTR	9	2219	TAGAAACAAATGCTTCCAGG	66	86
412342	3'-UTR	9	2230	TCATATCAAAGTAGAAACAA	12	87
412343	3'-UTR	9	2242	TCCGAAAAACAGTCATATCA	24	88
412368	Intron 1	10	1308	ACCCGGCTGCAGAGGGCGAG	0	89
412369	Intron 1	10	1313	CGCTTACCCGGCTGCAGAGG	0	90
412370	Intron 1	10	1410	GACAGGGCGGTCAGCGGCGC	0	91
412371	Intron 2	10	1730	AGTCCGAGCGGTTTCTTTTT	0	92
412372	Intron 2	10	1735	AACTCAGTCCGAGCGGTTTC	19	93
412373	Intron 2	10	1740	AAAGAACTCAGTCCGAGCG	10	94
412374	Intron 2	10	1745	TGGAGAAAGAACTCAGTCC	45	95
412375	Intron 2	10	1750	GCAGCTGGAGAAAGAACTC	14	96
412376	Intron 2	10	1755	TGGCAGCAGCTGGAGAAAGA	46	97
412377	Intron 2	10	1887	AGGAGCACCATCTTTGGCT	20	98
412378	Intron 3	10	2125	TCACCCGCGAGGGCAGGCC	33	99
412379	Intron 3	10	2137	GGAAGACTCGACTCACCCGC	0	100

Inhibition of human connective tissue growth factor mRNA levels by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap						
ISIS #	REGION	TARGET SEQ ID NO	TARGET SITE	SEQUENCE	% INHIB	SEQ ID NO.
412380	Intron 3	10	2142	TTAGAGGAAGACTCGACTCA	0	101
412381	Intron 3	10	2150	ACCCTGACTTAGAGGAAGAC	47	102
412382	Intron 3	10	2155	TCACGACCCTGACTTAGAGG	31	103
412383	Intron 3	10	2160	GAGAATCACGACCCTGACTT	2	104
412384	Intron 3	10	2165	TGGGAGAGAATCACGACCCT	31	105
412385	Intron 3	10	2170	CTCCCTGGGAGAGAATCACG	0	106
412386	Intron 3	10	2191	GGTCGGCACAGTTAGGACTC	53	107
412387	Intron 3	10	2196	CGTTCGGTCGGCACAGTTAG	30	108
412388	Intron 3	10	2216	CCTGGATAAGGTATTTCCCC	0	109
412389	Intron 3	10	2235	ACAAACACCATGTAAAACGC	11	110
412390	Intron 3	10	2241	GAGCACACAAACACCATGTA	0	111
412391	Intron 3	10	2251	TGCGAGAGCAGAGCACACAA	0	112
412392	Intron 3	10	2256	TAAGCTGCGAGAGCAGAGCA	2	113
412393	Intron 3	10	2261	GTCGGTAAGCTGCGAGAGCA	23	114
412394	Intron 3	10	2266	TTCCAGTCGGTAAGCTGCGA	15	115
412395	Intron 4	10	2472	ACATGTACCTTAATGTTCTC	0	116
412396	Intron 4	10	2477	GCAGAACATGTACCTTAATG	0	117
412397	Intron 4	10	2482	TAGGAGCAGAACATGTACCT	9	118
412398	Intron 4	10	2487	GTTAATAGGAGCAGAACATG	19	119
412399	Intron 4	10	2496	TGAAAAATAGTTAATAGGAG	0	120
412400	Intron 4	10	2511	CCACTGTTTTTTCCTGTGAAA	10	121
412401	Intron 4	10	2525	AAGTTGGGTCCTATCCACTG	28	122
412402	Intron 4	10	2530	GCCCTAAGTTGGGTCCTATC	20	123
412403	Intron 4	10	2535	CAAGAGCCCTAAGTTGGGTC	0	124
412404	Intron 4	10	2540	CGTGGCAAGAGCCCTAAGTT	64	125
412405	Intron 4	10	2558	CGGGCTTATACTAACAAGCG	6	126
412406	Intron 4	10	2563	GATAACGGGCTTATACTAAC	33	127
412407	Intron 4	10	2568	TTGGAGATAACGGGCTTATA	73	128
412408	Intron 4	10	2573	TAGTTTTGGAGATAACGGGC	51	129
412409	Intron 4	10	2578	TTAGATAGTTTTGGAGATAA	24	130
412410	Intron 4	10	2584	CAATGGTTAGATAGTTTTGG	36	131
412411	Intron 4	10	2589	CAGCTCAATGGTTAGATAGT	53	132
412412	Intron 4	10	2594	CAAAACAGCTCAATGGTTAG	34	133

Inhibition of human connective tissue growth factor mRNA levels by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap						
ISIS #	REGION	TARGET SEQ ID NO	TARGET SITE	SEQUENCE	% INHIB	SEQ ID NO.
412413	Intron 4	10	2599	TCCAGCAAAACAGCTCAATG	59	134
412414	Intron 4	10	2604	CTCATTCCAGCAAAACAGCT	42	135
412415	Intron 4	10	2609	AAGCTCTCATTCCAGCAAAA	57	136
412416	Intron 4	10	2614	TACACAAGCTCTCATTCCAG	44	137
412417	Intron 4	10	2623	GGTTGCTATTACACAAGCTC	72	138
412418	Intron 4	10	2628	CTGGTGGTTGCTATTACACA	61	139
412419	Intron 4	10	2633	GAAAACTGGTGGTTGCTATT	29	140
412420	Intron 4	10	2638	TAGTGGAACCTGGTGGTTG	5	141
412421	Intron 4	10	2663	TTAACTAACCTGTGGAAGA	15	142
412422	Intron 4	10	2672	TGTCTTGAATTAATAACCC	4	143
412423	Intron 4	10	2677	TGAATGTCTTGAATTAAT	0	144
412424	Intron 4	10	2691	GCCAGAGCCTCTCTTGAAT	36	145
412425	Intron 4	10	2698	AAAAATAGCCAGAGCCTCTC	59	146
412426	Intron 4	10	2703	TGTCCAAAAATAGCCAGAGC	28	147
412427	Intron 4	10	2708	TGCTATGTCCAAAAATAGCC	15	148
412428	Intron 4	10	2713	TCATTTGCTATGTCCAAAAA	28	149
412429	Intron 4	10	2718	GAGTCTCATTTGCTATGTCC	20	150
412430	Intron 4	10	2723	AGTTTGAGTCTCATTTGCTA	30	151
412431	Intron 4	10	2728	GAGGAAGTTTGAGTCTCATT	55	152
412432	Intron 4	10	2763	CTTCTGTTGTCTGACTTCTG	55	153
412433	Intron 4	10	2778	CCTCTGTGTTTGTAGTCTTCT	56	154
412434	Intron 4	10	2788	TTTCTTCAACCCTCTGTGTT	15	155
412435	Intron 4	10	2796	GGAGTGGCTTTCTTCAACCC	43	156
412436	Intron 4	10	2849	AGGAAGACAAGGGAAAAGAG	20	157
412437	Intron 4	10	2854	TTCTAAGGAAGACAAGGGAA	0	158
412438	Intron 4	10	2859	TGCCCTTCTAAGGAAGACAA	31	159
412439	Intron 2	10	1791	GGATGCGAGTTGGGATCTGG	0	160
412440	CDS	9	380	CCAGCTGCTTGGCGCAGACG	64	161
412441	CDS	9	1003	GCCAGAAAGCTCAAACCTGA	37	162
412442	3'-UTR	9	1783	CCACAAGCTGTCCAGTCTAA	32	163
412443	3'-UTR	9	2267	GGTCACACTCTCAACAAATA	59	164
412444	3'-UTR	9	2282	AAACATGTAACCTTTTGGTCA	55	165

Inhibition of human connective tissue growth factor mRNA levels by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap						
ISIS #	REGION	TARGET SEQ ID NO	TARGET SITE	SEQUENCE	% INHIB	SEQ ID NO.
418899	3'-UTR	9	1391	TGACATGGCACAATGTTTTG	ND*	166
*ND - i.e. not determined in the experiment but was highly active in another assay.						

[0237] As shown in Table 1, SEQ ID NOs 11-15, 17-20, 24, 26-34, 36-57, 59, 61, 63-82, 84-86, 88, 95, 97, 99, 102, 103, 105, 107, 108, 122, 125, 127-140, 145, 146, 149, 151-154, 156, 159, 161-165 demonstrated at least 24% inhibition of human connective tissue growth factor expression in this assay and are therefore preferred. The target sites to which these preferred sequences are complementary are herein referred to as "active sites" and are therefore preferred sites for targeting by compounds of the present invention.

[0238] The antisense compound is complementary within a range of nucleotides on the CTGF sequence, i.e. within the range of nucleotides 718-751, 1388-1423, 1457-1689, 2040-2069, 2120-2147, or 2267-2301 of SEQ ID NO: 9. In a certain embodiment the antisense compound is complementary within the range of nucleotides 2728-2797 of SEQ ID NO: 10. Compounds targeted to these ranges demonstrate at least 50% inhibition (i.e. SEQ ID NOs: 15, 29, 31, 42, 46-49, 53, 72, 81, 82, 152-154, 164, and 165). Certain target sites listed in Table 1 also demonstrate at least 50% inhibition (i.e. SEQ ID NOs: 12, 20, 33, 34, 76, 107, 129, 132, 134, 136, and 146).

[0239] In certain embodiments the antisense compound is complementary within the range of nucleotides 553-611, 1394-1423, 1469-1508, 1559-1605, 1659-1689 or 2100-2129. Compounds targeted therein demonstrate at least 60% inhibition (i.e. SEQ ID NOs: 27, 38, 43, 50, 52, 54, 55, 77, 79, and 86). Certain target sites listed in Table 1 also demonstrate at least 60% inhibition (i.e. SEQ ID NOs: 24, 61, 63, 67, 69, 73, 125, 139 and 161).

[0240] The antisense compound is also complementary within the range of nucleotides 1399-1423. Compounds targeted therein demonstrate at least 70% inhibition (i.e. SEQ ID NOs: 39 and 40). Certain target sites listed in Table 1 also demonstrate at least 70% inhibition (i.e. SEQ ID NOs: 28, 30, 45, 51, 56, 78, 128, and 138). One target site listed in Table 1 also demonstrates at least 80% inhibition (i.e. SEQ ID NO: 44). In certain embodiments, the percent inhibition is achieved when the antisense compound is delivered to HuVec cells at a concentration of 50nm.

[0241] Multiple leads with apparent activity greater than the historical ASO lead sequence, SEQ ID No. 15 (ISIS 124238), were identified in both exonic and intronic sequences.

Materials and Methods

[0242] Oligonucleotides were evaluated and activity confirmed at a concentration 50 nM in

human umbilical vein endothelial cells (HuVEC) using Lipofectin mediated transfection. HuVEC cells from Cascade Biologics (Portland, OR) maintained in Medium 200 supplemented with Low Serum Growth Supplement (from Cascade Biologics) were plated into 96-well plates at 5,000 cells per well and incubated overnight at 37°C in the presence of 5% CO₂. The following day the medium was aspirated and replaced with prewarmed Opti-MEM I (Invitrogen) containing Oligo-Lipofectamine 2000 (Invitrogen) mixture (3 mg of Lipofectamine 2000 per 1 ml of Opti-MEM I medium). After 4 hours, the transfection mixture was exchanged for fresh Medium 200 supplemented with Low Serum Growth Supplement and incubated at 37°C in the presence of 5% CO₂. After 16-24 hours, at approximately 80% confluence, the cells were washed with phosphate buffer saline (PBS) and lysed for RNA purification with the Qiagen RNeasy Kit. CTGF message was measured by quantitative real time polymerase chain reaction (RT-PCR) (Primer/Probe sets shown below) and the results were normalized to total RNA.

Statistical Analysis

[0243] Each sample was analyzed in duplicate, and vertical bars represent the spread between the two measurements.

Results and Discussion

[0244] Of the approximately 150 novel sequences per target synthesized and evaluated for activity against CTGF in cell-culture, the CTGF oligonucleotides (SEQ ID NOs: 28, 30, 39, 40, 45, 52, 56, 78, 125, and 166) show excellent inhibition of human CTGF mRNA expression.

Example 2: A Single-Dose Intra-Dermal Pharmacokinetic Study of CTGF Antisense Oligonucleotide in Rabbits

Study Objective

[0245] The purpose of this pharmacokinetic study in rabbit is to evaluate the diffusion and concentration of a CTGF antisense oligonucleotide (SEQ ID NO:39, ISIS 412294) in rabbit skin at different times subsequent to a single intra-dermal injection.

Study Design

[0246] On day 0 of the study all animals were dosed intra-dermally (ID) with a single 100 µL injection of CTGF antisense oligonucleotide SEQ ID NO:39 at a concentration of 50 mg/mL (5 mg total dose). The animals were dosed with the antisense oligonucleotide in a site to the left of the

spinal mid-line, roughly parallel to the rabbit's shoulders and adjacent to a suture 3 cm incisional wound (**Figure 1A**). The needle was inserted so that the test material was injected down towards the base of the animal's body. On days 1, 3, 7 or 14, the rabbits were euthanized and two full-thickness 1.0 cm punch biopsies were obtained, one centered over the original injection site and the other vertically below spaced 0.5 cm apart. The samples were snap frozen and stored at -80°C prior to analysis of the antisense oligonucleotide drug levels using a hybridization capture method. Results represent the mean antisense oligonucleotide levels from both biopsies at the indicated time.

Results and conclusions

[0247] Significant levels of the antisense oligonucleotide are present up to 14 days after intradermal dosing (see **Figure 1B**). The antisense oligonucleotide also remains close to the original site of injection (≤ 1 cm), with very limited lateral diffusion distal to the site of administration (**Figure 1B**). For example, levels of ASO are very low at distances 1.5cm distal to the injection site at all times post injection. Therefore the pharmacological effects of this class of molecule will be limited to areas of skin immediately adjacent to the injection site. To overcome this limitation, an intradermal injection threading technique has been developed (and used in clinical studies) which delivers equal amounts of antisense along the full length of the developing scar. These results demonstrate two novel findings. First, that there is a prolonged residence time of a 2'MOE antisense oligonucleotide with this chemical configuration in skin; and second, antisense oligonucleotides have very limited lateral diffusion in skin. The latter limitation of this class of molecule can be overcome by dosing the antisense oligonucleotide by a threading technique as described previously.

Example 3: Animal Study with CTGF Antisense Oligonucleotide Targeting Human Keloids In An In Vivo Model System

Study Objective

[0248] The purpose of this study was to evaluate the efficacy of antisense oligonucleotides targeting human CTGF in an *in vivo* model system using a human keloid/mouse xenograft model. The oligonucleotide tested was antisense oligonucleotide No. 412300 (SEQ ID NO: 45).

Methods

Human Keloid/Mouse Xenograft Model.

[0249] A human keloid/mouse xenograft model using transplanted human keloid tissue into nude

mice was used.

[0250] Fresh specimens of keloid tissue were obtained anonymously, from discarded tissue of patients undergoing elective excision of keloids for cosmetic reasons. The keloid samples were processed into 10x5x5 mm samples and weighed on an analytical balance. The keloid samples were then implanted into the mice as described below.

[0251] Mice were anaesthetized using 3% isoflurane. Buprenorphine was given before surgery and post-operatively, as needed (Buprenorphine at 0.3 mg/ml; 2 mg/kg; SC).

[0252] After achieving general anesthesia and prepping the animal, two 10 mm incisions were made in the skin, over the left and right scapula, and a pouch created using fine-tipped scissors, between subcutaneous fat and the fascia. One keloid sample was inserted into each pouch. The incisions were closed with veterinary grade cyanoacrylate glue (VetBond or Nexaband) and the area swabbed with 70% ethanol. The area was then dressed with sterile semi-permeable membranes (Op-Site™, Smith and Nephew).

Evaluation of ASOs *In Vivo* Against Keloids

[0253] An ASO targeting human (and not mouse) CTGF was used (antisense oligonucleotide No. 412300; SEQ ID NO: 45). To test the efficacy of the ASO in the *in vivo* model system described above, keloid implants were injected with either ASO (dissolved in PBS) or PBS control. There were two groups of animals with 8 animals per group (with two keloids/animal). Animals were allowed to acclimate for approximately 2 weeks post keloids implantation prior to ASO dosing.

[0254] A total dose of 500 µg of oligo per keloid sample was administered in a total volume of 100µl (from a stock solution of 5.0 mg/ml). The ASO or PBS control was administered immediately adjacent to each implant for a total of 4 weeks, twice a week. One week after the last injection, one implant was removed and subjected to qRT-PCR for gene expression analysis, and the contralateral keloid removed and analyzed histology for the collagen content using integrated density of fluorescence (IDF).

[0255] Total RNA was isolated and either CTGF or collagen, type III, alpha 1 (Col3A1) mRNA determined by quantitative real-time PCR using primer pairs that have been shown to be specific for human mRNA sequences. The mRNA levels were correlated with the GAPDH levels in the same samples, and any changes in the ASO-treated samples over the control treated by PBS alone were calculated.

Results

[0256] Results following 4 weeks of treatment with 500 µg of antisense oligonucleotide No. 412300 (SEQ ID NO: 45) in a total volume of 100µl per keloid sample indicates reduction in CTGF

and Col3A1 mRNA expression in individual keloid samples. Treatment with the CTGF ASO reduced CTGF mRNA expression in the keloid tissue to 67% control ($p=0.082$) (**Figure 2A**). Treatment with the CTGF ASO reduced Col3a1 mRNA expression in the keloid tissue to 45% control ($p=0.153$) (**Figure 2B**).

Conclusion

[0257] Keloids are characterized by abnormal proliferation of fibroblasts and overproduction of different forms of collagen. Histo-pathologically, they are characterized by the presence of whorls and nodules of thick, hyalinized collagen bundles or keloidal collagen with mucinous ground substance and relatively few fibroblasts in the dermis of keloid scars. The large thick collagen bundles and numerous thin fibrils are closely packed together. Type III collagen is the second most abundant collagen found in the skin, and is very abundant in keloids. Col3A1 is significantly elevated in keloids compared to normal skin.

[0258] It has been demonstrated here for the first time, the ability of 2'MOE chemically modified ASOs to reduce CTGF in intact, human keloid tissue. Treatment of the human keloid tissues with an ASO CTGF reduced the target CTGF mRNA expression by 33%. This has also resulted in a reduction in Col3A1 expression of 55%. This reduction in Col3A1 expression would lead to a significant therapeutic benefit in patients suffering from keloid growth, and demonstrate the utility of a 2'MOE ASO as a novel drug for the treatment of keloids.

Example 4: Breast Scar Revision Study in Humans

Study Objective

[0259] This is a randomized, double-blind, within-subject controlled clinical study evaluating efficacy and safety of a CTGF antisense oligonucleotides (EXC 001) in subjects undergoing elective revision of scars resulting from prior breast surgery. This study requires that the subjects to have pre-existing scars of sufficient severity to warrant scar revision surgery. Thus, this study pre-screen for subjects who could be expected to have a high rate of hypertrophic scar or keloids formation in the revised placebo-treated scars.

[0260] In patients who have had prior surgery of the breast and now have bilateral matching scars at the same anatomic locations, EXC 001 (SEQ ID NO:39) or placebo was administered to the portion of the revised breast scars via intradermal threading injections. The primary objective of the study was to assess the efficacy of EXC 001 in reducing subsequent skin scarring. The secondary objective of the study was to assess the safety of EXC 001.

Methods

[0261] A 6 cm section of either side of the revised breast wound/scar was treated with 4 doses of EXC 001 or placebo, at 2, 5, 8, and 11 weeks after the surgical incision was closed. Randomization determined which side was treated with EXC 001 or placebo in each subject.

[0262] Dosage of EXC 001 used was 5 mg per linear centimeter. Concentration of EXC 001 used was 25 mg/ml and 100 ul of EXC 001 was injected per linear centimeter of the revised breast wound/scar. Injections were made on both sides of each incision, with half of the amount per linear centimeter administered on each side. The injections on a given side were 3 cm apart. In order to deliver placebo or EXC 001 adjacent to and along the length of the incision, intradermal needles (3 cm long) were used for injections. The needle is inserted immediately adjacent to the surgical incision on each side by a threading technique, and EXC 001 or placebo is injected as needle is withdrawn, so that equal amounts of antisense drug are administered along the length of the scar.

[0263] The study duration was approximately 31 weeks. The subjects receive the scar revisions on Day 1, followed by 4 doses of EXC 001 and placebo, at 2, 5, 8, and 11 weeks after the surgical incisions were closed. Scar observation and assessment were performed at week 24.

[0264] Efficacy was determined by rating each matched pair of incisions from individual patients (within subject analysis). Efficacy was evaluated at week 24 following scar revision surgery, using three methods of rating severity of incisional scars:

- Subject assessment of their scars. On a scale of 1-10 the patient rated their "overall" opinion on the appearance of the scar.
- Physician (investigator) assessment of the scars. On a scale of 1-10 the physician rated overall opinion of scar appearance.
- Expert Panel assessment of pairs of blinded scar photographs, using a 100 mm Visual Analog Scale (VAS), where 0 = best possible scar and 100 = worst possible scar. This method gives information on the absolute severity of the scars as well as the differences between the two scars in the pair.

Results

[0265] 21 subjects completed this study. Examination of the week 24 post-surgery photographs indicate that nearly all of the subjects show recurrence of hypertrophic scars on at least one side following scar revision surgery. In some cases, the scars extend beyond the boundaries of the original incisions and are therefore keloidal scars.

[0266] This study achieved statistically significant results in favor of EXC 001 in all three endpoints (a negative score represents the difference between placebo and EXC 001 treated, in favor of EXC 001 - see Table 2 below).

- The subject assessment of their scars:

- The "overall" rating was statistically significant in favor of EXC 001 ($p=0.033$).
- The physician assessment of the scars:
 - The "overall" rating was highly statistically significant in favor of EXC 001 ($p<0.001$).
 - Expert panel VAS rating of photographs was also highly statistically significant in favor of EXC 001 ($p<0.001$).

TABLE 2

Scar Assessment Scale	Difference between placebo and EXC 001	p-value
Subject Overall	-2.4	0.003
Physician Overall	-2.3	<0.001
Expert VAS	-26.0	<0.001

[0267] Figure 3A shows that treatment with the CTGF antisense oligonucleotide, (EXC 001 or SEQ ID NO: 39), inhibits formation and growth of a hypertrophic scar at 24 weeks post surgery. Figure 3B shows results from a different subject, also at 24 weeks. In this second example, the patient has developed a keloid at 24 weeks post revision surgery in the placebo treated scar. In contrast, the formation and growth of a keloid scar at the adjacent scar revision site was almost completely prevented by treatment with EXC 001.

[0268] Therefore, in these two examples, the growth of both hypertrophic scars and keloid scars are inhibited by treatment with EXC 001. The scores below each set of pictures represent the degree of improvement between placebo- and EXC 001-treated scars. For example, an expert VAS score of -19.3 indicates that the placebo scar is worse than the corresponding EXC 001-treated scar by 19.3 on a 100 point scale. The physician and subject scores of -1 means that the placebo-treated scar is worse than the corresponding EXC 001-treated scar by 1 point on a 10 point scale. The result demonstrates that EXC 001 reduces the severity of both hypertrophic scars and keloid scars.

Example 5: Primary Prevention Abdominoplasty Study in Humans

Study Objective

[0269] This is a randomized, double-blind, within-subject controlled clinical study evaluating efficacy and safety of a CTGF antisense oligonucleotides (EXC 001) in subjects undergoing elective abdominoplast surgery.

Method

[0270] Study duration was 24 weeks. Subjects received the abdominoplasty on day 1, followed by treatment with either EXC 001 or placebo over a 9 week period.

[0271] Dosage of EXC 001 used was 5 mg per linear centimeter. Concentration of EXC 001 used was 25 mg/ml and 100 ul of EXC 001 was injected per linear centimeter of the abdominoplasty wound/scar. Injections were made on both sides of each incision, with half of the amount per linear centimeter administered on each side. Either drug or placebo was dosed along two 6 cm portions of the scar at each lateral end of the scar, and so the dosed sections are separated by at least 10cm untreated scar. The injections on a given side were 3 cm apart. In order to deliver placebo or EXC 001 adjacent to and along the length of the incision, intradermal needles (3 cm long) were used for injections. The needle is inserted immediately adjacent to the surgical incision on each side using a threading technique, and EXC 001 or placebo is injected as needle is withdrawn.

[0272] The subjects receive the scar revisions on Day 1, followed by 4 doses of EXC 001 and placebo, at 2, 5, 8, and 11 weeks after the surgical incisions were closed. Scar observation and assessment were performed at week 12.

[0273] Efficacy is determined by rating each matched portion of the dosed incision (placebo treated compared to EXC 001 treated) using the three methods of rating scar severity of incisional scars as described in the previous example.

Results

[0274] EXC 001 is efficacious by these criteria at week 12. An example of the efficacy is shown in **Figure 4**. In this example, the reduction in scar severity resulting from EXC 001 dosing compared to placebo dosing is clearly seen. The placebo treated section of the incision has developed into a hypertrophic scar whereas the EXC 001 treated section of the scar is more fine-line.

[0275] Another example of the ability of EXC 001 to reduce the formation of hypertrophic scars is shown in **Figure 5**. In this example, the section of the abdominoplasty on the right side of the scar (to the right of the vertical line) was treated with EXC 001 whereas the scar to the left of the vertical line did not receive any treatment. Clearly the scar severity to the right is less severe than to the left.

[0276] This example also demonstrates that the EXC 001 therapeutic benefit is limited to the region of scar directly adjacent to the site of drug intradermal threading dosing. Therefore the drug appears to have limited diffusion away from the site of administration and will require dosing immediately adjacent to the scar, for example by intradermal threading.

Example 6: Biomarker Study Demonstrating Effect of EXC 001 On mRNA Expression of Various Genes in Humans

Method

[0277] 13 weeks prior to an abdominoplasty procedure, an area between the umbilicus and the suprapubic hairline was used as a site to create a total of twenty 2 cm incisions. The 2 cm long incisions were in four columns of four incisions (A, B, C, D) and were used for RNA analysis at week 13 post-incisions. Two additional incisions lateral to these columns on each side of the abdomen (a, b, and c, d) were used for 4 or 8 weeks post-incisions mRNA analysis. Each column was separated by at least 4 cm and each incision separated by at least 3 cm.

[0278] Treatments of incisional wounds with either EXC 001 or placebo were randomly assigned to two treatment groups. All four incisional wounds in each of the columns A, B, C, and D received the same EXC 001 or placebo dose. All the incisional wounds/scars on one side of the abdomen received injections of EXC 001 and the other side received injections of placebo. All injections were blinded to the individual receiving the test agents. All incisions/scars in a given subject were treated on the same dosage schedule.

[0279] Thirty subjects were randomly assigned to one of three cohorts of 10 subjects each; each cohort was treated on a different dosage schedule (but the high and low doses were the same for all cohorts):

Cohort #1: Intradermal injections at weeks 2, 4, 6, 8, and 10

Cohort #2: Intradermal injections at weeks 2, 5, 8, and 11

Cohort #3: Intradermal injections at weeks 2, 6, and 10

[0280] A 27 gauge needle, approximately 38 mm long, was inserted intradermally 2 cm (the entire length of each incision), parallel to and approximately 3 mm from the incisional wound/scar (intradermal threading technique). Either EXC 001 or placebo was then injected while gradually withdrawing the needle so that the correct amount per linear centimeter was evenly deposited into the dermis along the incision line.

Biopsy of Incisions

[0281] One 6mm punch biopsy on each side adjacent to the lateral incisions were taken at day 1 for mRNA analysis and used as control for unwounded skin samples. At week 4, the 9 patients in cohort 1, and at week 8, the 20 patients in cohorts 2 and 3 were biopsied from their lateral incisions (a, b, c, d). Two of these incisions received EXC 001, and two received placebo through randomized assignment. Just prior to the abdominoplasty surgery (at week 13), each of the scars in columns A, B, C, and D were scored for scar severity (by Physician and Expert Panel Scales,

see **Example 5** above), and also sampled for both histological and RNA analysis.

Results

[0282] There was a statistically significant improvement observed for EXC 001 treated vs placebo treated scars for the Physician Overall Opinion when all cohorts were combined at the high dose level (8.7%, p-value = 0.018). There was also a statistically significant mean difference observed for the Overall evaluation of all cohorts combined and all doses combined (5.9%, p-value = 0.016). These results again demonstrate the ability of EXC 001 to reduce scar severity.

[0283] An example of the ability of EXC 001 to reduce the growth and formation of hypertrophic scars is shown in **Figure 6**. In this example, two matching scars are shown, one treated with 5mg/cm EXC 001 and one with placebo. The severity of the EXC 001 treated scar is less than the placebo treated scar. Histological analysis of these two scars also revealed an EXC 001 mediated reduction in the expression of CTGF protein (by immunohistochemistry) clearly demonstrating that EXC 001 is functioning to reduce the expression of its intended target (CTGF). Analysis of expression of 9 different mRNA transcripts was also performed at 4, 8, and 13 weeks post wounding (Table 3)

Table 3: mRNA transcripts analyzed by XP-PCR

Gene Measured	Identifier (Accession)
Collagen1-a1 (COL1A1)	NM_000088
CollagenI-a2 (COL1A2)	NM_000089
Collagen III-a1 (COL3A1)	NM_000090
Connective Tissue Growth Factor (CTGF)	NM_001901
Transforming Growth factor-beta1 (TGF- β 1)	NM_000660
Mothers Against Decapentaplegic Homolog 3 (SMAD3)	NM_005902
Elastin	M_36860
Matrix metalloproteinase 1 (MMP-1)	NM_002421
α -smooth muscle actin (α -SMA/ACTA2)	NM_001613

[0284] Following post-surgical wounding, increased mRNA expression of CTGF and collagen genes were anticipated. CTGF mRNA expression in the scars was increased from baseline unwounded skin at all three times points, and in all three cohorts (approximately 2-5 fold). Increased expression of a variety of genes known to be associated with scarring, including the collagen genes, such as Col1A2 (5-8 fold) and Col3A1 (3-7 fold), was also observed, as would be expected in developing scar tissues.

[0285] When compared to the corresponding placebo treated scar at all three time-points measured, suppression of CTGF mRNA induction was observed following EXC 001 injections. As shown in **Figure 7A**, at week 13, the overall (across all 3 cohorts) EXC 001 mediated reduction in

CTGF mRNA induction was 53%. The degree of CTGF mRNA suppression also varied with time and cohort dosing. For example, in one cohort a single dose of 5mg/cm reduced the induction in expression of CTGF by 74% ($p = 0.011$) to an induction of only 140% expression compared to unwounded skin (measurement taken two weeks after the last dose of EXC 001) (**Figure 7D**). In addition, the overall induced mRNA expression levels of Col1A2, Col3A1 (**Figure 7B**), and elastin fibers (ELASF) (**Figure 7C**) were also significantly decreased (by 40% ($p=0.0013$), 69% ($p<0.0001$), and 63% ($p=0.0004$), respectively) by EXC 001 treatment, when measured at week 13 (across all three cohorts).

[0286] Complete inhibition of collagen gene expression would likely not be a desirable outcome of drug treatment, as some collagen gene expression is required to facilitate normal wound repair and healing processes. As shown in **Figures 7D and E**, there was no significant inhibition of either SMAD3 or TGF β 1 mRNA expression by EXC 001 treatment compared to placebo at weeks 4 or 13.

[0287] These data demonstrate a mechanism of action for EXC 001 in human. These data also demonstrate a mechanism by which EXC 001 is able to reduce the severity of skin scarring.

SEQUENCE LISTING

[0288]

<110> Excaliard Pharmaceuticals, Inc.

Dean, Nicholas M.

Krochmal, Lincoln

Hardee, Gregory

Foulkes, J. Gordon

O'Donnell, Niall

Young, Leroy

Jewell, Mark

<120> Method of Treating Keloids Or Hypertrophic Scars Using Antisense Compounds Targeting Connective Tissue Growth Factor (CTGF)

<130> 81583-A-PCT/JPW/BI

<150> 61/438,879

<151> 2011-02-02

<150> 61/488,666

<151> 2011-05-20

<150> 61/527,821

<151> 2011-08-26

<160> 167

<170> PatentIn version 3.5

<210> 1

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Positive control oligonucleotide directed to human H-ras

<400> 1

tccgtcatcg ctctcaggg 20

<210> 2

<211> 2075

<212> DNA

<213> Homo sapiens

<220>

<221> exon

<222> (130)..(1180)

<400> 2

```

cccggccgac agccccgaga cgacagcccg gcgcgtcccg gtccccacct ccgaccaccg      60
ccagcgctcc aggccccgcg ctccccgctc gccgccaccg cgccctccgc tccgcccgcga      120
gtgccaaacc atg acc gcc gcc agt atg ggc ccc gtc cgc gtc gcc ttc gtg      171
          Met Thr Ala Ala Ser Met Gly Pro Val Arg Val Ala Phe Val
          1              5              10

gtc ctc ctc gcc ctc tgc agc cgg ccg gcc gtc ggc cag aac tgc agc      219
Val Leu Leu Ala Leu Cys Ser Arg Pro Ala Val Gly Gln Asn Cys Ser
15              20              25              30

ggg ccg tgc ccg tgc ccg gac gag ccg gcg ccg cgc tgc ccg gcg ggc      267
Gly Pro Cys Arg Cys Pro Asp Glu Pro Ala Pro Arg Cys Pro Ala Gly
          35              40              45

gtg agc ctc gtg ctg gac ggc tgc ggc tgc tgc cgc gtc tgc gcc aag      315
Val Ser Leu Val Leu Asp Gly Cys Gly Cys Cys Arg Val Cys Ala Lys
          50              55              60

cag ctg ggc gag ctg tgc acc gag cgc gac ccc tgc gac ccg cac aag      363
Gln Leu Gly Glu Leu Cys Thr Glu Arg Asp Pro Cys Asp Pro His Lys
          65              70              75

ggc ctc ttc tgt gac ttc ggc tcc ccg gcc aac cgc aag atc ggc gtg      411
Gly Leu Phe Cys Asp Phe Gly Ser Pro Ala Asn Arg Lys Ile Gly Val
          80              85              90

tgc acc gcc aaa gat ggt gct ccc tgc atc ttc ggt ggt acg gtg tac      459
Cys Thr Ala Lys Asp Gly Ala Pro Cys Ile Phe Gly Gly Thr Val Tyr
          95              100              105              110

cgc agc gga gag tcc ttc cag agc agc tgc aag tac cag tgc acg tgc      507
Arg Ser Gly Glu Ser Phe Gln Ser Ser Cys Lys Tyr Gln Cys Thr Cys
          115              120              125

ctg gac ggg gcg gtg ggc tgc atg ccc ctg tgc agc atg gac gtt cgt      555
Leu Asp Gly Ala Val Gly Cys Met Pro Leu Cys Ser Met Asp Val Arg
          130              135              140

ctg ccc agc cct gac tgc ccc ttc ccg agg agg gtc aag ctg ccc ggg      603

```

Leu Pro Ser Pro Asp Cys Pro Phe Pro Arg Arg Val Lys Leu Pro Gly	
145 150 155	
aaa tgc tgc gag gag tgg gtg tgt gac gag ccc aag gac caa acc gtg	651
Lys Cys Cys Glu Glu Trp Val Cys Asp Glu Pro Lys Asp Gln Thr Val	
160 165 170	
gtt ggg cct gcc ctc gcg gct tac cga ctg gaa gac acg ttt ggc cca	699
Val Gly Pro Ala Leu Ala Ala Tyr Arg Leu Glu Asp Thr Phe Gly Pro	
175 180 185 190	
gac cca act atg att aga gcc aac tgc ctg gtc cag acc aca gag tgg	747
Asp Pro Thr Met Ile Arg Ala Asn Cys Leu Val Gln Thr Thr Glu Trp	
195 200 205	
agc gcc tgt tcc aag acc tgt ggg atg gcc atc tcc acc cgg gtt acc	795
Ser Ala Cys Ser Lys Thr Cys Gly Met Gly Ile Ser Thr Arg Val Thr	
210 215 220	
aat gac aac gcc tcc tgc agg cta gag aag cag agc cgc ctg tgc atg	843
Asn Asp Asn Ala Ser Cys Arg Leu Glu Lys Gln Ser Arg Leu Cys Met	
225 230 235	
gtc agg cct tgc gaa gct gac ctg gaa gag aac att aag aag ggc aaa	891
Val Arg Pro Cys Glu Ala Asp Leu Glu Glu Asn Ile Lys Lys Gly Lys	
240 245 250	
aag tgc atc cgt act ccc aaa atc tcc aag cct atc aag ttt gag ctt	939
Lys Cys Ile Arg Thr Pro Lys Ile Ser Lys Pro Ile Lys Phe Glu Leu	
255 260 265 270	
tct ggc tgc acc agc atg aag aca tac cga gct aaa ttc tgt gga gta	987
Ser Gly Cys Thr Ser Met Lys Thr Tyr Arg Ala Lys Phe Cys Gly Val	
275 280 285	
tgt acc gac ggc cga tgc tgc acc ccc cac aga acc acc acc ctg ccg	1035
Cys Thr Asp Gly Arg Cys Cys Thr Pro His Arg Thr Thr Thr Leu Pro	
290 295 300	
gtg gag ttc aag tgc cct gac ggc gag gtc atg aag aag aac atg atg	1083
Val Glu Phe Lys Cys Pro Asp Gly Glu Val Met Lys Lys Asn Met Met	
305 310 315	
ttc atc aag acc tgt gcc tgc cat tac aac tgt ccc gga gac aat gac	1131
Phe Ile Lys Thr Cys Ala Cys His Tyr Asn Cys Pro Gly Asp Asn Asp	
320 325 330	
atc ttt gaa tcg ctg tac tac agg aag atg tac gga gac atg gca tga a	1180
Ile Phe Glu Ser Leu Tyr Tyr Arg Lys Met Tyr Gly Asp Met Ala	
335 340 345	
gccagagagt gagagacatt aactcattag actggaactt gaactgattc acatctcatt	1240
tttccgtaaa aatgatttca gtagcacaag ttattttaaatt ctgttttttct aactggggga	1300
aaagattccc acccaattca aaacattgtg ccatgtcaaa caaatagtct atcttcccca	1360
gacactgggtt tgaagaatgt taagacttga cagtggaaact acattagtac acagcaccag	1420
aatgtatatt aaggtgtggc tttaggagca gtgggagggt accggcccg ttagtatcat	1480
cagatcgact cttatacgag taatatgcct gctatttgaa gtgtaattga gaaggaaaat	1540
tttagcgtgc tcaactgacct gcctgtagcc ccagtgcacag ctaggatgtg cattctccag	1600
ccatcaagag actgagtcac gttgttcctt aagtcagaac agcagactca gctctgacat	1660
tctgattcga atgacactgt tcaggaatcg gaatcctgtc gattagactg gacagcttgt	1720
ggcaagtga tttgcctgta acaagccaga ttttttaaaa tttatattgt aaatattgtg	1780
tgtgtgtgtg tgtgtgtata tatatatata tatgtacagt tatctaagtt aatttaaagt	1840
tgtttgtgcc tttttatttt tgtttttaatt gctttgatat ttcaatgtta gcctcaattt	1900

```

ctgaacacca taggtagaat gtaaagcttg tctgacggtt caaagcatga aatggatact      1960
tatatggaaa ttctgctcag atagaatgac agtccgtcaa aacagattgt ttgcaaaggg      2020
gaggcatcag tgtcttgga ggctgatttc taggtaggaa atgtggtagc tcacg          2075

```

<210> 3

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Forward PCR primer directed to human connective tissue growth factor (CTGF)

<400> 3

acaagggcct cttctgtgac tt 22

<210> 4

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Reverse PCR primer directed to human connective tissue growth factor (CTGF)

<400> 4

ggtacaccgt accaccgaag at 22

<210> 5

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR probe directed to human connective tissue growth factor (CTGF)

<400> 5

tgtgcaccgc caaagatggt gct 23

<210> 6

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> Forward PCR primer directed to human GAPDH

<400> 6

gaaggagaag gtcggagtc 19

<210> 7

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Reverse PCR primer directed to human GAPDH

<400> 7

gaagatggtg atgggatttc 20

<210> 8

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR probe directed to human GAPDH

<400> 8

caagcttccc gttctcagcc 20

<210> 9

<211> 2358

<212> DNA

<213> Homo sapiens

<220>

<221> exon

<222> (207)..(1256)

<400> 9

```

aaactcacac aacaactctt ccccgctgag aggagacagc cagtgcgact ccaccctcca      60
gctcgacggc agccgccccg gccgacagcc cagagacgac agcccggcgc gtcccgggtcc      120
ccacctccga ccaccgccag cgctccaggc cccgccgctc cccgctcgcc gccaccgcgc      180
cctccgctcc gcccgcagtg ccaacc atg acc gcc gcc agt atg ggc ccc gtc      233
                        Met Thr Ala Ala Ser Met Gly Pro Val
                        1                      5

cgc gtc gcc ttc gtg gtc ctc ctc gcc ctc tgc agc cgg ccg gcc gtc      281
Arg Val Ala Phe Val Val Leu Leu Ala Leu Cys Ser Arg Pro Ala Val
10                      15                      20                      25

ggc cag aac tgc agc ggg ccg tgc cgg tgc ccg gac gag ccg gcg ccg      329
Gly Gln Asn Cys Ser Gly Pro Cys Arg Cys Pro Asp Glu Pro Ala Pro
                      30                      35                      40

cgc tgc ccg gcg ggc gtg agc ctc gtg ctg gac ggc tgc ggc tgc tgc      377
Arg Cys Pro Ala Gly Val Ser Leu Val Leu Asp Gly Cys Gly Cys Cys
                      45                      50                      55

cgc gtc tgc gcc aag cag ctg ggc gag ctg tgc acc gag cgc gac ccc      425
Arg Val Cys Ala Lys Gln Leu Gly Glu Leu Cys Thr Glu Arg Asp Pro
60                      65                      70

tgc gac ccg cac aag ggc ctc ttc tgt gac ttc ggc tcc ccg gcc aac      473
Cys Asp Pro His Lys Gly Leu Phe Cys Asp Phe Gly Ser Pro Ala Asn
75                      80                      85

```

cgc aag atc ggc gtg tgc acc gcc aaa gat ggt gct ccc tgc atc ttc 521
 Arg Lys Ile Gly Val Tyr Cys Thr Ala Lys Asp Gly Ala Pro Cys Ile Phe
 90 95 100 105

ggt ggt acg gtg tac cgc agc gga gag tcc ttc cag agc agc tgc aag 569
 Gly Gly Thr Val Tyr Arg Ser Gly Glu Ser Phe Gln Ser Ser Cys Lys
 110 115 120

tac cag tgc acg tgc ctg gac ggg gcg gtg ggc tgc atg ccc ctg tgc 617
 Tyr Gln Cys Thr Cys Leu Asp Gly Ala Val Gly Cys Met Pro Leu Cys
 125 130 135

agc atg gac gtt cgt ctg ccc agc cct gac tgc ccc ttc ccg agg agg 665
 Ser Met Asp Val Arg Leu Pro Ser Pro Asp Cys Pro Phe Pro Arg Arg
 140 145 150

gtc aag ctg ccc ggg aaa tgc tgc gag gag tgg gtg tgt gac gag ccc 713
 Val Lys Leu Pro Gly Lys Cys Cys Glu Glu Trp Val Cys Asp Glu Pro
 155 160 165

aag gac caa acc gtg gtt ggg cct gcc ctc gcg gct tac cga ctg gaa 761
 Lys Asp Gln Thr Val Val Gly Pro Ala Leu Ala Ala Tyr Arg Leu Glu
 170 175 180 185

gac acg ttt ggc cca gac cca act atg att aga gcc aac tgc ctg gtc 809
 Asp Thr Phe Gly Pro Asp Pro Thr Met Ile Arg Ala Asn Cys Leu Val
 190 195 200

cag acc aca gag tgg agc gcc tgt tcc aag acc tgt ggg atg ggc atc 857
 Gln Thr Thr Glu Trp Ser Ala Cys Ser Lys Thr Cys Gly Met Gly Ile
 205 210 215

tcc acc cgg gtt acc aat gac aac gcc tcc tgc agg cta gag aag cag 905
 Ser Thr Arg Val Thr Asn Asp Asn Ala Ser Cys Arg Leu Glu Lys Gln
 220 225 230

agc cgc ctg tgc atg gtc agg cct tgc gaa gct gac ctg gaa gag aac 953
 Ser Arg Leu Cys Met Val Arg Pro Cys Glu Ala Asp Leu Glu Glu Asn
 235 240 245

att aag aag ggc aaa aag tgc atc cgt act ccc aaa atc tcc aag cct 1001
 Ile Lys Lys Gly Lys Lys Cys Ile Arg Thr Pro Lys Ile Ser Lys Pro
 250 255 260 265

atc aag ttt gag ctt tct ggc tgc acc agc atg aag aca tac cga gct 1049
 Ile Lys Phe Glu Leu Ser Gly Cys Thr Ser Met Lys Thr Tyr Arg Ala
 270 275 280

aaa ttc tgt gga gta tgt acc gac ggc cga tgc tgc acc ccc cac aga 1097
 Lys Phe Cys Gly Val Cys Thr Asp Gly Arg Cys Cys Thr Pro His Arg
 285 290 295

acc acc acc ctg ccg gtg gag ttc aag tgc cct gac ggc gag gtc atg 1145
 Thr Thr Thr Leu Pro Val Glu Phe Lys Cys Pro Asp Gly Glu Val Met
 300 305 310

aag aag aac atg atg ttc atc aag acc tgt gcc tgc cat tac aac tgt 1193
 Lys Lys Asn Met Met Phe Ile Lys Thr Cys Ala Cys His Tyr Asn Cys
 315 320 325

ccc gga gac aat gac atc ttt gaa tcg ctg tac tac agg aag atg tac 1241
 Pro Gly Asp Asn Asp Ile Phe Glu Ser Leu Tyr Tyr Arg Lys Met Tyr
 330 335 340 345

gga gac atg gca tga agccagagag tgagagacat taactcatta gactggaact 1296
 Gly Asp Met Ala

tgaactgatt cacatctcat tttccgtaa aaatgatttc agtagcacia gttattttaa 1356

totgtttttc taactggggg aaaagattcc caccgaattc aaaacattgt gccatgtcaa 1416

acaaatagtc tatcaacccc agacactggt ttgaagaatg ttaagacttg acagtggaac 1476

tacattagta cacagcacca gaatgtatat taaggtgtgg cttaggagc agtgggaggg 1536

taccagcaga aaggttagta tcatcagata gcatcttata cgagtaatat gcctgctatt 1596

tgaagtgtaa ttgagaagga aaatttttagc gtgctcactg acctgcctgt agccccagtg	1656
acagctagga tgtgcattct ccagccatca agagactgag tcaagttgtt ccttaagtca	1716
gaacagcaga ctacgctctg acattctgat tCGaatgaca ctgttcagga atcggaatcc	1776
tgtcgattag actggacagc ttgtggcaag tgaatttgcc tgtaacaagc cagatttttt	1836
aaaatttata ttgtaaatat tgtgtgtgtg tgtgtgtgtg tatatatata tatatgtaca	1896
gttatctaag ttaattttaa gttgtttgtg cctttttatt tttgttttta atgctttgat	1956
atttcaatgt tagcctcaat ttctgaacac cataggtaga atgtaaagct tgtctgatcg	2016
ttcaaagcat gaaatggata cttatatgga aattctgctc agatagaatg acagtccgtc	2076
aaaacagatt gtttgcaaag gggaggcatc agtgtccttg gcaggctgat ttctaggtag	2136
gaaatgtggt agcctcactt ttaatgaaca aatggccttt attaaaaact gagtgactct	2196
atatagctga tcagtttttt cacctggaag catttgtttc tactttgata tgactgtttt	2256
toggacagtt tatttgttga gagtgtgacc aaaagttaca tgtttgcacc tttctagtgtg	2316
aaaataaagt gtatatTTTT tctataaaaa aaaaaaaaaa aa	2358

<210> 10

<211> 6001

<212> DNA

<213> Homo sapiens

<400> 10

tatattattc actgtcaatc ttagtttata tccagataca acaggggtaca ctgctcttgt	60
aatggaatca gacttcttat tttaacaaga caaaccaaat ccaatccaca ttggaagatt	120
ataggtttta atataagaaa atgcactcat ttctcaaaga ccctagtga gctgtgttta	180
aatgctccta ggtgaacccc ctttgcaccc cagtgttccc accctgacac ccagagcccc	240
tacctaccca acacagaatc atttgctctg atagaacaat ggatcccttt ttctggaaac	300
attgatggcc actcctccct tgtccttgcc tatataaaac tcctacatat attaagagaa	360
aactaagcaa gagttttgga aatctgcccc aggagactgc atcctgagtc acacgcgtct	420
ttgttctctt tcttgtccca aaaccgttac ctcaagtga aaatgatcaa atctcaaata	480
tagaattcag ggttttacag gtaggcatct tgaggatttc aaatggttaa aagcaactca	540
ctccttttct actctttgga gagtttcaag agcctatagc ctctaaaacg caaatcattg	600
ctaaggggtg ggggggagaa accttttcga attttttagg aattcctgct gtttgccctc	660
tcagctacct acttcctaaa aaggatgtat gtcagtggac agaacagggc aaacttattc	720
gaaaaagaaa taagaaataa ttgccagtgt gtttataaat gatatgaatc aggagtgggtg	780
cgaagaggat agggaaaaaa aaattctatt tgggtgctgga aatactgcgc tttttttttt	840
cctttttttt tttttctgtg agctggagtg tgccagcttt ttcagacgga ggaatgctga	900
gtgtcaaggg gtcaggatca atccggtgtg agttgatgag gcaggaaggt ggggaggaat	960
gcgaggaatg tccctgtttg tgtaggactc cattcagctc attggcgagc cgcggccgcc	1020
cggagcgtat aaaagcctcg ggcgccccgc cccaaactca cacaacaact cttccccgct	1080
gagaggagac agccagtgcg actccaccct ccagctcgac ggcagccgcc ccggccgaca	1140
gccccgagac gacagcccg ggcgtcccg tccccacctc cgaccaccgc cagcgtcca	1200

ggccccgcgc	ctccccgcgc	gccgccaccg	cgccctccgc	tccgcccgca	gtgccaaacca	1260
tgaccgcgcg	cagtatgggc	cccgtccgcg	tgccttcgt	ggctctctc	gccctctgca	1320
gccgggtaag	cgccgggagc	ccccgcgcg	gccggcggt	gccagggagg	gactcggggc	1380
cgcccgggga	ggcggtgcgc	gccgaccgag	cgccgcgtgac	cgccctgtcc	tccctgcagc	1440
cgcccgctgg	ccagaactgc	agcgggccgt	gccggtgccc	ggacgagccg	gcgcgcgcgt	1500
gccccggcgg	cgtgagcctc	gtgctggacg	gctgcggctg	ctgccgcgtc	tgcgccaagc	1560
agctgggcga	gctgtgcacc	gagcgcgacc	catgcgaccc	gcacaagggc	ctattctgtc	1620
actcggcctc	cccggccaac	cgcaagatcg	gcgtgtgca	cggtaaagacc	cgagaccccc	1680
accgctaggt	gtccggccgc	ctcctccctc	acgcccaccc	gcccgcctgga	aaaagaaacc	1740
gctcggaactg	agttttcttc	tccagctgct	gccagcccg	ccctgcagc	ccagatccca	1800
actcgcatcc	ctgacgcctc	ggatgtgaga	gtgccccaat	gcctgacctc	tgcatcccc	1860
acctctctct	tcccttcctc	ttctccagcc	aaagatggtg	ctccctgcat	cttcggtggg	1920
acggtgtacc	gcagcggaga	gtccttcag	agcagctgca	agtaccagtg	cacgtgcctg	1980
gacggggcgg	tgggctgcat	gcccctgtgc	agcatggacg	ttcgtctgcc	cagccctgac	2040
tgcccccttc	cgaggagggt	caagctgccc	gggaaatgct	gcgaggagtg	ggtgtgtgac	2100
gagcccaagg	accaaaccgt	ggttgggcct	gcccctcgcg	gtgagtcgag	tcttcctcta	2160
agtcagggtc	gtgattctct	cccagggagg	gagtcctaac	tgtgccgacc	gaacggggga	2220
aataccttat	ccaggcggtt	tacatggtgt	ttgtgtgctc	tgctctcgca	gcttaccgac	2280
tggaaagacac	gtttggccca	gacccaacta	tgattagagc	caactgcctg	gtccagacca	2340
cagagtggag	cgccctgttc	aagacctgtg	ggatgggcat	ctccacccg	gttaccaatg	2400
acaacgcctc	ctgcaggcta	gagaagcaga	gccgcctgtg	catggtcagg	ccttgccaag	2460
ctgacctgga	agagaacatt	aaggtagatg	ttctgctcct	attaactatt	tttcacagga	2520
aaaacagtgg	ataggaccca	acttagggct	cttgccacgc	ttgttagtat	aagcccgtta	2580
tctccaaaac	tatctaacca	ttgagctgtt	ttgctggaat	gagagcttgt	gtaatagcaa	2640
ccaccagttt	tccactacga	aatcttcac	agggttagtt	aattcaagac	attccaagag	2700
aggctctggc	tatttttggg	catagcaaat	gagactcaaa	cttcctcccc	tcaaaatata	2760
aacagaagtc	agacaacaga	agactaaaac	acagaggggt	gaagaaagcc	actcctcttg	2820
tagagtcgct	gatttttttt	ttcctctct	ctttccctt	gtcttcctta	gaagggcaaa	2880
aagtgcaccc	gtactcccaa	aatctccaag	cctatcaagt	ttgagctttc	tggctgcacc	2940
agcatgaaga	cataccgagc	taaattctgt	ggagtatgta	ccgacggccg	atgctgcacc	3000
ccccacagaa	ccaccaccct	gccggtggag	ttcaagtgcc	ctgacggcga	ggtcatgaag	3060
aagaacatga	tgttcatcaa	gacctgtgcc	tgccattaca	actgtcccgg	agacaatgac	3120
atctttgaat	cgctgtacta	caggaagatg	tacggagaca	tggcatgaag	ccagagagtg	3180
agagacatta	actcattaga	ctggaacttg	aactgattca	catctcattt	ttccgtaaaa	3240
atgatttcag	tagcacaagt	tatttaaato	tgtttttcta	actgggggaa	aagattccca	3300
cccaattcaa	aacattgtgc	catgtcaaac	aaatagtcta	tcaaccccag	acactggttt	3360
gaagaatggt	aagacttgac	agtggaaacta	cattagtaca	cagcaccaga	atgtatatata	3420
aggtgtggct	ttaggagcag	tgggagggtta	ccagcagaaa	ggttagtatc	atcagatagc	3480

atcttatacg agtaatatgc ctgctatttg aagtgttaatt gagaaggaaa attttagcgt	3540
gctcactgac ctgcctgtag cccagtgac agctaggatg tgcattctcc agccatcaag	3600
agactgagtc aagttgttcc ttaagtcaga acagcagact cagctctgac attctgattc	3660
gaatgacact gttcaggaat cggaatcctg tcgattagac tggacagctt gtggcaagtg	3720
aatttgccctg taacaagcca gattttttaa aatttatatt gtaaattattg tgtgtgtgtg	3780
tgtgtgtgta tatatatata tatgtacagt tatctaagtt aatttaaagt tgtttgtgcc	3840
tttttatttt tgtttttaat gctttgatat ttcaatgtta gcctcaattt ctgaacacca	3900
taggtagaat gtaaagcttg tctgatcgtt caaagcatga aatggatact tatatggaaa	3960
ttctgctcag atagaatgac agtccgtcaa aacagattgt ttgcaaaggg gaggcacag	4020
tgtccttggc aggtcgattt ctaggtagga aatgtggtag cctcactttt aatgaacaaa	4080
tggcctttat taaaaactga gtgactctat atagctgac agttttttca cctggaagca	4140
tttgtttcta ctttgatatg actgttttcc ggacagttta tttgttgaga gtgtgaccaa	4200
aagttacatg tttgcacctt tctagttgaa aataaagtgt atattttttc tataaagggc	4260
ttggttattc atttatcctt ctaaacattt ctgagttttc ttgagcataa ataggaagtt	4320
cttattaatc ataagataat tcaccaataa ttttctaaat atctttaatt attctataca	4380
ttaataaatt gattattcca tagaattttt atgtaaacat acttcacact gaatcaagta	4440
tcacagactt gcaggcatac acaccacatt gactatacag ccattttttt tgttatcttc	4500
acagaacttt atagacactt taaattcaat tctctctaga ttacttcagt ctccattaac	4560
cctgttgtat tacacttggc ccttttggca tttgtacctc tctggccgtt ataggtagt	4620
ttccaacctt tcacatcaca aactagtcta tgtgccttgc acgtggaaaa tgtttacatt	4680
ttttaaaaat tttatgctct aggtctgttt ctgaacttca ttaccttact gttaaatctg	4740
aaaattatga aatgaaatcc tcattttaa atgtgctattt cataagtctt gttttgtata	4800
attccgtttt tggttgccat gataaccaat gacaacaga tggcataaat agaaaaggga	4860
ggatgagcaa atcttccatt cattaacatt aatagaaatt tgttttgaaa gtaattcctc	4920
catttgccca agtcttttagc tttatcagac ttccagatta atgcatacta cttaccaag	4980
tggtttatac atgagaaaa atggaattgttc aagaagcctc atgtggaaac aatattgtac	5040
ctaccaggt aggtttttac taaagagtga accaaagtga atggtaaaca aaagcaatac	5100
accaaaggca actagaatct tctccacatg aggatagctg aggattctag gggaaaaaaa	5160
aattgcagac agactaactt ttccaagggt aattagcaac gttgtagtgc caatgtcatt	5220
tggacagaca aaaatacacc tgaaaaataa gactagctct acaaacact gtccacacca	5280
caaaccaag ggaaaacttc ccgtgttcag aatgtgaaa tttatggtca aaactctggg	5340
ctttaaggat acaccacat ctgtatatag cagtgtgcc aggagcagca cccacctcc	5400
ccaaataaat gcgcatgtac acatacacat aggcacacac acagagtaca ctgttagttc	5460
acacttcctt tctgtcaatt aattcctaac tgcaaagatg aagggccatg catgataaac	5520
gagactgact actgaattag agcattctgg aatatagaa gcagcaggaa aagcatagat	5580
ttcacatttt ccaaataccc acattaaaga aaaaaaaag agtcactaga ttgcaaaaca	5640
aaaatcccac aggoaatgtt tctacaaaaa ttagatggoa atgcacactt tcacccccca	5700
aatatcgag gtaggggggtg ccaaatcatc aaccaccgta agatctgcac cgtgtcagca	5760
catgtgtgag aaaagcagag aaacaacaag gtatctgatg cttctgagaa cagcagagct	5820

ctcaaacagc cagcaggtag tcactagata tatagaaggc caggetgaca gcagctgttg	5880
aatctagtag gggtttggcc tagcactcca acaaagctta caagccaggg ctgcctccca	5940
ggagaagatc ctcatactcc tggaagtgga atctaaattg agcaggtcac cagacagatg	6000
t	6001

<210> 11

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 11

ccagctgctt ggccgagacg 20

<210> 12

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 12

gccagaaagc tcaaactga 20

<210> 13

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 13

ccacaagctg tccagtctaa 20

<210> 14

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 14

ggtcacactc tcaacaata 20

<210> 15

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 15

aaacatgtaa ctttgggtca 20

<210> 16

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 16

gggaagagtt gttgtgtgag 20

<210> 17

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 17

agggtggagt cgactggct 20

<210> 18

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 18

acgaaggcga cgcggacggg 20

<210> 19

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 19

gccgacggcc ggccggctgc 20

<210> 20

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 20

ggtgcacacg ccgatcttgc 20

<210> 21

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 21

tctttggcgg tgcacagcc 20

<210> 22

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 22

gcaccatctt tggcggtgca 20

<210> 23

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 23

gcagggagca ccatctttgg 20

<210> 24

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 24

aagatgcagg gagcaccatc 20

<210> 25

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 25

ccaccgaaga tgcagggagc 20

<210> 26

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 26

ccgtaccacc gaagatgcag 20

<210> 27

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 27

gtacttgcag ctgctctgga 20

<210> 28

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 28
gggcatgcag cccaccgccc 20

<210> 29
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 29
aggcccaacc acggtttggt 20

<210> 30
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 30
agggcaggcc caaccacggt 20

<210> 31
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 31
taagccgcga gggcaggccc 20

<210> 32
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 32
cccacaggtc ttggaacagg 20

<210> 33
<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 33

agatgcccat cccacaggtc 20

<210> 34

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 34

ccagtctaag gagttaatgt 20

<210> 35

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 35

ttcaagttcc agtctaagga 20

<210> 36

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 36

ttttcccca gtagaaaaa 20

<210> 37

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 37

cacaatgttt tgaattgggt 20

<210> 38

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 38

acatggcaca atgttttgaa 20

<210> 39

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 39

gtttgacatg gcacaatgtt 20

<210> 40

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 40

tatttgtttg acatggcaca 20

<210> 41

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 41

tgatagacta ttgtttgac 20

<210> 42

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 42

gttcactgt caagtcttaa 20

<210> 43

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 43

tgtactaatg tagttccact 20

<210> 44

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 44

cattctggtg ctgtgtacta 20

<210> 45

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 45

taatatacat tctggtgctg 20

<210> 46

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 46

acaccttaat atacattctg 20

<210> 47

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 47

taaagccaca ccttaatata 20

<210> 48

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 48

gtaccctccc actgctccta 20

<210> 49

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 49

aagatgctat ctgatgatac 20

<210> 50

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 50

cgtataagat gctatctgat 20

<210> 51

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 51

aatagcaggc atattactcg 20

<210> 52

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 52

tacacttcaa atagcaggca 20

<210> 53

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 53

tcaattacac ttcaaatagc 20

<210> 54

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 54

ggagaatgca catcctagct 20

<210> 55

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 55

atggctggag aatgcacatc 20

<210> 56

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 56

tcttgatggc tggagaatgc 20

<210> 57

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 57

gaatcagaat gtcagagctg 20

<210> 58

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 58

cattgaaata tcaaagcatt 20

<210> 59

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 59

ggctaacatt gaaatatcaa 20

<210> 60

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 60

aattgaggct aacattgaaa 20

<210> 61

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 61

gttcagaaat tgaggctaac 20

<210> 62

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 62

tatggtgttc agaaattgag 20

<210> 63

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 63

ctacctatgg tggtcagaaa 20

<210> 64

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 64

tacattctac ctatggtgtt 20

<210> 65

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 65

gacaagcttt acattctacc 20

<210> 66

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 66

gatcagacaa gctttacatt 20

<210> 67

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 67

atgctttgaa cgatcagaca 20

<210> 68

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 68

atttcagtct ttgaacgac 20

<210> 69

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 69

gtatccattt catgctttga 20

<210> 70

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 70

ccatataagt atccatttca 20

<210> 71

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 71

gaatttccat ataagtatcc 20

<210> 72

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 72

tctgagcaga atttccatat 20

<210> 73

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 73

tgtcattcta tctgagcaga 20

<210> 74

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 74

tttgacggac tgtcattcta 20

<210> 75

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 75

aacaatctgt tttgacggac 20

<210> 76

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 76

tgatgcctcc ccttgcaaa 20

<210> 77

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 77

tgccaaggac actgatgcct 20

<210> 78

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 78

cagcctgccaggacactga 20

<210> 79

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 79

gaaatcagcc tgccaaggac 20

<210> 80

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 80

acctagaaat cagcctgccaggac 20

<210> 81

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 81

ttcttaccta gaaatcagcc 20

<210> 82

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 82

taccacattt cctacctaga 20

<210> 83

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 83

tgaggctacc acatttcta 20

<210> 84

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 84

taaaagtgag gctaccacat 20

<210> 85

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 85

caaatgcttc caggtgaaaa 20

<210> 86

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 86

tagaaacaaa tgcttcagg 20

<210> 87

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 87

tcatatcaaa gtagaaacaa 20

<210> 88

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 88

tccgaaaaac agtcatatca 20

<210> 89

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 89

acccggctgc agagggcgag 20

<210> 90

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 90

cgcttaccgc gctgcagagg 20

<210> 91

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 91

gacagggcgg tcagcggcgc 20

<210> 92

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 92

agtccgagcg gtttctttt 20

<210> 93

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 93

aactcagtc gagcggtttc 20

<210> 94

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 94

aaagaaactc agtccgagcg 20

<210> 95

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 95

tggagaaaga aactcagtc 20

<210> 96

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 96

gcagctggag aaagaaactc 20

<210> 97

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 97

tggcagcagc tggagaaaga 20

<210> 98

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 98

agggagcacc atcttggct 20

<210> 99

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 99

tcacccgcga gggcaggccc 20

<210> 100

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 100

ggaagactcg actcacccgc 20

<210> 101

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 101

ttagaggaag actcgactca 20

<210> 102

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 102

accctgactt agaggaagac 20

<210> 103

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 103

tcacgaccct gacttagagg 20

<210> 104

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 104

gagaatcacg accctgactt 20

<210> 105

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 105

tgggagagaa tcacgaccct 20

<210> 106

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 106

ctccctggga gagaatcacg 20

<210> 107

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 107

ggtcggcaca gttaggactc 20

<210> 108

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 108

cgttcggtcg gcacagttag 20

<210> 109

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 109

cctggataag gtatttcccc 20

<210> 110

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 110

acaaacacca tgtaaaacgc 20

<210> 111

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 111

gagcacacaa acaccatgta 20

<210> 112

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 112

tgcgagagca gagcacacaa 20

<210> 113

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 113

taagctgcga gagcagagca 20

<210> 114

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 114

gtcggtaagc tgcgagagca 20

<210> 115

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 115

ttccagtcgg taagctgcga 20

<210> 116

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 116

acatgtacct taatgttctc 20

<210> 117

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 117

gcagaacatg taccttaatg 20

<210> 118

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 118

taggagcaga acatgtacct 20

<210> 119

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 119

gttaatagga gcagaacatg 20

<210> 120

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 120

tgaaaaatag ttaataggag 20

<210> 121

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 121

ccactgtttt tcctgtgaaa 20

<210> 122

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 122

aagttgggtc ctatccactg 20

<210> 123

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 123

gccctaagtt gggctctatc 20

<210> 124

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 124

caagagccct aagttgggtc 20

<210> 125

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 125

cgtggcaaga gccctaagtt 20

<210> 126

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 126

cgggcttata ctaacaagcg 20

<210> 127

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 127

gataacgggc ttatactaac 20

<210> 128

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 128

ttggagataa cgggcttata 20

<210> 129

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 129

tagttttgga gataacgggc 20

<210> 130

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 130

ttagatagtt ttggagataa 20

<210> 131

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 131

caatggtag atagttttgg 20

<210> 132

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 132

cagctcaatg gtagatagt 20

<210> 133

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 133

caaaacagct caatggtag 20

<210> 134

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 134

tccagcaaaa cagctcaatg 20

<210> 135

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 135

ctattccag caaaacagct 20

<210> 136

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 136

aagctctcat tccagcaaaa 20

<210> 137

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 137

tacacaagct ctcatccag 20

<210> 138

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 138

ggttgctatt acacaagctc 20

<210> 139

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 139

ctggtggttg ctattacaca 20

<210> 140

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 140

gaaaactggt ggttgctatt 20

<210> 141

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 141

tagtgaaaa ctggtggttg 20

<210> 142

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 142

ttaactaacc ctgtggaaga 20

<210> 143

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 143

tgtcttgaat taactaacc 20

<210> 144

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 144

tggaatgtct tgaattaact 20

<210> 145

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 145

gccagagcct ctcttgaat 20

<210> 146

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 146

aaaaatagcc agagcctctc 20

<210> 147

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 147

tgtcaaaaa tagccagagc 20

<210> 148

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 148

tgctatgtcc aaaaatagcc 20

<210> 149

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 149

tcatttgcta tgtcaaaaa 20

<210> 150

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 150

gagtctcatt tgctatgtcc 20

<210> 151

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 151

agtttgagtc tcatttgcta 20

<210> 152

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 152

gaggaagttt gagtctcatt 20

<210> 153

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 153

cttctgttgt ctgactctg 20

<210> 154

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 154

cctctgtgtt ttagtcttct 20

<210> 155

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 155

tttctcaac cctctgtgtt 20

<210> 156

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 156

ggagtggcctt tcttcaaccc 20

<210> 157

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 157

aggaagacaa gggaaaagag 20

<210> 158

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 158

ttctaaggaa gacaaggaa 20

<210> 159

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 159

tgcccttcta aggaagacaa 20

<210> 160

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 160

ggatgcgagt tgggatctgg 20

<210> 161

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 161

ccagctgctt ggcgcagacg 20

<210> 162

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 162

gccagaaagc tcaaactga 20

<210> 163

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 163

ccacaagctg tccagtctaa 20

<210> 164

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 164

ggtcacactc tcaacaaata 20

<210> 165

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 165

aaacatgtaa ctttgggtca 20

<210> 166

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 166

tgacatggca caatgttttg 20

<210> 167

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense directed to human connective tissue growth factor (CTGF)

<400> 167

ccttcctga aggttctcc 20

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- US6152782A [0001]

- [US6148866B \[0001\]](#)
- [US61438879B \[0001\]](#)
- [US6965025B2 \[0004\] \[0006\]](#)
- [WO2010042281A \[0017\]](#)
- [WO2010027830A \[0017\]](#)
- [US2007068401W \[0096\]](#)
- [US3687808A \[0115\] \[0139\] \[0140\]](#)
- [US4469863A \[0115\]](#)
- [US4476301A \[0115\]](#)
- [US5023243A \[0115\]](#)
- [US5177196A \[0115\]](#)
- [US5188897A \[0115\]](#)
- [US5264423A \[0115\]](#)
- [US5276019A \[0115\]](#)
- [US5278302A \[0115\]](#)
- [US5286717A \[0115\]](#)
- [US5321131A \[0115\]](#)
- [US5399676A \[0115\]](#)
- [US5405939A \[0115\]](#)
- [US5453496A \[0115\]](#)
- [US5455233A \[0115\]](#)
- [US5466677A \[0115\] \[0117\]](#)
- [US5476925A \[0115\]](#)
- [US5519126A \[0115\]](#)
- [US5536821A \[0115\]](#)
- [US5541306A \[0115\]](#)
- [US5550111A \[0115\]](#)
- [US5563253A \[0115\]](#)
- [US5571799A \[0115\]](#)
- [US5587361A \[0115\]](#)
- [US5194599A \[0115\]](#)
- [US5565555A \[0115\]](#)
- [US5527899A \[0115\]](#)
- [US5721218A \[0115\]](#)
- [US5672697A \[0115\]](#)
- [US5625050A \[0115\]](#)
- [US5034506A \[0117\] \[0119\]](#)
- [US5166315A \[0117\]](#)
- [US5185444A \[0117\]](#)
- [US5214134A \[0117\]](#)
- [US5216141A \[0117\]](#)
- [US5235033A \[0117\]](#)
- [US5264562A \[0117\]](#)
- [US5264564A \[0117\]](#)
- [US5405938A \[0117\]](#)

- [US5434257A \[0117\]](#)
- [US5470967A \[0117\]](#)
- [US5489677A \[0117\] \[0119\]](#)
- [US5541307A \[0117\]](#)
- [US5561225A \[0117\]](#)
- [US5596086A \[0117\]](#)
- [US5602240A \[0117\] \[0117\] \[0119\]](#)
- [US5610289A \[0117\] \[0117\]](#)
- [US5608046A \[0117\] \[0155\]](#)
- [US5618704A \[0117\]](#)
- [US5623070A \[0117\]](#)
- [US5663312A \[0117\]](#)
- [US5633360A \[0117\]](#)
- [US5677437A \[0117\]](#)
- [US5792608A \[0117\]](#)
- [US5646269A \[0117\]](#)
- [US5677439A \[0117\]](#)
- [US5539082A \[0118\]](#)
- [US5714331A \[0118\]](#)
- [US5719262A \[0118\]](#)
- [US7399845B \[0120\]](#)
- [WO2007146511A \[0120\]](#)
- [WO9839352A \[0130\]](#)
- [WO9914226A \[0130\]](#)
- [US4981957A \[0131\]](#)
- [US5118800A \[0131\]](#)
- [US5319080A \[0131\]](#)
- [US5359044A \[0131\]](#)
- [US5393878A \[0131\]](#)
- [US5446137A \[0131\]](#)
- [US5466786A \[0131\]](#)
- [US5514785A \[0131\] \[0155\]](#)
- [US5519134A \[0131\]](#)
- [US5567811A \[0131\]](#)
- [US5576427A \[0131\]](#)
- [US5591722A \[0131\]](#)
- [US5597909A \[0131\]](#)
- [US5610300A \[0131\]](#)
- [US5627053A \[0131\]](#)
- [US5639873A \[0131\]](#)
- [US5646265A \[0131\]](#)
- [US5658873A \[0131\]](#)
- [US5670633A \[0131\]](#)
- [US5792747A \[0131\]](#)
- [US5700920A \[0131\]](#)

- [US4845205A \[0140\]](#)
- [US5130302A \[0140\]](#)
- [US5134066A \[0140\]](#)
- [US5175273A \[0140\]](#)
- [US5367066A \[0140\]](#)
- [US5432272A \[0140\]](#)
- [US5457187A \[0140\]](#)
- [US5459255A \[0140\]](#)
- [US5484908A \[0140\]](#)
- [US5502177A \[0140\]](#)
- [US5525711A \[0140\]](#)
- [US5552540A \[0140\]](#)
- [US5587469A \[0140\]](#)
- [US5594121A \[0140\]](#)
- [US5596091A \[0140\]](#)
- [US5614617A \[0140\]](#)
- [US5645985A \[0140\]](#)
- [US5830653A \[0140\]](#)
- [US5763588A \[0140\]](#)
- [US6005096A \[0140\]](#)
- [US5681941A \[0140\]](#)
- [US5750692A \[0140\]](#)
- [US5013830A \[0152\]](#)
- [US5149797A \[0152\]](#)
- [US5220007A \[0152\]](#)
- [US5256775A \[0152\]](#)
- [US5366878A \[0152\]](#)
- [US5403711A \[0152\]](#)
- [US5491133A \[0152\]](#)
- [US5565350A \[0152\]](#)
- [US5623065A \[0152\]](#)
- [US5652355A \[0152\]](#)
- [US5652356A \[0152\]](#)
- [US5700922A \[0152\]](#)
- [US9209196W \[0154\]](#)
- [US33413099A \[0154\]](#)
- [US4828979A \[0155\]](#)
- [US4948882A \[0155\]](#)
- [US5218105A \[0155\]](#)
- [US5525465A \[0155\]](#)
- [US5541313A \[0155\]](#)
- [US5545730A \[0155\]](#)
- [US5552538A \[0155\]](#)
- [US5578717A \[0155\]](#)
- [US5580731A \[0155\] \[0155\]](#)

- [US5591584A \[0155\]](#)
- [US5109124A \[0155\]](#)
- [US5118802A \[0155\]](#)
- [US5138045A \[0155\]](#)
- [US5414077A \[0155\]](#)
- [US5486603A \[0155\]](#)
- [US5512439A \[0155\]](#)
- [US5578718A \[0155\]](#)
- [US4587044A \[0155\]](#)
- [US4605735A \[0155\]](#)
- [US4667025A \[0155\]](#)
- [US4762779A \[0155\]](#)
- [US4789737A \[0155\]](#)
- [US4824941A \[0155\]](#)
- [US4835263A \[0155\]](#)
- [US4876335A \[0155\]](#)
- [US4904582A \[0155\]](#)
- [US4958013A \[0155\]](#)
- [US5082830A \[0155\] \[0155\]](#)
- [US5112963A \[0155\] \[0155\]](#)
- [US5214136A \[0155\] \[0155\]](#)
- [US5245022A \[0155\]](#)
- [US5254469A \[0155\]](#)
- [US5258506A \[0155\]](#)
- [US5262536A \[0155\]](#)
- [US5272250A \[0155\]](#)
- [US5292873A \[0155\]](#)
- [US5317098A \[0155\]](#)
- [US5371241A \[0155\]](#)
- [US5391723A \[0155\]](#)
- [US5416203A \[0155\]](#)
- [US5451463A \[0155\]](#)
- [US5510475A \[0155\]](#)
- [US5512667A \[0155\]](#)
- [US5565552A \[0155\]](#)
- [US5567810A \[0155\]](#)
- [US5574142A \[0155\]](#)
- [US5585481A \[0155\]](#)
- [US5587371A \[0155\]](#)
- [US5595726A \[0155\]](#)
- [US5597696A \[0155\]](#)
- [US5599923A \[0155\]](#)
- [US5599928A \[0155\]](#)
- [US5688941A \[0155\]](#)
- [WO9324510A \[0165\]](#)

- [WO9426764A \[0165\]](#)
- [US5770713A \[0165\]](#)
- [US31529899A \[0179\]](#)
- [US4837028A \[0197\]](#)
- [WO8804924A \[0197\]](#)
- [US5543152A \[0197\] \[0219\]](#)
- [WO9713499A \[0197\]](#)
- [US4426330A \[0198\] \[0219\]](#)
- [US4534899A \[0198\] \[0219\]](#)
- [EP0445131B1 \[0198\]](#)
- [WO9004384A \[0198\]](#)
- [US5013556A \[0198\] \[0219\]](#)
- [US5356633A \[0198\] \[0219\]](#)
- [US5213804A \[0198\] \[0219\]](#)
- [EP0496813B1 \[0198\]](#)
- [WO9105545A \[0198\]](#)
- [US5225212A \[0198\]](#)
- [WO9420073A \[0198\]](#)
- [WO9610391A \[0198\]](#)
- [US5540935A \[0198\]](#)
- [US5556948A \[0198\] \[0219\]](#)
- [WO9640062A \[0199\]](#)
- [US5264221A \[0199\] \[0219\]](#)
- [US5665710A \[0199\]](#)
- [WO9704787A \[0199\]](#)
- [US5705188A \[0214\]](#)
- [WO9730731A \[0214\]](#)
- [US5108921A \[0219\] \[0219\]](#)
- [US5354844A \[0219\]](#)
- [US5416016A \[0219\] \[0219\]](#)
- [US5459127A \[0219\]](#)
- [US5521291A \[0219\]](#)
- [US5543158A \[0219\]](#)
- [US5547932A \[0219\]](#)
- [US5583020A \[0219\]](#)
- [US5591721A \[0219\]](#)
- [US5227170A \[0219\]](#)
- [US5395619A \[0219\]](#)
- [US5417978A \[0219\]](#)
- [US5462854A \[0219\]](#)
- [US5469854A \[0219\]](#)
- [US5512295A \[0219\]](#)
- [US5527528A \[0219\]](#)
- [US5534259A \[0219\]](#)
- [US5580575A \[0219\]](#)

- [US5595756A \[0219\]](#)

Non-patent literature cited in the description

- **LAULAM**Exp. Cell Res., 1999, vol. 248, 44-57 [\[0007\]](#)
- **BRADHAM et al.**J. Cell Biol., 1991, vol. 114, 1285-1294 [\[0007\]](#)
- Exp. Cell Res., 2000, vol. 259, 213-224 [\[0010\]](#)
- Plast. Reconstr. Surg., 2005, vol. 116, 1387-90 [\[0010\]](#)
- Ann. Surg., 2007, vol. 246, 5886-95 [\[0010\]](#)
- J. Invest. Derm., 1996, vol. 106, 729-733 [\[0011\]](#)
- J. Japan Soc. Plastic Reconstr. Surg., 2002, vol. 22, 560-565 [\[0011\]](#)
- Plast. Reconstr. Surg., 2005, vol. 116, 1387-1390 [\[0011\]](#)
- J. Cell Physiol., 2006, vol. 208, 2336-43 [\[0011\]](#)
- **WOOLF et al.**Proc. Natl. Acad. Sci. USA, 1992, vol. 89, 7305-7309 [\[0093\]](#)
- **GAUTSCHI et al.**J. Natl. Cancer Inst., 2001, vol. 93, 463-471 [\[0094\]](#)
- **MAHERDOLNICK**Nuc. Acid. Res., 1988, vol. 16, 3341-3358 [\[0095\]](#)
- **NIELSEN et al.**Science, 1991, vol. 254, 1497-1500 [\[0118\]](#)
- **MARTIN et al.**Helv. Chim. Acta, 1995, vol. 78, 486-504 [\[0129\]](#)
- **SINGH et al.**Chem. Commun., 1998, vol. 4, 455-456 [\[0130\]](#)
- Antisense Research and ApplicationsCRC Press19930000276-278 [\[0135\]](#) [\[0139\]](#)
- The Concise Encyclopedia Of Polymer Science And EngineeringJohn Wiley & Sons19900000858-859 [\[0139\]](#)
- **ENGLISCH et al.**Angewandte Chemie, International Edition, 1991, vol. 30, 613- [\[0139\]](#)
- **SANGHVI, Y. S.**Antisense Research and ApplicationsCRC Press19930000289-302 [\[0139\]](#)
- **LETSINGER et al.**Proc. Natl. Acad. Sci. USA, 1989, vol. 86, 6553-6556 [\[0154\]](#)
- **MANOHARAN et al.**Bioorg. Med. Chem. Let., 1994, vol. 4, 1053-1060 [\[0154\]](#)
- **MANOHARAN et al.**Ann. N.Y. Acad. Sci., 1992, vol. 660, 306-309 [\[0154\]](#)
- **MANOHARAN et al.**Bioorg. Med. Chem. Let., 1993, vol. 3, 2765-2770 [\[0154\]](#)
- **OBERHAUSER et al.**Nucl. Acids Res., 1992, vol. 20, 533-538 [\[0154\]](#)
- **SAISON-BEHMOARAS et al.**EMBO J., 1991, vol. 10, 1111-1118 [\[0154\]](#)
- **KABANOV et al.**FEBS Lett., 1990, vol. 259, 327-330 [\[0154\]](#)
- **SVINARCHUK et al.**Biochimie, 1993, vol. 75, 49-54 [\[0154\]](#)
- **MANOHARAN et al.**Tetrahedron Lett., 1995, vol. 36, 3651-3654 [\[0154\]](#) [\[0154\]](#)
- **SHEA et al.**Nucl. Acids Res., 1990, vol. 18, 3777-3783 [\[0154\]](#)
- **MANOHARAN et al.**Nucleosides & Nucleotides, 1995, vol. 14, 969-973 [\[0154\]](#)
- **MISHRA et al.**Biochim. Biophys. Acta, 1995, vol. 1264, 229-237 [\[0154\]](#)
- **CROOKE et al.**J. Pharmacol. Exp. Ther., 1996, vol. 277, 923-937 [\[0154\]](#)
- **BERGE et al.**Pharmaceutical SaltsJ. of Pharma Sci., 1977, vol. 66, 1-19 [\[0167\]](#)
- **MIYAO et al.**Antisense Res. Dev., 1995, vol. 5, 115-121 [\[0170\]](#)
- **TAKAKURA et al.**Antisense & Nucl. Acid Drug Dev., 1996, vol. 6, 177-183 [\[0170\]](#)
- **ROSOFF**Pharmaceutical Dosage FormsMarcel Dekker, Inc.19880000vol. 1, 245- [\[0187\]](#)
- **WANG et al.**Biochem. Biophys. Res. Commun., 1987, vol. 147, 980-985 [\[0191\]](#)

- **ZHOU et al.**Journal of Controlled Release, 1992, vol. 19, 269-274 [\[0192\]](#)
- **WEINER et al.**Journal of Drug Targeting, 1992, vol. 2, 405-410 [\[0194\]](#)
- **DU PLESSIS et al.**Antiviral Research, 1992, vol. 18, 259-265 [\[0194\]](#)
- **HU et al.**S.T.P.Pharma. Sci., 1994, vol. 4, 6466- [\[0195\]](#)
- **ALLEN et al.**FEBS Letters, 1987, vol. 223, 42- [\[0196\]](#)
- **WU et al.**Cancer Research, 1993, vol. 53, 3765- [\[0196\]](#)
- **PAPAHADJOPOULOS et al.**Ann. N.Y. Acad. Sci., 1987, vol. 507, 64- [\[0197\]](#)
- **GABIZON et al.**Proc. Natl. Acad. Sci. U.S.A., 1988, vol. 85, 6949- [\[0197\]](#)
- **SUNAMOTO et al.**Bull. Chem. Soc. Jpn., 1980, vol. 53, 2778- [\[0198\]](#)
- **ILIUM et al.**FEBS Lett., 1984, vol. 167, 79- [\[0198\]](#)
- **KLIBANOV et al.**FEBS Lett., 1990, vol. 268, 235- [\[0198\]](#)
- **BLUME et al.**Biochimica et Biophysica Acta, 1990, vol. 1029, 91- [\[0198\]](#)
- **RIEGER**Pharmaceutical Dosage FormsMarcel Dekker, Inc.19880000285- [\[0201\]](#) [\[0206\]](#)
- **LEE et al.**Critical Reviews in Therapeutic Drug Carrier Systems, 1991, 92- [\[0208\]](#) [\[0209\]](#) [\[0210\]](#) [\[0211\]](#) [\[0212\]](#) [\[0213\]](#)
- **TAKAHASHI et al.**J. Pharm. Pharmacol., 1988, vol. 40, 252- [\[0209\]](#)
- **MURANISHI**Critical Reviews in Therapeutic Drug Carrier Systems, 1990, vol. 7, 1-33 [\[0210\]](#) [\[0212\]](#) [\[0213\]](#)
- **EL HARIRI et al.**J. Pharm. Pharmacol., 1992, vol. 44, 651-654 [\[0210\]](#)
- **BRUNTON et al.**Goodman & Gilman's The Pharmacological Basis of TherapeuticsMcGraw-Hill19960000934-935 [\[0211\]](#)
- **SWINYARD**Remington's Pharmaceutical SciencesMack Publishing Co.19900000782-783 [\[0211\]](#)
- **MURANISHI**Critical Reviews in Therapeutic Drug Carrier Systems19900000vol. 7, 1-33 [\[0211\]](#)
- **YAMAMOTO et al.**J. Pharm. Exp. Ther., 1992, vol. 263, 25- [\[0211\]](#)
- **YAMASHITA et al.**J. Pharm. Sci., 1990, vol. 79, 579-583 [\[0211\]](#)
- **JARRETT**J. Chromatogr., 1993, vol. 618, 315-339 [\[0212\]](#)
- **BUUR et al.**J. Control Rel., 1990, vol. 14, 43-51 [\[0212\]](#)
- **YAMASHITA et al.**J. Pharm. Pharmacol., 1987, vol. 39, 621-626 [\[0213\]](#)

P a t e n t k r a v

1. Sammensætning, som omfatter et modificeret antisense-oligonukleotid bestående af 12-30 forbundne nukleosider, hvoraf mindst en 12-nukleobase-sekvensdel er komplementær til nukleotider, der er tilstede i en region udvalgt blandt nukleotiderne 1388-1423, 1394-1423 og 1399-1423 med SEQ ID NO: 9, eller et salt eller en ester deraf, til anvendelse ved behandling af en keloid eller forebyggelse af dannelse, gendannelse eller vækst af en keloid efter en skade på huden hos et individ med behov herfor, hvor sammensætningen indgives til individet ved hjælp af en eller flere tråd-injektioner på stedet for keloiden eller skaden på huden, i en mængde, der er virksom til at behandle eller til at forebygge dannelse, gendannelse eller vækst af keloiden, hvor den virksomme mængde er fra 0,1 til 50 mg af det modificerede oligonukleotid pr. injektion pr. lineær centimeter af keloiden eller skaden på huden.

2. Sammensætning, som omfatter et modificeret antisense-oligonukleotid bestående af 12-30 forbundne nukleosider, hvoraf mindst en 12-nukleobase-sekvensdel er komplementær til nukleotider, der er tilstede i en region udvalgt blandt nukleotiderne 1388-1423, 1394-1423 og 1399-1423 med SEQ ID NO: 9, eller et salt eller en ester deraf, til anvendelse ved behandling af et hypertrofisk ar eller forebyggelse af dannelse, gendannelse eller vækst af et hypertrofisk ar efter en skade på huden hos et individ med behov herfor, hvor sammensætningen indgives til individet ved hjælp af en eller flere tråd-injektioner på stedet for det hypertrofiske ar eller skaden på huden, i en mængde, der er virksom til at behandle eller til at forebygge dannelse, gendannelse eller vækst af det hypertrofiske ar, hvor den virksomme mængde er fra 0,1 til 25 mg af det modificerede oligonukleotid pr. injektion pr. lineær centimeter af det hypertrofiske ar eller skaden på huden.

3. Sammensætning til anvendelse ifølge et hvilket som helst af kravene 1-2, hvor sammensætningen indgives intradermalt.

4. Sammensætning til anvendelse ifølge et hvilket som helst af kravene 1-3, hvor den ene eller de flere injektioner omfatter flere tråd-injektioner pr. ar.

5 **5.** Sammensætning til anvendelse ifølge et hvilket som helst af kravene 1-4, hvor det modificerede antisense-oligonukleotid indgives mindst en gang hver anden uge i mindst fire uger, mindst en gang hver tredje uge i mindst seks uger, mindst en gang hver fjerde uge i mindst otte uger, mindst en gang hver ottende uge i mindst seksten uger, indgives i løbet af et tidsrum på mindst ni uger eller indgives i løbet af et tidsrum på 26 uger.

10 **6.** Sammensætning til anvendelse ifølge et hvilket som helst af kravene 1 til 5, hvor mindst en 12-nukleobase-sekvensdel af det modificerede antisense-oligonukleotid er til stede i nukleobase-sekvensen anført i en hvilken som helst af sekvenserne anført i SEQ ID NO: 39, 40 eller 166.

15 **7.** Sammensætning til anvendelse ifølge et hvilket som helst af kravene 1 til 6, hvor det modificerede antisense-oligonukleotid omfatter mindst 14 forbundne nukleosider.

20 **8.** Sammensætning til anvendelse ifølge et hvilket som helst af kravene 1 til 7, hvor det modificerede antisense-oligonukleotid omfatter 20 forbundne nukleosider.

25 **9.** Sammensætning til anvendelse ifølge et hvilket som helst af kravene 1 til 8, hvor det modificerede antisense-oligonukleotid er et enkeltstrengt oligonukleotid, er et dobbeltstrengt oligonukleotid, omfatter mindst et oligodeoxyribonukleotid eller omfatter mindst et oligoribonukleotid.

30 **10.** Sammensætning til anvendelse ifølge krav 6, hvor det modificerede antisense-oligonukleotid har en sekvens, som er 100 % identisk over sin længde med en del af en hvilken som helst af sekvenserne anført i SEQ ID NO: 39, 40 eller 166.

35 **11.** Sammensætning til anvendelse ifølge et hvilket som helst af kravene 1 til 10, hvor det modificerede antisense-oligonukleotid omfatter mindst en modificeret internukleosid-binding, eventuelt hvor mindst en modificeret internukleosid-binding er en phosphorothioat-internukleosid-binding.


12. Sammensætning til anvendelse ifølge krav 11, hvor alle internukleosid-bindingerne er phosphorothioat-internukleosid-bindinger.

5 **13.** Sammensætning til anvendelse ifølge et hvilket som helst af kravene 1 til 10, hvor mindst et nukleosid omfatter et modificeret sukker, eventuelt hvor det modificerede sukker er et bicyklisk sukker.

10 **14.** Sammensætning til anvendelse ifølge krav 13, hvor mindst et af det modificerede sukker omfatter et 2'-O-methoxyethyl.

15. Sammensætning til anvendelse ifølge et hvilket som helst af kravene 1 til 10, omfattende mindst et tetrahydropyran-modificeret nukleosid, hvor en tetrahydropyranring erstatter furanoseringen.

15 **16.** Sammensætning til anvendelse ifølge krav 15, hvor hvert af det mindst ene tetrahydropyran-modificerede nukleosid har strukturen:



hvor Bx er en eventuelt beskyttet heterocyklisk baseenhed.

20 **17.** Sammensætning til anvendelse ifølge et hvilket som helst af kravene 1 til 10, hvor mindst et nukleosid omfatter en modificeret nukleobase.

18. Sammensætning til anvendelse ifølge krav 17, hvor den modificerede nukleobase er et deoxynukleosid, et ribonukleosid eller en 5'-methylcytosin.

25 **19.** Sammensætning til anvendelse ifølge et hvilket som helst af kravene 1 til 10, hvor det modificerede antisense-oligonukleotid omfatter:

(a) et spaltesegment bestående af forbundne deoxynukleosider;

(b) et 5'-fløjsegment bestående af forbundne modificerede nukleosider; og

30 (c) et 3'-fløjsegment bestående af forbundne modificerede nukleosider; hvor spaltesegmentet er anbragt mellem 5'-fløjsegmentet og 3'-fløjsegmentet, og hvor hvert modificerede nukleosid i hvert fløjsegment omfatter et modificeret sukker.

20. Sammensætning til anvendelse ifølge krav 19, hvor det modificerede antisense-oligonukleotid omfatter:

- (a) et spaltesegment bestående af tretten forbundne deoxynukleosider;
 - (b) et 5'-fløjsegment bestående af to forbundne modificerede nukleosider; og
 - (c) et 3'-fløjsegment bestående af fem forbundne modificerede nukleosider;
- hvor spaltesegmentet er anbragt mellem 5'-fløjsegmentet og 3'-fløjsegmentet, og hvor hvert modificerede nukleosid i hvert fløjsegment omfatter et 2'-O-methoxyethylsukker; og hvor hver internukleosid-binding er en phosphorothioat-binding.

21. Sammensætning til anvendelse ifølge krav 6, hvor sekvensen af nukleobasen er sekvensen anført i SEQ ID NO:39, SEQ ID NO:40 eller SEQ ID NO:166.

22. Sammensætning til anvendelse ifølge et hvilket som helst af kravene 1 til 21, hvor sammensætningen omfatter det modificerede antisense-oligonukleotid eller et salt deraf og en farmaceutisk acceptabel bærer eller fortyndingsmiddel.

23. Sammensætning til anvendelse ifølge et hvilket som helst af kravene 1 til 22, som yderligere omfatter indgivelse til individet af en anden antisense-forbindelse rettet mod den samme eller en anderledes sekvens.

24. Sammensætning til anvendelse ifølge krav 23, hvor det modificerede antisense-oligonukleotid og den anden antisense-forbindelse indgives samtidigt eller sekventielt.

25. Sammensætning til anvendelse ifølge et hvilket som helst af kravene 1 til 24, hvor det modificerede antisense-oligonukleotid er til stede i et konjugat med en enhed, som forstærker optagelsen af forbindelsen i, og/eller øger opholdstiden af forbindelsen i, individet, hvor opholdstiden fortrinsvis er 7 til 60 dage.

26. Sammensætning til anvendelse ifølge krav 25, hvor enheden er polyethylenglycol, hyaluronsyre, kolesterol, adamantin-eddikesyre, 1-pyren-butansyre, dihydrotestosteron, 1,3-Bis-O-(hexadecyl)glycerol, hexadecylglycerol, hexadecylamin, geranyloxyhexyl, palmitinsyre, myristinsyre, spermin, spermidin,

folsyre, vitamin E, et kulhydrat-cluster, et peptid (herunder antenapedia-spiral, HIV Tat-fragmenter, integrin-bindende peptid), transportin eller porphyrin.

5 **27.** Sammensætning til anvendelse ifølge et hvilket som helst af kravene 1 til 26, hvor det modificerede antisense-oligonukleotid indgives i et afgivelsessystem, som forstærker optagelsen af forbindelsen i, og/eller øger opholdstiden af forbindelsen i, individet, hvor opholdstiden fortrinsvis er 7 til 60 dage.

10 **28.** Sammensætning til anvendelse ifølge krav 27, hvor afgivelsessystemet omfatter et kationisk lipid, et liposom, en mikropartikel, en nanopartikel, en flydende formulering med suspenderede partikler med eller uden lægemiddel i opløsningen til øjeblikkelig frigivelse eller med lægemiddeldepot i partikler (især PLGA og poly-Arg-partikler), en flydende formulering, der gelerer efter injektioner, såsom termohærdende/responsive væsker (f.eks. pluronic-geler),
15 væsker, der indeholder en polymer og lægemiddel i et biokompatibelt opløsningsmiddel, der præcipiterer, når opløsningsmidlet fortyndes af kropsvæsker (f.eks. atrigel), en gel, en halvfast formulering såsom hydrogel.

20 **29.** Sammensætning til anvendelse ifølge et hvilket som helst af kravene 1 til 28, hvor det modificerede antisense-oligonukleotid indgives til individet efter en kirurgisk ekscision af keloiden, arret eller den fibrøse læsion.

25 **30.** Sammensætning til anvendelse ifølge et hvilket som helst af kravene 1 til 29, hvor skaden på huden skyldes en kirurgisk incision, en biopsi, en hudpiercing, en hudfjernelse, en forbrænding eller et sår.

30 **31.** Sammensætning til anvendelse ifølge et hvilket som helst af kravene 1 til 30, hvor den virksomme mængde er ca. 5 mg af det modificerede antisense-oligonukleotid pr. injektion pr. lineær centimeter af keloiden, det hypertrofiske ar, skaden på huden, læsionsstedet, det allerede eksisterende ar eller den allerede eksisterende fibrøse læsion.

35 **32.** Sammensætning til anvendelse ifølge et hvilket som helst af kravene 1 til 31, hvor det modificerede antisense-oligonukleotid indgives i op til 6 måneder eller i op til 1 år.

33. Sammensætning til anvendelse ifølge et hvilket som helst af kravene 1 til 32, som yderligere omfatter indgivelse til individet af et andet terapeutisk middel.

5 **34.** Sammensætning til anvendelse ifølge krav 33, hvor et sådant andet terapeutisk middel er et steroid, en silikone-indpakning, TGF- β 3 (dvs. Juvista), kollagenase (dvs. Xyflex), 17 β -estrodial (dvs. Zesteem), IL-10 (dvs. Prevascar), mannose-6-phosphat (dvs. Juvidex), afslapningsmiddel til glatte muskler (dvs. AZX100, et syntetisk 24-aminosyrepeptid), en stamcelleterapi (dvs. GBT009),
10 serumamyloidprotein, antistoffer rettet mod integrin $\alpha\beta$ 6, CTGF, TGF β eller molekyler, der hæmmer aktiviteten af ALK-4 og/eller ALK-5 (TGF-beta-receptorerne), en hvilken som helst inhibitor, der er konstrueret til at blokere TNF-aktivitet (f.eks. etanercept), okklusive forbindinger, kompressionsterapi, kryokirurgi, kirurgisk ekscision, laserbehandling, strålebehandling, interferonbehandling, bleomycin, 5-fluorouracil, verapamil, imiquimod-creme, et middel,
15 der kan fremme sårheling, såsom Dermagraft, Apligraf, PDGF (Regranex), elektrisk stimulering, "vækstfaktorer" som kategori, forbindinger som kategori, tyndtarm-submucosa (SIS), Promogran, hyperbarisk oxygen eller kombinationer deraf.

20 **35.** Sammensætning til anvendelse ifølge et hvilket som helst af kravene 1 til 34, hvor det modificerede antisense-oligonukleotid indgives ved hjælp af en formulering, ultralyd, elektroporese, iontoforese eller mikronål.

25 **36.** Sammensætning til anvendelse ifølge et hvilket som helst af kravene 1 til 35, hvor det modificerede antisense-oligonukleotid indgives i umiddelbar nærhed af keloiden, det hypertrofiske ar, skaden på huden, læsionsstedet, det allerede eksisterende ar eller den allerede eksisterende fibrøse læsion.

30 **37.** Sammensætning til anvendelse ifølge krav 36, hvor det modificerede antisense-oligonukleotid indgives langs hele længden eller langs hver side af keloiden, det hypertrofiske ar, skaden på huden, læsionsstedet, det allerede eksisterende ar eller den allerede eksisterende fibrøse læsion.

38. Sammensætning til anvendelse ifølge et hvilket som helst af kravene 1 til 37, hvor det modificerede antisense-oligonukleotid indgives direkte ind i keloiden, det hypertrofiske ar, skaden på huden, læsionsstedet, det allerede eksisterende ar eller den allerede eksisterende fibrøse læsion.

5

39. Sammensætning til anvendelse ifølge et hvilket som helst af kravene 1 til 38, hvor individet er genetisk prædisponeret for dannelse af keloider eller hypertrofiske ar eller begge dele.

10

40. Kit omfattende sammensætningen til anvendelse ifølge et hvilket som helst af kravene 1 til 39, som omfatter:

- a. en indretning, der er forfyldt med sammensætningen omfattende det modificerede antisense-oligonukleotid; og
- b. brugsanvisning.

DRAWINGS

FIGURE 1A




FIGURE 1B




FIGURE 2A




FIGURE 2B




FIGURE 3A (hypertrophic scar 24 weeks post revision surgery)




FIGURE 3B (keloid scar 24 weeks post revision surgery)





FIGURE 4: Hypertrophic scar 12 weeks post abdominoplasty surgery.



Expert VAS Score = -47.2mm
Physician Overall = -2
Subject Overall = -1

FIGURE 5: Example of limited lateral diffusion of EXC 001 distal to injection site.

Abdominoplasty Study (#202)
Week 12




FIGURE 6

EXC 001 mediated reduction in abdominal scar severity and CTGF protein expression.




FIGURE 7A




FIGURE 7B




FIGURE 7C




FIGURE 7D




FIGURE 7E

